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Abstract
Sydenham’s chorea (SC) is a neurological manifestation following group A Streptococcus 
infection (GABHS) and has been proposed as an antibody-mediated autoimmune disease. Other 
movement and psychiatric manifestations following GABHS have been recognised and termed 
Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections 
(PANDAS). It is proposed that PANDAS may be caused by the same antibody as SC. As the 
symptoms of PANDAS are identical to Tourette’s syndrome (TS), the possibility that TS might 
turn out to be an autoimmune disorder has implications for the treatment and understanding of 
these disorders.
Evidence of GABHS was found in all patients with SC and PANDAS and 60% of patients with 
TS. Autoantibodies against basal ganglia (ABGA) were found in all acute SC and PANDAS 
patients. Only 25% of TS patients were ABGA positive. There was little evidence for ABGA in 
controls. There was a higher prevalence of ABGA in systemic diseases associated with GABHS 
but this did not reach significance.
ABGA bound to proteins with molecular weights (40, 45, 60 and 98 kDa) and these responses 
were variably found in SC, PANDAS and TS. The identification of these antigens proved to be 
problematic due to contamination with other proteins with the same molecular weights. Neurone 
specific enolase (NSE) was identified as one of the antigens. As this protein was not specific to 
basal ganglia it cast doubt as to the specificity of ABGA. Interestingly, however, enolase is also 
found on the surface of GABHS and has extensive homology with human enolase, thus lending 
support to the possibility of molecular mimicry derived autoimmunity.
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1 Introduction
1.1 The aims of this introduction
• Examine the role of autoantibodies, cytokines and cellular responses in putative 
autoimmune syndromes.
• To examine neurological disorders thought to be immune or autoimmune 
mediated
• Focus on the role of group A streptococcus in immune-mediated disorders.
• To outline the clinical and scientific aspects of Rheumatic fever and its 
neurological manifestation, Sydenham’s chorea
• To introduce the putative post-streptococcal disorder Paediatric Autoimmune 
Neuropsychiatric Disorders Associated with Streptococcal infections (PANDAS) 
and its relationship to Tourette’s syndrome
• Suggest how putative autoantigens can be identified using proteomic methods
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1.2 Background to autoimmune diseases
Autoimmune diseases can affect individual organs such as the kidneys, liver, pancreas, 
thyroid, adrenal gland and perhaps brain (organ-specific autoimmunity) or affect multiple 
body systems simultaneously (non-organ specific autoimmunity), (Erman et al., 2001). 
The causes for autoimmunity are complex and probably include genetic, environmental, 
infectious factors and perhaps several in combination. It is probable that aberrant 
lymphocyte responses and failure of tolerance (un-responsiveness to self antigens) is the 
major mechanism behind autoimmunity, but autoantibodies (antibodies against self­
antigens), complement and cytokines are also important for disease induction and 
persistence.
1.3 Identification of autoantibodies in immune mediated disorders
In autoimmune syndromes, alterations in the immune system can result in the survival of 
autoreactive B lymphocytes which upon activation produce large amounts of 
autoantibodies which persist for years, such as anti-nuclear antibodies (Davidson et al., 
2001; Sato e ta l., 1996). High levels of autoantibodies have been found in most 
autoimmune diseases, although their specific pathological role is frequently unclear. The 
exception has been the identification of the functional effects of autoantibodies in 
diseases such as myaesthenia gravis and the Lambert-Eaton myasthenia syndrome, where 
antibodies disrupt or block synaptic transmission of nerves (Vincent et al., 1999 a; 
Whitney et al., 1999). Graves disease, an autoimmune thyroiditis is also thought to be 
antibody- mediated, as the autoantibodies stimulate the thyroid hormone receptor,
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causing dysfunction (Weetman., 2001). Apart from their role in autoimmunity, 
autoantibodies of low affinity are also produced as a consequence of infection, tissue 
trauma and tumours, but usually disappear after recovery and are probably a feature of 
inflammation and tissue repair (Dighiero eta l., 1999; Rose., 1998; Silverman., 1997).
The major use of autoantibodies is as a laboratory marker, as their detection is useful as a 
diagnostic tool when identifying a possible autoimmune syndrome. Results need to be 
interpreted in the context of clinical presentation, age of the patient (numbers of 
naturally-occurring autoantibodies increase with age) and other underlying conditions 
such as infection and tumours. Autoantibodies are typically detected in serum using 
indirect immunofluorescence, enzyme or radio-ligand-linked immunoabsorbant assays 
(ELISA), particle agglutination or Western immunoblotting (electrophoresis). The 
various assays have different sensitivities and specificities due to the presentation and 
concentration of antigens and the methods of visualising antibody binding (colorimetric, 
turbidimetric, fluorometric, enzymatic, radioactive or chemiluminescent). These 
differences are important when considering an autoantibody as a surrogate marker of 
autoimmunity.
1.4 Immune-mediated neurological syndromes 
Apart from MS, which is considered to be the classic immune-mediated central nervous 
system (CNS) syndrome, paraneoplastic neurological syndromes (PNS) are the most 
widely studied of these CNS disorders (Dropcho., 1999; Sutton et al, 2002). The 
pathophysiology of PNS involves the development of an immune response against a 
tumour outside the CNS, commonly small-cell lung (SCLC) or gynaecological tumours 
(Rees et al., 2003). This immune response is targeted against CNS antigens expressed by 
the tumour (Rees et al, 2003; Sutton et al, 2002). This leads to a cross-reactive immune 
response between the tumour and normal brain tissue resulting in the destruction of 
neurons via immune mechanisms, rather than through the secondary spread of the 
tumour. Neurological symptoms associated with PNS include encephalitis, ataxia and 
motor or sensory neuropathies (Dropcho., 1999; Scaravilli et al, 1999; Rees et al, 2003; 
Sutton., 2002; Sutton et al, 2002). Most paraneoplastic syndromes cause progressive 
brain damage and have characteristically high mortality rates.
An important feature of PNS is the presence of anti-tumour antibodies that recognise 
CNS antigens (anti-neuronal antibodies), and include: anti- Hu, Yo, Ri, Ma or Tr 
amongst others (Dropcho., 1999; Inuzuka., 2000). In addition, antibodies can also be 
directed against neuronal ion channels including (voltage-gated calcium and potassium 
channels). The ion channel antibodies are thought to be directly pathogenic to neuronal 
function (Newson-Davis., 1999; Rees etal., 2003). Anti-calcium channel antibodies are 
found in patients with the Lambert-Eaton myaesthenic syndrome (LEMS) which is 
associated with SCLC (Lang et al., 2003; Newson-Davis., 1999; Rees et al, 2003). IgG
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from patients with LEMS has been shown to bind to surface P/Q type voltage-gated 
calcium channels and cause a reduction in cell calcium currents leading to a motor 
disorder (Lang et al., 2003; Motomura et al., 1997; Vincent A., 1999 b).
There is controversy however as to whether antibodies against CNS antigens such as Hu 
and Yo are an important mechanism in PNS or are simply an epiphenomen. Unlike ion 
channel antibodies, the antigens recognised by some anti-neuronal antibodies are 
intracellular, which casts doubt as to whether they are capable of damaging neurons or 
altering their function (Dropcho., 1999; Rees et al, 2003; Sutton., 2002). Transfer of 
anti-neuronal antibodies into animal models has so far failed to replicate the neuronal 
destruction seen in PNS (Tanaka et al, 1994; Tanaka et al, 1995). Alternatively these 
antibodies may be produced following neuronal damage and loss. Once produced these 
antibodies could then act to continually prime or up-regulate the immune response, 
thereby maintaining a state of pathological autoimmunity. This has been suggested by a 
recent study showing that anti-neuronal antibodies can induce expression of adhesion 
molecules and neuronal differentiation (Tanaka et a l, 2004).
The alternative mechanism of immune mediated neuronal loss in PNS is via cytotoxic T- 
lymphocytes (CTL) which are directed primarily against the tumour but also recognise 
CNS antigens. This cell-mediated, anti-tumour response probably explains the small size 
of tumours associated with PNS (Rees et al, 2003). Expanded populations of MHC class 
I restricted CTLs directed against a tumour antigen which cross-reacts with the brain 
antigen (cdr2) have been reported in the blood of patients with PNS and may contribute
35
to development of CNS autoimmune destruction (Albert et al, 1998). Evidence from 
histological analysis of the most common paraneoplastic syndrome (Hu-positive 
encephalomyelitis associated with SCLC) showed a cellular inflammatory infiltration of 
the cerebellum with a preponderance of T lymphocytes clustered around neurons (Bernal 
et al, 2002). It has also been shown that the T lymphocytes associated with this 
paraneoplastic syndrome are predominantly cytotoxic (CD8+) T cells and can be 
activated by peptides from the common paraneoplastic antigens Hu and Yo (Tanaka et 
al., 2001). Further work to examine cytotoxic neuronal damage is important to elucidate 
this hypothesis further. However it is becoming clear that a cellular response, rather than 
antibody activity is probably responsible for the damage in PNS, although anti-neuronal 
antibodies remain a useful diagnostic marker (Rees et a l , 2003; Sutton., 2002).
1.5 Molecular mimicry hypothesis of post-infectious immune-mediated 
disorders
In addition to a tumour-triggered autoimmune phenomenon, many investigators have 
argued the possibility that pathogens could trigger autoimmune or para-infectious 
immune-mediated diseases (Kirch., 1993; Levin et a l , 2002; Ruckenstein et al, 1993; 
Tsunoda et al, 2002). This has been termed the molecular mimicry theory of 
autoimmunity, although several factors including genetic, environmental and hormonal 
are probably required for induction of disease. There is some, albeit conflicting, evidence 
for a molecular mimicry mechanism in the peripheral nervous system diseases: Guillain 
Barre syndrome (GBS) and acute inflammatory demyelinating polyneuropathy, which 
can be triggered by the bacterium Campylobacter jejuni (Rees et al, 1995; Tsang et al,
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2002). It is normal for an infection to trigger an antibody response against the bacteria 
but, due to similarity in structure or sequence of bacterial antigens and nerve 
gangliosides, such as GM1 and GQlb, antibody binding is thought to lead to conduction 
block in peripheral nerves (O’Hanlon et a l, 2001; Weber et al, 2000).
Antibodies binding to the GM1 ganglioside have been shown to block the normal action 
of sodium channels of nerves in the presence of complement, supporting a possible 
pathological mechanism for conduction block (Weber et al, 2000). However, a 
functional effect of anti-ganglioside antibodies on conduction is not always found. A 
recent study of twelve patients with GBS showed no effect on axonal conduction by anti- 
ganglioside antibodies (Dilley et al, 2003). The variations in results may mean that other 
immune mediators such as cytokines, cells or the presence or absence of complement 
components are important in GBS. Alternatively the concentration of antibody may be 
associated with an increase of functional effects (Odaka et al, 2003). The presence of 
anti-ganglioside antibodies alone is not sufficient to prove their role.
1.5.1 Viral associated autoimmune disease and molecular mimicry 
Whilst viruses are proposed as a trigger for autoimmunity in many disorders including 
MS, the exact mechanisms of this are unclear, but using GBS as a model, molecular 
mimicry could be one likely cause. An alternative hypothesis for viral-induced neuronal 
damage is apoptosis of neurons as a consequence of infection or the immune response.
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1.5.2 The Human T-cell Lymphotropic Virus type one: associated central 
nervous system disorders 
One possible model for autoimmune CNS disorders is infection with the Human T-cell 
Lymphotropic Virus type one (HTLV-1). HTLV-1 infects CD4+ T-helper lymphocytes 
and can cause adult T cell leukaemia or lymphoma (Poiesz et al., 2003). HTLV-1 
infection can also lead to a CNS disorder: HTLV associated myelopathy/tropical spastic 
paraparesis (HAM/TSP), (Osame et al., 1986; Levin et al., 2002). HAM/TSP clinically 
resembles MS, featuring limb spasticity, bladder disturbance, muscle weakness and 
sensory disruption (Ishak et al., 2002; Izumo et al., 2000). These neurological symptoms 
are associated with demyelination and axonal loss of neurones which are predominantly 
located in the spinal tracts where there is an associated lymphocytic infiltration (Izumo et 
al., 2000; Levin et al., 2002; Moore G et al., 1989).
An immune mediated cause has been proposed for HAM/TS (Levin et al., 2002; Jernigan 
et al., 2003) since cytotoxic T cells infected with HTLV-1 have been found in the CSF of 
patients with the condition (Nagai et al., 2001). The viral load of these infected cells may 
be associated with disease severity (Matsuzaki et al., 2001; Yamano et al, 2002). It is 
also known that HTLV-1 infected CD4+ lymphocytes become activated and can enter the 
CNS through interactions with the endothelium of the blood/brain barrier allowing 
activated CD8+ cytotoxic lymphocytes, antibodies and cytokines into the CNS (Giraudon 
et al., 2000; Romero etal., 2000). The cytotoxic CD8+ lymphocytic response in 
HAM/TSP has been shown to be specific for the N terminus of the HTLV-1 tax antigen 
(Jacobson et al., 1990; Lai et al., 1994). The tax antigen is similar to the human leukocyte
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antigen-A2 (Jacobson et al., 1990). It is possible that the infected T cells may be causing 
the immune-mediated destruction of neurones in HAM/TSP. Interestingly, the HTLV-1 
tax antigen CTL response has also been proposed as a protective anti-viral response so 
that autoimmunity or protection might be a host-specific reaction rather than one induced 
by a virus (Bangham., 2000).
It has also been reported that antibodies reactive against the C terminus of the HTLV tax 
antigen are found in HAM/TSP (Jerningan et al., 2003; Lai et al., 1994; Levin et al.,
2002). These antibodies cross-react with the human nuclear, ribonuclear protein-A1 
(hnRNP A), and IgG isolated from brain and CSF from HAM/TSP patients also binds to 
hnRNP A-antigen (Jernigan et al., 2003; Levin et al., 2002).These antibodies have been 
shown to react strongly with Betz cells (Levin et al., 2002), which are an important cell 
in the spinal tract (Lassek., 1940). Whilst antibodies may be important in HAM/TSP, it is 
likely that a combination of the CTL and the antibody response is involved in neuronal 
dysfunction and loss.
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1.6 Bacteria and autoimmunity 
In addition to viruses, a number of other pathogens including bacteria have been 
associated with autoimmune disease. For example the spirochete, Borrelia burgdorferi, 
which is transmitted by tics, typically causes cutaneous disease, encephalitis and arthritis 
(Steere., 2001). Borrelia burgdorferi sensu stricto infection is usually associated with a 
reactive arthritis, but 10% of these patients also develop an autoimmune form of Lyme’s 
disease arthritis. This form of arthritis is associated with constant inflammation and 
treatment resistance (Guerau-de-Arellano et al., 2002; Steere., 2001).
A HLA marker, HLA-DRB 1*0401 has been associated with susceptibility to this form of 
Lyme’s disease arthritis, which may be an immune complication of infection with 
Borrelia species (Guerau-de-Arellano M et al., 2002; Steere eta l 1998). Lyme’s disease 
arthritis is also associated with an immune response against a surface antigen of Borrelia 
burgdorferi (OspA) which is homologous to the human lymphocyte function antigen-1 
(LFA-1), (Gross et a l, 1998; Steere etal., 2003). It is not known why patients develop 
arthritis rather than having a disseminated or organ-specific autoimmune disorder. 
Infection with Borrelia has occasionally been associated with chorea (movement 
disorder) although the cause of this is unknown (Piccolo et al., 1998). The common 
bacterial infection associated with movement disorders is thought to be the group A beta 
haemolytic streptococcal bacteria.
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1.7 Group A beta haemolytic streptococcal bacteria
Beta-haemolytic streptococcal bacteria are frequent pathogens in humans causing 
pharyngitis, skin and soft tissue infections but also have the potential to cause severe 
complications such as septicaemia, toxic-shock syndrome, meningitis and post-infectious 
immune-mediated syndromes (Barnham., 1989; Bisno e ta l , 2003; Cunningham., 2000; 
Keefer et a l , 1937; Stillerman et a l , 1961). The incidence of asymptomatic colonisation 
of the throat has been reported to be as high as 60% in school children although typical 
rates are more probably 7-30% (Quinn e ta l, 1957; Cornfield., 1958). The incidence of 
infections and community outbreaks has been linked to overcrowding, poor sanitation 
and inadequate access to healthcare (Dagan et a l, 1987; Rushdy et a l, 1995; Quinn et 
al, 1957).
The original laboratory classification of different streptococcal species was based on the 
ability of cultured bacteria to cause different types of haemolysis when grown on blood 
containing agar plates. This was described as: alpha, (partial), beta, (clear) and no 
haemolysis, based on appearance and amount of haemolysis (Brown., 1919). Lancefield 
was the first to carry out serological grouping of the known streptococcal species based 
upon differences in the cell-wall polysaccharides, and designated them as types A-G 
(Lancefield., 1933; Lancefield., 1962). Thirteen streptococcal species have been 
identified to date, but streptococcus pyogenes, which is a gram positive, beta-haemolytic 
streptococcus and contains the cell-wall group A carbohydrate is considered to be the 
most important and frequent species causing human disease. However the other 
streptococcal species can also cause disease in humans, such as the group B streptococci
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which are an important source of infection in neonates (Franciosi etal., 1973). Group C 
and G streptococci have also been associated with pharyngitis and more rarely fasciitis, 
cellulitis and glomerulonephritis (Turner et al., 1990; Efstratiou., 1989).
The cell wall of the group A beta haemolytic streptococcus (GABHS) consists of a 
peptidoglycan backbone with lipoteichoic acid components which provide structural 
stability and facilitate adherence to pharyngeal epithelial cells (Figure 1.1, Hasty et al., 
1992). The cell wall also contains the group A carbohydrate, which is composed of N- 
acetylglucosamine linked to a rhamnose polymer backbone. Streptococcal species can 
also be encapsulated but this varies according to the strain (Bisno et al., 2003). 
Encapsulation of the bacterium influences infectivity and non-capsulated strains may be 
100 fold less virulent than a capsulated bacterium (Wessels MR et al., 1991). The cell 
wall additionally contains a number of proteins which increase adherence to epithelial 
cells and infer pathogenicity. For example streptococcus binds to fibronectin which 
enhances adherence to pharyngeal cells and this is mediated by a streptococcal binding 
protein (protein F), (Dinkla et al., 2003; Okada etal., 2003). Pathogenic strains which 
contain large amounts of protein F are more likely to cause invasive disease (Natanson et 
al., 1995). Other proteins infer protection from the immune response such as the 
complement inhibitory protein, which is an extracellular protein and capable of 
inactivating the membrane attack complex which is the end-stage of the complement 
pathway (Akesson et al., 1996).
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Figure 1-1 diagrammatical representation of the Streptococcal cell wall proteins 
http://www.nature.com/embor/iournal/v3/n8/rig tab/emborl06 f2.html
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Teichoic acids (TAs) and lipoteichoic acids (LTAs) (both in green) are carbohydrate phosphate polymers 
rich in choline (orange spheres). TAs are linked to the peptidoglycan via a phosphodiester linkage, whereas 
LTAs are linked to the cell membrane via a C-terminal fatty acyl group (in red). Choline-binding proteins 
are linked to cell-wall TAs or LTAs via choline-binding domains (CBDs) (red ribbon diagram). In 
Streptococcal Pneumococcal strains, a surface antigen (PsaA) is located underneath the peptidoglycan layer 
and is attached to the cell membrane via an LXXC motif; penicillin-binding proteins (PBPs) are located in 
the periplasmic space and interact with the peptidoglycan, and display a single, N-terminal transmembrane 
helix (in blue). Hyaluronate lyase (Hyl) is tethered to the peptidoglycan via an LPXTG motif.
Enolase is present in the cytoplasm and in small quantities on the cell wall; the mechanism for translocation 
to the cell surface is not known (Pancholi V, 1998 and 2001).
In addition to streptococcal identification and typing using differences in the cell wall 
carbohydrate, GABHS can also be sub-divided into serotypes due to variations in an 
important cell-wall protein, the M protein (Lancefield., 1962). The M protein is a coiled 
fibrillar protein, consisting of 4 regions of repeating amino acid sequences with a proline- 
rich area which, in conjunction with a hydrophobic region, anchors the protein into the 
cell-wall (Harbaugh et a l, 1993; Khandke et al., 1990; Robinson et al., 1992). There are 
currently 124 M proteins identified which are coded for by emm genes (Bisno et al.,
2003), which are now used to type outbreaks (Tanaka D et a l, 2002). The variability of 
M proteins from GABHS strains is probably due to iatrogenic recombination and 
acquired mutations so that a particular emm gene does not always produce the same M 
protein type (Harbaugh et a l, 1993; Penney et al, 1995). In addition to M protein, the ‘T 
protein’, is also present on the cell surface and can be helpful in distinguishing strains 
when the M protein type cannot be identified (Cunningham., 2000). The M types and 
emm genes are usually associated with a particular T type thus determining the T type 
enables M protein identification to be carried out rapidly (Beall et al., 1997; Beall et al., 
1998; Cunningham., 2000).
The M protein is conserved between strains carrying the same M type, except for 2 
regions close to the N terminus which protrude from the cell and contains both variable 
and hypervariable regions (Fischetti et al., 1989; Robinson et al., 1992). Antibodies 
raised to the hypervariable region confer host protection from re-infection with GABHS 
carrying the same M protein, but not from other heterologous strains because of the 
antigenic variations in this region (Beachey et al, 1981). Equally the M protein is an
important protective factor for the streptococcus as its presence confers anti-phagocytic 
properties and therefore protection from complement binding opsonisation and 
phagocytosis (Beachey et al., 1980; Bisno et al., 2003., Ehlenberger et al., 1977; Jones et 
al., 1988). The mechanism of protection from phagocytosis is attributed to the specific 
binding of serum complement factor H to the conserved M protein region along with 
fibrinogen, thereby preventing complement component C3b from being deposited on the 
surface of the streptococcus and causing inactivation of C3b (iC3b), (Berggard et a l , 
2001; Bisno et al., 2003; Fischetti., 1995; Horstmann et al., 1992). The importance of the 
protein is also underlined by its alternative function as an adhesion factor aiding 
attachment to pharyngeal epithelial cells and keratinocytes (Caparon et a l, 1991; Ellen et 
al., 1974).
The function of the M protein variable regions however is poorly understood. These 
regions may confer pathogenicity and protection from the immune response again 
through interfering with complement deposition. Human complement inhibitory factors 
(C4BP and Factor H-like protein-1) both bind to the variable region of the M-protein and 
may also prevent phagocytosis by degrading complement component C3 (Berggard et al, 
2001; Johnsson et a l, 1998; Them et al., 1995). This may act in conjunction with Factor 
H binding to the conserved region of the M protein to protect virulent strains from 
complement-mediated immune attack (Johnsson et al., 1998).
Streptococci also produce a number of extracellular pyogenic exotoxins (SPE: A, B, C 
and F amongst others) which are important as they cause direct tissue damage (Hallas.,
1985; Saouda et a l, 2001; Watson., 1960) by initiation of apoptotic pathways or 
disruption of mammalian cell-membranes. The example of this process is SPE-B 
produced by GABHS, which is a serine protease enzyme and has been shown to induce 
apoptosis in cell lines (Kuo et a l, 1999; Tsai et a l, 1999). SPE-B has been shown to 
cleave immunoglobulins, vitronectrin and fibronectin thereby protecting from immune 
attack and in turn damaging the basement membranes in an infected host, damaging 
tissue and facilitating invasion (Bisno et a l, 2003; Collin et a l, 2001).The exotoxins can 
also act as superantigens which activate the immune system through interactions with 
MHC class II and the VP portion of the T-cell receptor (Marrack et a l, 1990). This can 
non-specifically activate large numbers of lymphocytes which produce a host of pro- 
inflammatory cytokines including TNFa and interferon-y which can directly damage cells 
(Scherer et a l, 1993; Leonard e ta l,  1991).
The streptococcal exotoxins and their role as superantigens have been implicated in a 
number of streptococcal diseases including Kawasaki’s syndrome, which is an acute 
febrile systemic vasculitis of children (Yarwood et a l, 2000; Yoshioka et al., 2003). The 
exotoxin is thought to cause an inappropriate T-cell mediated response through clonal 
expansion of lymphocytes, vascular infiltration and localised inflammation (Jason et a l, 
1997; Yarwood eta l, 2000).
Streptococci also produce streptokinase, which is an extracellular protein that can bind to 
plasminogen to activate plasmin (Damaschun et a l, 1992; Norstrand et al., 1996). These 
aids bacterial spread and may be important in the development of post-streptococcal
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glomerulonephritis (Norstrand et al., 1996). The remaining proteins such as the 
streptolysins and deoxyribonucleases are also toxins, aid infectivity and are useful for 
diagnosis and these will be discussed later.
Recent evidence has shown that GABHS is capable of invading human cells and being 
internalised where it can form a reservoir for persistent infection or colonisation (Cue et 
al., 1998; Facinelli et al., 2001; Hagman et al., 1999; LaPenta et al., 1994).
Internalisation is thought to require multiple interactions with M protein and a 
fibronectin-binding protein, Sfbl (Cue et al., 1998; Dombek et al., 1999; Molinari et a l, 
1997). It has been proposed that skin and pharyngeal GABHS isolates are more invasive 
than those that cause blood sepsis (Gladstone et al., 2003). GABHS has been recovered 
from tonsils of patients with recurrent streptococcal infection and from asymptomatic 
carriers who were free of symptoms at the time of surgery (Osterlund et al., 1995; 
Osterland et al., 1997). Survival of GABHS within host immune cells may be an 
additional route of internalisation and a method of circumventing the host immune 
response. A murine model of GABHS skin infection found that viable GABHS could be 
obtained from mouse phagocytic cells after in vitro or during in vivo infection (Medina et 
al., 2003). A study of phagocytosis of GABHS by human neutrophils showed that 
GABHS is capable of surviving and therefore chronically infecting cells (Staali et al.,
2003).
47
1.8 Streptococcal infections
Pharyngitis is the most common consequence of streptococcal infection and typically 
presents as an acute fever with sore throat and is commonly associated with headache, 
nausea and sometimes vomiting. The pharynx is reddened with enlarged tonsils which are 
commonly covered in purulent exudates. The tongue may be red and swollen 
(‘strawberry tongue’), and palatal petechiae may also be seen (Wannamaker., 1984). The 
majority of individuals with pharyngitis recover without treatment but because of the risk 
of serious post-infectious complications, antibiotic treatment is indicated even in cases of 
suspected infection. The clinical differentiation from other causes of pharyngitis such as 
viruses can, however be difficult (Breese., 1977).
The development of a diffuse red rash on the skin in addition to the pharyngeal symptoms 
is an important sign of scarlet fever and although now rare, in the later part of the 19th 
century mortalities between 25-30% were not uncommon (Rotch., 1896). Death was 
caused by upper airway obstruction, meningitis or damage to the jugular vein or carotid 
artery (Rotch., 1896). Scarlet fever is now thought to result from infection with a strain of 
streptococcus producing the pyogenic exotoxin C, which can cause direct tissue damage 
(Hallas., 1985; Watson., 1960). Other streptococcal skin infections include erysipelas 
which presents as an abrupt fiery red rash with defined margins and intense pain (Bernard 
et al., 1989) and impetigo which is characterised by single or multiple thick crusted 
lesions (Dajani etal., 1972). Streptococcus is also an important cause of cellulitis 
(Bernard et al., 1989; Darmstadt et al., 1994) and can also cause septicaemia, meningitis, 
vaginitis and, rarely, necrotising fasciitis.
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1.9 Anti-streptococcal antibodies as surrogate markers of infection
Due to the delayed clinical manifestations in some of the post-streptococcal syndromes 
identification (culturing) and serotyping of the GABHS is not always possible as the 
infection may have cleared. In addition to a clinical history of pharyngitis or skin 
infection, surrogate markers can be used instead to assess recent infection. Surrogate 
markers measure the concentrations of host antibody levels against the extracellular 
antigens of GABHS. Increases or decreases in these antibodies can give some indication 
as to the course of the infection (acute, chronic, relapse or recovery) and hence the 
indication for treatment.
1.9.1 Anti-streptolysin O titre 
Streptolysin O (SO) is an oxygen-labile, thiol-activated cytolysin, produced by GABHS 
and causes broad haemolysis on blood agar plates (Stevens., 2000). Two forms exist with 
molecular weights between 50-70 kDa and contain active fragments (Alouf et al., 1988; 
Bhakdi et al., 1984). The action of SO is through binding of the toxin to cholesterol on 
cell membranes resulting in toxin-cholesterol aggregates which cause cell lysis through 
an osmotic mechanism (Bhakdi etal., 1985; Palmer e ta l , 1998; Sekiya et al., 1993; 
Sekiya et al., 1996). Streptolysin O is also capable of affecting the immune response by 
impairing neutrophil function and inducing monocytes to produce tumour necrosis factor 
(TNF) and keratinocytes to produce a host of inflammatory cytokines (Bremm et al., 
1987; Hackett et al., 1993; Ruiz et al., 1998).
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Neutralising antibodies are produced by the host as a protective measure against SO and 
are called anti-streptolysin O antibodies (ASO), (Todd., 1932; Wannamaker., 1958). 
Antibody titres against SO (ASOT) rise during GABHS infection and usually reach a 
peak between 3 and 6 weeks after acute infection before falling (Todd., 1932). A raised 
ASOT is found in 80% of patients with acute pharyngitis, and rising titres are suggestive 
of a very recent infection (Special Writing Group of the Committee of Rheumatic Fever., 
1992). The measurement of ASOT does have limitations, however, as streptococcal skin 
infections usually elicit a poor ASOT response (Kaplan et al., 1974).
1.9.2 Anti-deoxyribonuclease B titre 
Streptococcus also produces a number of deoxyribonucleases (DNAses A, B, C and D) 
which can break down DNA and also elicit an immune response (Ayoub et al., 1962; 
Wannamaker., 1958). Due to the limitations of ASOT, measuring antibodies against 
DNAse is also a useful indicator of GABHS as it is raised in skin infections and is 
elevated for longer than ASOT (Ayoub etal., 1962). Neutralising antibodies against 
DNAse B rather than A, C or D result in the strongest response during streptococcal 
infections (Wannamaker., 1959). The benefit of anti-DNAse B is that the antibody 
response is still detectable later on in the disease course compared to ASOT and is more 
pronounced (Tiesler et al., 1976). Anti-DNAse titres are not thought to reach their 
maximum titre until 6 to 8 weeks after acute infection (Kaplan et al., 1974). Other 
surrogate markers exist such as anti-hyaluronidase, although it closely mirrors that of 
anti-DNAse B and adds little to the diagnostic utility of the anti-DNAse B test.
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ASOT and DNAse B titres are both measured in serum samples, usually by particle 
agglutination, enzyme-linked immunoassays or the increasingly common, rate 
nephelometry methods. A streptococcal serology result is considered raised if the level is 
above the upper-limit of normal for a population (Kaplan et al., 1998). Recently it has 
been proposed that cut-off limits should be used in conjunction with age ranges, as raised 
streptococcal serology is usually undetectable in neonates and infants and mean normal 
values also fall in adults (Igari et al., 1983; Klein et al., 1971; Renneberg et al., 1989). A 
World Heath Organization standard exists for ASOT (ASOT <200IU/mL), (Spaun etal., 
1961). A normal value for anti-DNAse B is considered by most UK laboratories to be 
<300 IU/mL and results are usually reported as international units per millilitre (IU/mL).
1.10 Post-streptococcal immune-mediated syndromes 
There are a number of post-streptococcal, immune-mediated clinical syndromes which 
have been suggested as being autoimmune. They are typically latent or delayed 
manifestations of infection occurring weeks to months after acute infection and are 
thought to be caused by GABHS triggering a hyperimmune or autoimmune reaction. 
These syndromes include post-streptococcal glomerulonephritis (PSGN), vasculitides 
such as Kawasaki’s syndrome, reactive arthritis (PSA), rheumatic fever (RHF) and 
Sydenham’s chorea.
1.10.1 Post-streptococcal glomerulonephritis 
Post-streptococcal glomerulonephritis (PSGN) usually occurs in a minority of people 3-6 
weeks after infection with a nephritogenic strain of GABHS (Nissenson et al., 1979). The
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clinical presentation is variable but the most common features are: oedema, haematuria, 
back pain, malaise and disruption of normal kidney function (Norstrand et al., 1999; 
White etal., 2001).
The pathophysiology of PSGN has been studied in depth using histological methods 
which showed that there is an early infiltration of white blood cells with a preponderance 
of CD4+ lymphocytes, deposition of IgG and complement component C3 within the 
mesangium and capillaries of the kidney (Matsell et al., 1994; Parra et al., 1984). 
Initiation of this immune response may be triggered by deposition of erythrogenic toxin 
B within the glomeruli which triggers a local inflammatory reaction perhaps causing 
innocent bystander damage (Rincon et al., 2003; Treser et a l, 1969). Alternatively M 
protein from GABHS has been identified as part of immune complexes found in the renal 
glomeruli of PSGN patients (Kantor e/a/., 1965; Nordstrand et al., 1996). Immune 
complexes are highly immunogenic and may cause secondary inflammation in the 
glomeruli resulting in impaired renal function. Nephritogenic strains of GABHS also 
produce streptokinase and proteinases which have been shown to deposit in and alter 
glomerular architecture (Cu et al., 1998; Norstrand et al., 1998; Nordstrand et al., 1999; 
Peake et al., 1991). It is possible that all these mechanism are involved in PSGN and each 
may be important in different stages of the disease (acute, chronic and relapses). The 
majority of the studies have all found that streptococcal proteins either on the cell surface 
or extracellular are important in the pathogenesis of PSGN.
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In addition to T-lymphocyte responses and complement activation, antibodies may also 
be important in streptococcal immune mediated syndromes. Autoantibodies have been 
identified in post-streptococ’cal syndromes and may play a functional role. Antibodies 
directed against glomerular heparin sulphate proteoglycan have been shown to bind to 
mammalian and streptococcal hyaluronate, and have been reported in PSGN (Fillit et al., 
1985). Similarities in amino acid sequences and structure between streptococcal and 
human proteins have been described, such as the similarities between the coiled, coil 
structure of cardiac myosin, laminin and M protein (Cunningham et al., 1993; Manjula et 
al., 1985). These cross-reactive antibodies might serve to boost or prolong the immune 
response or may have a direct cytotoxic effect on tissue or, through the action of 
complement, cause localised inflammation and initiate an immune response.
1.10.2 Post-streptococcal arthritis 
Arthritis is usually a major symptom of rheumatic fever (Special Writing Group of the 
Committee of Rheumatic fever., 1992) but isolated post-streptococcal, reactive arthritis 
affects young children and adolescents, causing pain and inflammation of joints and can 
relapse several times or lead to chronic arthritis (Ayoub et al., 2000; Iglesias-Gamarra et 
al., 2001).
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1.11 Rheumatic Fever 
Rheumatic fever (RHF) is a serious consequence of GABHS infection of the upper 
respiratory tract and there is a worldwide distribution of disease (Peter et al., 1977; Smith 
et al., 1993). The incidence of RHF has dramatically declined in developed countries 
since the 1940’s probably due to better sanitation, healthcare and introduction of 
antibiotics. Nevertheless several outbreaks of RHF have occurred recently in western 
countries, underlying the importance of the disease and the differences in virulence 
between streptococcal strains (Bonora et al., 1989; Veasy et al., 1994; Wallace et al., 
1989). There is also evidence that susceptibility to RHF may have a genetic element since 
RHF occurs 4-8 times more frequently in relatives of patients who have had RHF (Read 
et al., 1938; Wilson et al., 1954). It has been suggested that familial susceptibility might 
be inferred by the presence of an autosomal recessive gene (Wilson et al., 1954).
Later studies have suggested that genetic factors may be more important in the clinical 
manifestations of post-streptococcal disease than in susceptibility to RHF (Di Sciascio et 
al., 1980; Gibofsky et al., 1998). For example, in comparison with rates of RHF, arthritis 
and Sydenham’s chorea (discussed later) were found to be more concordant in 
monozygotic than dizygotic twins (DiSciascio et al., 1980). Attention has instead focused 
on finding a HLA trait marker for disease, but no single specific locus has yet emerged, 
although this may be related to population and ethnic differences. Attention has recently 
focused on a B-cell marker (D8/17) which was identified in patients with RHF (Herdy et 
al., 1992; Khanna etal., 1989; Taneja etal., 1989; Zabriskie etal., 1985). This marker
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has been found in 100% of patients with RHF in one study but only 20-64% in another 
study, compared to 5-15% in controls (Herdy et al., 1992; Khanna et al., 1989).
RHF is an important model of the pathophysiology of post-streptococcal autoimmune 
syndromes because of the range of symptoms that are associated with it. Apart from 
familial or genetic traits, there may be an immune pre-disposition to developing RHF as 
people with innate immune hyper-responsiveness to vaccines and streptococcal antigens 
appear to be at greater risk for developing RHF or other post-streptococcal immune 
complications compared to controls (Ayoub et al., 1980; Dudding., 1968; Meiselas et al., 
Rejholec., 1957; Shulman et al., 1974). It has been shown that those patients with high 
antibody responses against brucella vaccines are more likely to develop RHF compared 
to age/sex matched controls (Rejholec., 1957; Meiselas et al., 1961). It has also been 
proposed that patients with RHF and valvular disease have higher antibody titres against 
a number of streptococcal antigens in comparison to patients with uncomplicated 
GABHS pharyngitis (Dudding et al., 1968; Shulman et al., 1974). This may support a 
tendency to immune hyper-responsiveness against the streptococcal bacteria, which could 
be linked to induction of post-streptococcal autoimmunity, due to failure of immune 
tolerance or regulation.
1.11.1 Diagnosis o f rheumatic fever 
Correct diagnosis of RHF is essential as it can cause permanent cardiac valvular damage, 
can recur after further infections leading to cumulative damage. Clinical criteria were 
developed in 1944 (Jones., 1944), (A high probability of diagnosis can be made using the
55
revised Jones criteria of 1992), (Special Writing Group of the Committee of Rheumatic 
fever., 1992). Diagnosis requires the fulfilment of 2 major criteria or 1 major and 2 minor 
criterions (Special Writing Group of the Committee of Rheumatic fever., 1992), (Table 1- 
1).
Table 1-1 The Jones criteria for diagnosing Rheumatic fever
Major Jones criteria Minor Jones criteria
Arthritis Fever
Carditis Arthralgia
Chorea Elevated acute phase proteins (CRP, ESR)
Erythema Marginatum Abnormal EEG (prolonged PR interval)
Skin nodules • Evidence of GABHS (throat culture and/ or
positive serology)
The major complication of RHF is carditis, which can lead to death in the acute stage 
(Special Writing Group of the Committee of Rheumatic fever., 1992). Carditis is usually 
associated with a murmur at the cardiac apex which indicates mitral valve involvement, 
which is the common site of cardiac inflammation. Pericarditis and congestive heart 
failure are relatively rare complications but can lead to sudden death. In addition to 
carditis, arthritis is a common manifestation and is associated with severe pain and 
progressively affects the major joints of the extremities (migratory polyarthritis), (Special 
Writing Group of the Committee of Rheumatic fever., 1992). The skin rash of RHF 
(erythema marginatum) is an early clinical manifestation which typically begins as bright 
pink spots on the trunk but sparing the face (Special Writing Group of the Committee of
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Rheumatic fever., 1992). Painless subcutaneous nodules are very uncommon but present 
on the extensor surface of the major joints. The last major clinical criterion is chorea, 
which is a disorder of the central nervous system (CNS), and also termed Sydenham’s 
chorea (Aron., eta l 1965).
The minor RHF diagnostic criteria are fever, arthralgia and laboratory abnormalities such 
as elevated acute phase proteins (C-reactive protein and erythrocyte sedimentation rate), 
(Special Writing Group of the Committee of Rheumatic fever., 1992). A prolonged PR 
interval on electrocardiogram (ECG) shows interruption of normal cardiac function. Only 
25% of RHF patients have a positive throat culture for GABHS at the time of diagnosis, 
so streptococcal serology tests are used as a surrogate marker of infection (Special 
Writing Group of the Committee of Rheumatic fever., 1992).
1.11.2 Immune system and Rheumatic fever 
Apart from streptococcal antibody responses, autoantibodies directed against the heart 
have also been identified in the serum from patients with RHF using an indirect 
immunofluorescence technique (Cavelti., 1945). Immunoglobulins have also been found 
deposited in the cardiac tissue of patients who died from RHF suggesting a role for 
antibodies in pathogenesis (Kaplan et al 1964). These anti-myocardial antibodies have 
been shown to react against important structural components: myosin, tropomyosin and 
sarcolemmal sheath proteins (Dale JB et al., 1982; Khanna et al., 1992; Krisher et al., 
1985; Quinn A et al., 1998).
Myosin has been considered to be the most important antigen in RHF due to the 
recognition of anti-myosin antibodies in patients with RHF and their cross-reactivity with 
the M protein on the streptococcal surface (Cunningham et al., 1988; Cunningham et al., 
1989; Cunningham., 2003; Dale JB etal., 1985). Immunisation of mice and rats against 
myosin has resulted in experimental myocarditis, confirming it is an important 
autoantigen in the pathogenesis of RHF, although the exact mechanism is unclear 
(Kodama etal., 1991; Neu etal., 1987). An amino acid sequence (Gln-Lys-Ser-Lys-Gly) 
has been identified that is common to both the structure of streptococcal M protein and 
myosin, and could possibly trigger the anti-myosin antibody response seen in RHF 
(Cunningham et al., 1989). Interestingly the M protein, myosin and tropomyosin share a 
similar structure as all are coiled a-helical proteins (Cunningham et al., 1993).
Mice immunized with streptococcal M proteins have been shown to produce antibodies 
which react against both myosin and tropomyosin (Fenderson et al., 1989; Mertens et al., 
2000). Mice immunised with streptococcal M protein produce monoclonal antibodies that 
have been reported to be cytotoxic to cardiac cells but only in the presence of 
complement (Adderson etal., 1998; Cunningham etal., 1992). Anti-myocardial 
antibodies could therefore be directly cytotoxic; causing the tissue damage associated 
with RHF. However, transfer of the heart/streptococcal reactive antibodies into animal 
models has not always caused carditis (Smith et a l, 1993; Zabriskie., 1966; Zabriskie et 
a l, 1970). Anti-cardiac antibodies have also been reported following cardiac surgery so 
they are not unique to RHF (de Scheerder et al., 1989). It is possible that anti-myosin 
antibodies are produced as a consequence of myosin being exposed from myocardial cells
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that have been damaged by another process. This may be indicated by the presence of 
antibodies within myocardial cells as well as surrounding them (Kaplan et al., 1964) and 
the production of myocardial autoantibodies following surgery (de Scheerder et al.,
1989).
The alternative role of anti-myocardial antibodies is to aid or perpetuate an autoimmune 
mediated, streptococcal driven CTL response against cardiac antigens. Studies of human 
monoclonal, anti-myocardial antibodies have found that in addition to myosin, 
autoantibodies also recognise the antigen: N-acetyl-p-D-glucosamine (GlcNAc), 
(Shikhman et al., 1994). Affinity-purified human anti-myosin antibodies have been 
shown to react with GlcNAc and also cross-react with streptococcal M protein 
(Cunningham et al., 1988). Interestingly it has been found that these antibodies also 
cross-react with connective tissue components, Vimentin and Keratin, suggesting they are 
not monospecific (Shikman et al., 1993; Shikman et al., 1994). A further study has also 
shown that a ‘monoclonal’ antibody reactive against myosin also recognises GlcNAc, is 
cytotoxic for endothelial cells but also reacts with the extracellular matrix protein, 
Laminin (Galvin et al., 2002). This could mean that the antigenic epitope(s) recognised 
by the myocardial antibodies define cytotoxicity or the ability to affect the basement 
membrane and hence vasculature. Anti-myocardial antibodies may have an effect on the 
vascular endothelium causing damage and up-regulation of adhesion molecules which aid 
the recruitment of T-cells, because of the poly specific moieties of the myocardial 
autoantibodies (Cunningham etal., 1986; Cunningham., 2003; Galvin etal., 2000;
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Gulizia et al., 1991). Therefore, it appears to be the common reactive antigen, myosin is 
not necessarily the most important pathologically.
Monoclonal anti-myosin antibodies raised in mouse models, especially monoclonal 
antibody (36.2.2) have, like the human antibodies, been shown to be reactive to 
endothelial antigens, including the vascular epitopes such as laminin (Antone e ta l,  1997; 
Gulizia et al., 1991). The polyspecificity of anti-myocardial antibodies may be an 
important mechanism in the pathogenesis of RHF as studying anti-myosin antibodies 
from patients with RHF and valvular disease showed that the antibodies also reacted with 
valvular endothelium. This affected vascular permeability and recruitment of immune 
mediators into the valve tissue (Galvin et al., 2000; Gulizia et al., 1991). Activation of 
the endothelium by these antibodies may aid cellular infiltration of the valve and expose 
myosin and other cardiac antigens to the immune system (Cunningham., 2003). Therefore 
antibodies may be directly pathogenic to cardiac cells in the early phase of the disease but 
are more important in aiding infiltration of CTLs and causing widespread damage such as 
valvulitis at a later stage.
In addition to antibodies, T-lymphocytes may be important and perhaps central to the 
pathogenesis of RHF. Patients with RHF have been reported to have heightened skin 
responses against streptococcal antigens when compared to controls and may show the 
importance of T-cells in the pathogenesis of RHF (Smith et al., 1993; Humphrey et al., 
1949). T cells from patients with RHF have been shown to be highly reactive against 
streptococcal antigens compared to T-cells from controls (Gray et al., 1981; Guilherme et
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al., 2001; Read etal., 1974). Increases in streptococcal-activated CD4+ T lymphocytes 
have been reported by some in the peripheral blood of RHF patients, although others 
have shown a decrease in lymphocyte proliferation (Morris et al., 1993; Bahr et al.,
1991). This discrepancy may be related to the fact that myocardial autoantibodies can 
transiently block lymphocyte proliferation (Bhatia et al., 1989) so although antibodies 
may not be directly responsible for all the damage to heart tissue their presence certainly 
modulates the disease process.
Lymphocytes from patients with RHF have been shown to be cytotoxic to cardiac cells 
in- vitro (Friedman et al., 1971; Yang et al., 1977), as has stimulation of peripheral T 
cells with M protein (Dale et al., 1987). Transfer of an experimental myocarditis-like 
disease into animals has also been achieved through the transfer of T-lymphocytes that 
were reactive to heart and streptococcal antigens and probably caused CTL mediated 
cellular damage (Neu et al., 1990; Smith et al., 1993; Quinn et al., 2001). Only a few 
studies have investigated whether CTL isolated from human RHF patients are specific 
against myosin, other cardiac antigens or streptococcal epitopes (Guilherme et al., 1995; 
Pruksakom et al., 1994). A link between streptococcus and the CTL response has only 
been reported in studies in RHF cardiac valvular disease, either through T-cells isolated 
from valve tissue of RHF patients (Guilherme et al., 1995) or a study showing reactivity 
of myosin activated T-cells to streptococcal M protein-5 (Galvin et al., 2002). Isolated T- 
cells clones have also been found to be reactive to the same M-5 protein of the 
streptococcus, which is of a serotype, associated with RHF (Guilherme et al., 1995). M
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protein has also been proposed as a superantigen for T-cells, perhaps activating cells non- 
specifically via the V-beta portion of the T-cell receptor (Watanabe-Ohnishi et al., 1994).
Further evidence of the importance of cell-mediated pathogenesis in RHF comes from 
histopathological studies of hearts from patients who have died from RHF. An infiltration 
of lymphocytes, macrophages and mast cells, although predominantly CD4+ lymphocytic 
infiltrates, have been reported in RHF (Marboe et al., 1985; Raizada et al., 1983). 
Histological studies have also shown an increase in HLA-DR expression on both the 
infiltrating leucocytes and the surrounding vascular endothelium (Kemeny et al., 1989). 
However, the exact relationship between streptococcal infection, antibody production, 
CTL response and autoantigens remains uncertain.
1.11.3 Detection o f anti-myocardial antibodies in Rheumatic fever 
Despite the controversy surrounding the pathological role of anti-myocardial antibodies 
they are a useful immunodiagnostic tool in RHF. The standard method for detecting anti­
myocardial antibodies is IF (Cavelti., 1945). Fluorescent staining produces a 
characteristic appearance of striations in the presence of IgG or IgM autoantibodies. Anti­
myocardial antibodies which react against myosin have been reported in RHF but the 
presence of these antibodies in neurological manifestations of GABHS has not been 
studied.
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1.12 Neurological manifestations of streptococcal infections
The neurological manifestations of GABHS infection include meningitis, meningo­
encephalitis and acute disseminated encephalitis (van de Beek D et al., 2002; Pergami et 
al., 1996). These are rare complications and mainly effect neonates, young children or 
adults with immune-deficiencies.
The classical neurological manifestation is Sydenham’s chorea (SC) which is an acute 
onset movement disorder resulting from involvement of an area of the brain, the striatum, 
which controls movement and influences mood.
1.13 The striatum (basal ganglia)
The basal ganglia actually refer to a collection of nuclei which are located in the centre of 
the brain (deep grey matter). They include the caudate nucleus, putamen, globus pallidus 
and the subthalamic nucleus (part of the thalamus) and are collectively referred to as the 
striatum. The basal ganglia have been considered an important area in motor control of 
musculature since the 19 century (Ferrier., 1876). In addition to motor function the basal 
ganglia are also involved in emotional, behavioural and cognitive functions (Alexander et 
a l, 1986; Brown et al., 1999; Nakano., 2000; Rolls., 1994).The basal ganglia do not have 
direct output connections to the spinal cord so the motor functions are mediated through 
the pyramidal system of neurones (Percheron et al., 1994), (Fig 1-2).
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Figure 1-2 Direct and indirect pathways through the basal ganglia, resulting (under 
non-pathological states) in a balance between excitation and inhibition
(Graybiel, 2001)
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The neurons comprising the basal ganglia are arranged in a complex system but the 
efferent neurons are GABAergic medium spiny neurones (Parent etal., 1993). These 
neurones contain the inhibitory neurotransmitter gamma-amino-butyric acid (GABA) and 
can be typed depending on the dopamine receptor type they contain (Albin et al., 1989; 
Ribak et al., 1979). Neuronal function within the basal ganglia is modulated by
dopaminergic innervations from both within and outside the striatum, especially from the 
substantia nigra (Cossete et al., 1999). The main transmission system of the basal ganglia 
originates in the neocortex and the basal ganglia receive inputs from the associative areas 
of the neocortex and sensori-motor cortex (Gerfen., 1984; Haber et al., 1995). The cortex 
utilises glutamate as the neurotransmitter and interact with the medium spiny neurones in 
the striatum (Bouyer et al., 1984; Cherubini et al., 1998).
The consequences of disorders affecting the basal ganglia are not completely understood 
but include hypo and hyperkinetic movement abnormalities and a range of 
neuropsychiatric symptoms. The neurotoxin, l-methyl-4-phenyl-l,2,3,6- 
tetrahydropyridine (MPTP) has given some insights into the relationship of the basal 
ganglia to Parkinson’s disease (PD), a classical hypokinetic movement disorder 
characterised by rigidity and slow movements. MPTP causes extensive neuronal 
dopaminergic degeneration and a Parkinsonian phenotype due to over-reactivity of the 
neurones in the striatum and dysregulation of dopaminergic neurones (Herrero et al., 
1993).
Overt damage to the basal ganglia resulting in tissue lesions results from infections, 
tumours, vascular disorders, genetic disorders and trauma. Such lesions commonly result 
in apathy and loss of self initiative (abulia). The movement disorder dystonia, an 
extrapyramidal movement disorder with slow and sustained muscle contractions, is also 
common (Bhatia et al., 1994; Fahn., 1988). The other common outcomes of basal ganglia 
lesions are chorea (fast, purposeless movements-hyperkinetic disorder) and athetoid-type
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movement disorder (slow, sinuous movements), (Destee etal., 1990; Denny-Brown., 
1968). Diseases of the basal ganglia associated with progressive neuronal loss and a 
genetic pathogenesis or association, include Huntington’s disease. This is typically a 
progressive hyperkinetic movement disorder with associated cognitive loss and dementia 
(Graveland etal., 1985).Wilson’s disease, involving abnormal copper metabolism, is 
another genetic disorder associated with degeneration of the putamen and globus pallidus 
causing tremor and rigidity (Giagheddu et al., 2001; Wilson., 1912).
The basal ganglia are also involved in behavioural and emotional processing (Alexander 
et al., 1986; Brown et al., 1999; Nakano., 2000; Rolls., 1994). Lesions in the basal 
ganglia have also been related to the clinical onset of abulia, depression, disinhibition and 
confusion (Bhatia et al., 1994). Psychiatric symptoms such as obsessive-compulsive and 
behavioural abnormalities have also been described associated with basal ganglia lesions 
(Laplane et al., 1989). The reason for the psychiatric abnormalities is that basal ganglia 
circuits have functional roles in occulomotor, pre-frontal, and cingulate pathways which 
are central to attention, learning and behavioural control (Brown et al., 1999; Gerfen., 
1984; Haber et al., 1995; Yamashiro et al., 1997). Disruption in these circuits can 
therefore result in a range of extrapyramidal movement disorders and neuropsychiatric 
symptoms of which Sydenham’s chorea is a good example. This disorder has been 
proposed as having an immune mediated pathogenesis.
1.14 Sydenham’s chorea
Sir Thomas Sydenham described the extrapyramidal movement disorder (chorea) named 
after him in 1686 (Sydenham., 1848). Chorea was described as ‘unsteadiness and 
convulsions of movements’ which mainly affected the arms and legs. The movements 
were reported to be difficult to control or stop, and distinguished the disease from the 
form of religious dancing mania prevalent at the time (St Vitus dance) (Dale., 2003; 
Jummani etal., 2001). There was speculation until the 19th century that Sydenham’s 
chorea (SC) was the same as Huntington’s disease (HD) which also presents with chorea, 
but they are now recognised as clearly different diseases. (Aron et al., 1965; Dale et al., 
2003; Jummani et al., 2001). It was not until the 19th century however that a link between 
infection and SC was made, with the discovery that a large number of patients with SC 
had rheumatic fever (Bouteille., 1810). Epidemiological studies have confirmed the 
relationship between GABHS infection, RHF and SC (Aron et al., 1965; Ayoub etal., 
1966; Taranta et al., 1956). SC is a major diagnostic feature of RHF (Jones., 1935; 
Special Writing Group of the Committee of Rheumatic fever., 1992) and may be a 
complication of RHF or a separate syndrome.
In common with other streptococcal pathologies there appears to be a limited number of 
strains associated with most cases of SC, typically M5, M6, M l9 and M24 (Bronze et al., 
1993), although other strains or groups may be involved. Throat culture for GABHS is 
positive in 25%- 40% of patients with SC (Special Writing Group of the Committee of 
Rheumatic fever., 1992; Moore., 1996). Serotyping and strain tracking of GABHS 
infection(s) is complicated due to the latency of SC and RHF, which makes isolating the
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organism in culture difficult (Taranta et al., 1956; Cardoso et al., 1993; Swedo et al., 
1993). The latency also means that other laboratory evidence of GABHS infection such 
as serology is not always positive. For example ASOT has been reported to be raised in 
18-100% of SC patients depending on the study (Ayoub et al., 1966; Eshel et al., 1993; 
Moore., 1996). Other surrogate markers of inflammation such as the erythrocyte 
sedimentation rate and C-reactive protein can also be normal (Ayoub et a l, 1966; Special 
Writing Group of the Committee of Rheumatic fever., 1992; Shiffman., 1995).
SC is now considered to be a classic CNS manifestation occurring post-GABHS infection 
and is one of the major Jones criteria for the clinical diagnosis of RHF (Jones., 1945; 
Special Writing Group of the Committee of Rheumatic fever., 1992). SC is reported to 
occur in 20-30% of patients with RHF and is usually latent, occurring up to 6 months 
after the acute infection, but may sometimes be the primary diagnostic symptom of RHF 
(Aron etal., 1965; Cardoso etal., 1997; Swedo etal., 1993; Terreri etal., 2002). SC is 
more common in females than males (Aron et al., 1965; Money., 1883; Swedo et al., 
1993) and most patients are children, below 18 years of age (Moore., 1996; Thayer et al., 
1906). Adult onset of SC is comparatively rare and most of the adult cases are associated 
with exacerbation of chorea following childhood SC.
SC is characterised by the acute onset (sometimes a few hours) of motor symptoms, 
classically chorea, usually affecting all limbs. Other motor symptoms include facial 
grimacing, hypotonia, loss of fine motor control and a gait disturbance (Aron et a l, 1965; 
Creak et al., 1935; Kerbeshian et al., 1990; Mercadante et al., 2000; Swedo et al., 1993). 
Fifty percent of patients with acute SC spontaneously recover between 2 to 6 months
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(Cardoso etal., 1993; Swedo etal., 1993). Mild or moderate chorea or other motor 
symptoms can persist for up to and over 2 years in some cases (Cardoso etal., 1993;
Gibb etal., 1985)
Recurrences of SC in childhood have been reported with the relapse rate reaching as high 
as 59% after 29 years of follow up in 1 study (Jones et al., 1935). Re-exacerbation of 
chorea has also been associated with pregnancy (chorea gravidarum) with the majority of 
cases having had a previous history of SC (Beresford etal., 1950; Cardoso., 2002). This 
may be influenced by infection, host susceptibility or more likely alterations in hormonal 
networks during pregnancy (Cardoso et al., 1993; Cardoso et al., 2002). Residual 
dopaminergic sensitivity following SC has also been reported (Nausieda et al., 1983).
This may indicate a potential cause of relapsing SC and chorea gravidarum, due to 
neuronal damage which occurred in the acute disease. This residual damage could 
manifest as chorea as a consequence of ageing. Re-exacerbation of SC has been reported 
to occur despite penicillin prophylaxis (Terreri et al., 2002). This may also indicate the 
presence of subtle neuronal damage or perhaps failure of penicillin to protect from further 
streptococcal infections and recurrences of RHF (Murphy et al., 2000).
Psychiatric manifestations are also common in SC (Freeman et al., 1965;
Moore., 1996; Swedo etal., 1993). In one study 75% of patients were found to have co- 
morbid acute onset of obsessive-compulsive disorder (OCD), anxiety, depression and 
disruptive behaviour which persisted after resolution of the motor symptoms (Freeman et 
al., 1965). Recent studies have suggested that OCD is the most common psychiatric
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finding in SC (Swedo et al., 1989) and an increasingly common presentation in those 
patients with relapsing SC (Asbahr et al., 1999). A recent study looked at patients with 
RHF without chorea and found a high incidence of psychiatric symptoms including OCD 
(Mercadante et al., 2000). The prevalence of OCD in RHF and acute and relapsing SC 
could therefore have implications in understanding the pathogenesis of idiopathic OCD 
and other emotional disorders and supports a pathophysiological link between RHF and 
SC.
Due to the rapid treatment of pharyngitis in Western countries with penicillin to prevent 
post-streptococcal complications, SC has become rare, although it is still a common cause 
of chorea and heart disease in children in developing countries (Cardoso et al., 1993; 
Cardoso et al., 1997; Kulkami et al., 1996; Swedo et al., 1993). However, increases in 
the incidence of SC have also been reported unrelated to changes in healthcare (Goldberg 
et al., 1993). Outbreaks of SC have recently been reported in developed countries even 
amongst communities with good access to healthcare, although this worldwide increase 
could be coincidental, it could also, suggest the emergence of highly pathogenic or 
antibiotic resistant strains (Ayoub., 1992).
1.14.1 Pathology studies o f Sydenham’s chorea brains 
Due to the non-fatal course of SC, pathological studies of brain abnormalities have been 
rare and those that exist may only reflect severe or complicated cases, or inadvertently 
include cases of encephalitis, metabolic or genetic syndromes. The pathology reports all 
found abnormalities mostly localised in the basal ganglia, which included cellular
infiltration and neuronal loss with relative sparing of other brain areas (Colony et al., 
1956; Marie et al., 1920), (Table 1-2). These focal changes have also been reported in the 
context of diffuse neuronal loss, which was the predominant feature, and an encephalitic 
pathogenesis was proposed (Greenfield etal., 1922), (Table 1-2). The consistent findings 
appeared to be specific abnormalities of the basal ganglia with conflicting evidence 
regarding disseminated brain pathogenesis (Table 1-2). The clinical similarities of SC to 
HD may have influenced early reports of degenerative changes in SC brains (Table 1-2). 
However the similarities of SC to HD and the recognition of the basal ganglia as an area 
controlling movement, lead to the hypothesis that the basal ganglia were also the central 
area of pathogenesis causing SC (Aron., 1965; Jummani et al., 2001; Dale RC., 2003).
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Table 1-2 Pathological reports in Sydenham’s chorea
Reference
Delcourt, Sand, 1908
Guizzetti, Camisa, 1911 
Harvier, Levaditi, 1920
Marie, TreitiakofF 1920
Greenfield, Wolfsohn, 1922
Lewy etal., 1923 
Ziegler, 1927 
Lhermitte, Pagniez, 1930 
Von Santha, 1932
Glaser, 1952 
Colony etal., 1956
Pathology
Inflammatory
Inflammatory & vascular 
Inflammatory
Inflammatory
Inflammatory
Inflammatory
Degenerative
Inflammatory/degenerative
Vascular
Vascular
?Degenerative
Conclusions
Perivascular inflammation 
of basal ganglia and cortex 
Disseminated encephalitis 
Perivascular inflammation 
of mesencephalon 
Perivascular inflammation 
of basal ganglia 
Perivascular inflammation 
of basal ganglia and cortex 
Widespread 
Basal ganglia 
Basal ganglia 
Encephalitic
Inflammatory features 
Cortex & Thalamic 
involvement
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1.14.2 Imaging studies in Sydenham’s chorea
Brain imaging studies have been reported as normal in most cases of SC, casting doubt as 
to whether widespread neuronal loss is an important feature of the disease, although this 
does not rule out subtle alterations in neuronal function (Dale RC., 2003; Giedd et al., 
1995; Swedo etal., 1993). Only rarely have suspected inflammatory changes seen on 
MRI, been associated with SC, and these have been predominantly localised to the basal 
ganglia (Castillo et al., 1999; Kienzle et al., 1991; Robertson et al., 2002). These cases of 
SC have been shown to be reversible with disease remission, suggesting that temporary 
neuronal disruption rather than neuronal loss is a likely mechanism of pathogenesis 
(Giedd et al., 1996; Trail et al., 1995). One study reported an increased association 
between MRI and basal ganglia abnormalities, in SC patients who had repeated episodes 
of chorea during a 1-year study (Faustino et al., 2003/ The reports of MRI lesions in 
some cases of SC may be linked to severe disease spectrum or a tendency of SC to recur 
or become persistent in some patients.
Volumetric imaging studies have also confirmed basal ganglia (caudate nucleus and 
putamen) involvement in SC. The basal ganglia have been reported to be enlarged during 
acute SC compared to controls which may suggest inflammation (Giedd et al., 1995). 
Further evidence for basal ganglia involvement in SC has come from magnetic resonance 
spectroscopy studies which have shown increased glucose turnover and 
hypermetabolism, which could suggest that alterations in local metabolism are important
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(Goldman et al., 1993; Lee et al., 1999; Weindl et al., 1993). It has been shown that these 
metabolic changes can be reversible with disease recovery which may be important in 
light of the reversible volumetric changes (Goldman et al., 1993).
1.15 Pathogenesis of Sydenham’s chorea 
The pathogenesis of SC has shown some similarity to RHF in that SC has also been 
associated with autoantibodies that react both with rheumatogenic strains of streptococci 
and human basal ganglia (Husby et al., 1976). The autoantibody is thought to derive from 
an immune response to streptococcal M or other surface protein, which cross-reacts with 
shared epitope(s) in the basal ganglia (Bronze et al., 1993). The basal ganglia antibody 
response was removed by incubating positive serum with streptococcal membranes 
(Husby et al., 1976). SC has therefore been proposed as another example of autoimmune 
molecular mimicry. The reactive basal ganglia and streptococcal antigens have not been 
identified so any functional or cytotoxic effects are unknown. Initially an IF method 
using human caudate/putamen frozen sections was used for detecting basal ganglia 
antibodies in SC (Husby et al., 1976; Kiessling et al., 1993; Kotby et al., 1998). The 
original description of anti-basal ganglia antibodies (ABGA) reported antibodies that 
reacted against both caudate and subthalamic nuclei in 46% of patients with SC (Husby et 
al., 1976), whilst a later report found 100% positivity in acute and 93% in chronic SC 
patients (Kotby et al., 1998). Due to the inconsistency of these results and the small 
percentage of patients with ABGA in 1 study, the role of antibodies in an autoimmune SC 
model is still unclear.
The latency of disease onset in both RHF and SC supports an autoantibody-mediated 
pathogenesis; where as an immune-mediated cellular response would be more likely to 
result in a rapid onset of symptoms. Unfortunately no cellular studies have been reported 
in SC to date. One study has looked at genetic predisposition to SC but, like RHF, no 
HLA class I and II locus predicted susceptibility to disease (Donadi et al., 2000). In 
common with RHF the B-cell marker D8/17 has also been proposed as a susceptibility 
marker in SC but the identity and function of the marker is unknown (Gibofsky et al., 
1998; Khanna et al., 1989). Further evidence for an immune pathogenesis comes from 
case studies which indicate treatment with immune modulating drugs such as intravenous 
immunoglobulins (IVIG) and steroids are beneficial as they have been shown to decrease 
symptoms (Green., 1978; Cardoso eta l 2003). Identification of the autoreactive antigens 
involved in SC would provide insights into the pathological effect of ABGA on the 
normal function of the basal ganglia circuits. This would allow for improved diagnostic 
tests and monitoring during treatment with immuno-modulating therapies, as antibody 
levels may decline with clinical recovery.
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1.16 Paediatric Autoimmune Neuropsychiatric Disorders Associated with 
Streptococcal infections
As neuropsychiatric symptoms occur commonly in association with SC, it has been 
proposed that disruption to basal ganglia circuits may result in primary psychiatric 
manifestations in addition to the movement disorder commonly seen (Moore., 1996; 
Swedo et al., 1989). It was proposed that there was a possible relationship between 
outbreaks of streptococcal infections and a subsequent increase in children reported with 
acute onset of OCD, attention deficit hyperactivity disorder (ADHD) behavioural 
abnormalities and motor tics (Kiessling etal., 1993; Swedo et al., 1998). Dramatic 
symptom exacerbations were reported in these children following further streptococcal 
infections and recovery of symptoms appeared to mirror that of recovery from infection 
(Swedo et al., 1998). None of the children had evidence of RHF or SC. Subsequently a 
clinical classification was devised: Paediatric Autoimmune Neuropsychiatric Disorders 
Associated with Streptococcal infections (PANDAS), (Swedo etal., 1998). It was 
reported that PANDAS are phenotypically similar if not identical to Tourette’s syndrome 
(Swedo et al., 1998). However the clinical concept of PANDAS remains controversial 
(Kurlan., 1998).
The PANDAS classification is defined as the presence of OCD and/or a tic disorder 
which meets DSM-III-R or DSM-IV criteria with an acute, paediatric (pre-pubescent) 
onset occurring after 3 years of age, with a later episodic course of symptom 
exacerbations and recovery (Swedo et al., 1998). The association with streptococcal
infection(s) was shown by a positive GABHS throat culture with initial raised 
streptococcal serology which declined with clinical recovery (Swedo etal., 1989).
Patients with RHF, SC or other neurological disease were excluded from the study in 
order to meet the clinical diagnosis of PANDAS (Swedo etal., 1998). As a large number 
of patients are excluded by the narrow definition of the PANDAS classification, the 
phenotypic breadth of neuropsychiatric and motor disorder symptoms associated with 
streptococcal infections is currently unknown. In addition to PANDAS (OCD and Tics), a 
clinical description of 3 proposed PANDAS patients with anorexia as the major 
neuropsychiatric presentation has been reported (Sokol., 2000). Recently 2 adult cases 
which conform to a wider definition of PANDAS have been described, expanding the 
proposed syndrome classification (Bodner et al., 2001; Martinelli et al., 2002).
A link between the pathophysiology of SC and PANDAS has been suggested because of 
the temporal association between streptococcal infection and similar neuropsychiatric 
manifestations (Swedo., 1994). A further link between SC and PANDAS has been 
proposed due to the presence of ABGA in PANDAS. To date, this has only been 
investigated in 1 study, which reported that 44% of patients conforming to the PANDAS 
criteria, with childhood OCD and tics were ABGA positive (Kiessling et al., 1993). 
Imaging studies have also suggested that PANDAS in common with SC is also associated 
with volumetric enlargement of the basal ganglia, particularly the caudate and putamen 
with sparing of other brain areas (Giedd et al., 2000; Peterson et al., 2000). Two studies 
have investigated the effects of infusing antibodies from patients with PANDAS into rat 
striatum with both reporting an increase in stereotypical movements (Hallett et al., 2000;
Taylor et al., 2002). However, another group have failed to reproduce this work (Singer 
et al., 2003). The B-cell marker, D8/17 associated with RHF and SC has been reported in 
PANDAS using IF (Murphy et al., 1997; Swedo et al., 1997). Using a more specific flow 
cytometric analysis, D8/17 was also found to be increased but there was considerable 
overlap with controls casting some doubt as to its specificity and hence its ability to 
identify patients with these disorders (Hoekstra et al., 2001).
Further evidence of an immune pathogenesis for PANDAS has come from the results of 
an IVIG and plasma exchange treatment study which showed a decrease in 
neuropsychiatric symptoms with treatment compared to controls, (Perlmutter et al.,
1999). Treatment studies have also investigated the use of antibiotics to clear the 
streptococcal infection or prevent further infections and symptom exacerbations. A 
double blind study using penicillin prophylaxis failed to show clinical benefit (Garvey et 
al., 1999). Unfortunately compliance was reported to be a problem in this study. A 
prospective study of antibiotic use did demonstrate a clinical improvement in OCD 
symptoms (Murphy et al., 2002). Unfortunately this was a descriptive study (Murphy et 
al., 2002) so further appropriately controlled blinded studies are required. The potential 
of GABHS to reside within epithelial cells will influence the choice of antibiotics, dose 
and duration of treatment when conducting studies of this nature.
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1.17 T o u r e tte ’s syn d ro m e
Georges Gilles de la Tourette gave his name to a syndrome which was first described in 
nine patients with a chronic tic disorder, neuropsychiatric and behavioral symptoms 
Tourette’s syndrome (TS) is a neuropsychiatric disease characterised by chronic motor 
tics in addition to 1 or more vocal tics, which begins in childhood and persists in some 
cases to adulthood (Jancovic., 2001; Robertson., 2000). The prevalence of TS is thought 
to be 5 per 10,000 and is much higher in males (3-1, M: F ratio), (Hornsey et al., 2001; 
Kadesjo et al., 2000; Kurlan et al., 2001/ Tics begin in childhood, occur several times a 
day and for a diagnosis of TS must persist for greater than 1 year although fluctuations in 
the severity and presiding type of tic can also occur over several years (Leckman et al., 
1998; Robertson., 2000). TS is ubiquitous throughout the world and its expression is not 
significantly different between cultural or socio-economic groups (Robertson., 2000).
A common feature of TS is the presence of co-morbid neuropsychiatric symptoms 
including OCD, ADHD, amtiety and depression (Jankovic., 2000; Kurlan et al., 2001; 
Robertson., 2000). As with motor symptoms, neuropsychiatric symptoms vary in severity 
and type over time, a typical waxing and waning course being the classic feature of TS. 
The clinical course is typically of a childhood onset (mean age 7 years old) and whilst 
most children have complete or partial resolution of the symptoms on reaching 
adulthood, some patients will have persistent disease (Robertson., 2000). The reason for 
this is not currently understood, but may reflect a different pathogenesis or a particular 
phenotype indicated by permanent brain alterations.
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Large family studies have suggested that TS is, at least partly, genetically determined, 
(Singer., 2000; Robertson., 2000). Early reports supported an autosomal dominant 
inheritance although no gene has yet been identified (Eapen et al., 1994; Kurlan et al., 
1986; Price etal., 1985). A systematic whole-genome screen has revealed 2 regions, 4q 
and 8p, with increased lod scores. These loci might yet reveal TS-related susceptibility 
genes (The TS Association., 1999). However, a multi-factorial aetiology has now been 
proposed with both genetic predisposition and environmental factors (such as infection) 
associated with disease expression (Walkup et al., 1996). The pathogenesis of TS 
remains obscure but is considered to be an inherited neuro-developmental disorder 
resulting in disinhibition of cortico-striatal-thalamic-cortical circuitry (Jankovic., 2001). 
Although a variety of neurotransmitter abnormalities have been implicated in the 
pathogenesis of TS, subtle abnormalities of the dopaminergic system remain the most 
favoured site of pathogenesis (Robertson., 2000; Singer., 2000). As a genetic basis for TS 
has yet to be uncovered, alternative pathological models are being considered and TS 
may yet be due to heterogeneous pathologies (Walkup et al., 1996).
Due to the similarities of the symptoms of PANDAS with TS (waxing/waning tics and 
OCD) it has been suggested that streptococcal infection(s) may also play a role in a 
subgroup of TS patients (Dale., 2003; Swedo et al., 1998). In comparison of PANDAS 
with TS, there is a high prevalence of OCD, anxiety, depression and motor disorders in 
both with recovery of the movement disorder being generally mirrored by recovery of the 
psychiatric symptoms (Swedo etal., 1998). The finding of similar clinical symptoms to
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TS, in the post-streptococcal neurological syndromes, and the fact that they may mimic 
the relapses and remissions in TS, has lead to speculation that a subgroup of patients with 
TS may have post-infectious, autoimmune basal ganglia pathogenesis perhaps 
precipitated by streptococcal infection (Dale., 2003).
Patients with TS have been reported to have significantly higher streptococcal serology 
(ASOT and anti-DNAse B) compared to control subjects (Cardona et al., 2001; Morshed 
et al, 2001; Muller et al., 2000), which may support a post-streptococcal hypothesis in 
some patients. Not all studies have, however, have shown this association and has cast 
doubt on the streptococcal hypothesis of TS (Singer et al., 1998; Singer et al., 1999). 
Preliminary analysis of antibody reactivity to streptococcal M-proteins has demonstrated 
higher titers to M12 and M19, but not to M l, M4 and M6 in 25 adult TS patients 
compared to 25 control subjects (Muller et al., 2001). This may suggest that only certain 
strains are associated with a'subset of TS as has been observed for other streptococcal 
autoimmune diseases (Bronze etal., 1993; Cunningham., 2003; Muller etal., 2001).
Antibodies reactive against basal ganglia neurons have been reported in TS but studies 
have not produced consistent findings, perhaps due to variations in detection 
methodology. Increased antibody binding to putamen rather than caudate neurones has 
been reported in TS using ELISA and Western immunoblotting, and antibody reactivity 
against basal ganglia antigens of molecular weights 60, 67 and 83 kDa was proposed 
(Singer et al., 1998). A second study using Western immunoblotting suggested that 
ABGA bound to 52, 58, 64 and 88 kDa basal ganglia proteins in TS; although a complex
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multivariate analysis was required to establish the association (Wendlandt et ah, 2001). 
Results from another group also suggested that an 83 kDa protein was common in 
patients with TS and OCD, (Trifiletti et ah, 1999; Trifiletti et al 2000). However, not all 
studies have shown similar findings. Two studies using a neuroblastoma cell line as the 
antigen source rather than human basal ganglia found no discriminating antibody 
responses in TS (Morshed et ah, 2001; Singer et ah, 1999). Two other studies using the 
same cell line did however find increased antibody responses in TS (Laurino etal., 1997; 
Wendlandt et ah, 2001). These discordant results could suggest that only a subgroup of 
TS patients have a post-streptococcal autoimmune phenotype, implying that the selection 
and numbers of patients tested for ABGA studies is crucial. Alternatively the differences 
in methodology IF, ELISA and Western immunoblotting may have a significant impact 
on results and the choice of antigen may be important (human basal ganglia vs. cell line). 
Investigations using large cohorts of specimens and detecting the sensitivity and 
specificity of ABGA using several methods may help to solve this issue.
Volumetric MRI studies in TS cohorts have reported basal ganglia asymmetry or 
volumetric abnormalities compared to controls (Moriarty et ah, 1997; Peterson et ah, 
1993). This is similar to that found in PANDAS and SC studies. In addition, some MRI 
studies have also shown that another area of the brain, the corpus callosum was abnormal, 
with changes usually found in males (Baumgardner et ah, 1996; Moriarty et ah, 1997). 
This suggests some patients have predominantly basal ganglia abnormalities whilst others 
have abnormalities of the corpus callosum, and some even have normal appearances on 
imaging. This may also support TS as a heterogeneous disorder. A post-mortem study has
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reported that there may be basal ganglia involvement in some patients, as differences in 
striatal dopamine receptor (D1 and D2) binding was found in TS patients (Singer et al.,
1991). The studies into dopaminergic abnormalities have been somewhat contradictory 
(Robertson., 2000; Singer., 2000) showing further evidence that the pathogenesis of TS 
may be heterogeneous.
1.18 Isolated extrapyramidal syndromes
Although the clinical phenotypes of ABGA-positive individuals include chorea and tics, 
it is not known if these are the only movement disorders associated with ABGA and 
streptococcal infection. No post-streptococcal autoimmune studies have yet been reported 
in dystonia, myoclonus, tremor or parkinsonism or indeed in isolated psychiatric 
disorders.
1.19 Conclusions
Autoimmunity is an important cause of disease, although the exact mechanisms of 
disease induction are sometimes unclear, although viruses and bacteria have been 
implicated. Molecular mimicry is one hypothesis, and the central nervous system 
disorder, Sydenham’s chorea which is post-streptococcal, may be a model of this 
mechanism. Due to similarity of SC with neuropsychiatric disorders, investigating a 
common autoantibody in other CNS disorders is warranted.
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1.20 H y p o th esis
Anti-basal ganglia antibodies are central to the pathogenesis of SC and a significant 
proportion of patients should be positive. If SC is an autoimmune disease there should be 
other indicators of immune activation. Anti-basal ganglia antibodies and evidence of 
streptococcal infection could be important in the pathogenesis of TS as they are proposed 
to be part of a spectrum of post-infectious neuropsychiatric disorders (PANDAS). 
Identification of candidate basal ganglia auto-antigens is important to enable us to 
understand the pathological consequences of ABGA.
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2 Methods
2.1 Aims of the methods
• The presence of anti-basal ganglia antibodies (ABGA) was investigated in SC, 
PANDAS and TS using traditional IF methods against human brain tissue to 
assess previous published results
• To develop ELISA and Western immunoblotting methods to investigate whether 
antibodies bind to proteins of similar molecular weight(s)
• Investigate the evidence for streptococcal infection using throat culture when 
available and surrogate serological markers of infection
• Examine other indicators of autoimmunity, including cytokine levels and 
oligoclonal bands
• Identify candidate autoantigens using proteomic techniques
2.2 Diagnosis of Sydenham’s chorea, PANDAS and Tourette’s 
Sydenham’s chorea
All SC patients were assessed and diagnosed by an associate Professor of Neurology, Dr 
F Cardoso, who recruited the cases from his outpatient paediatric clinic at the Federal 
University of Minas Gerais, Brazil. SC was diagnosed if the patient had acute onset of 
chorea and met the modified Jones criteria for RHF, other causes of chorea having been 
excluded (Jones., 1945; Special Writing Group of the Committee of Rheumatic Fever.,
1992). Acute SC was diagnosed if the patient had chorea lasting less than 2 years 
regardless of the use of neuroleptics and/or valproic acid. Persistent chorea was
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diagnosed if the patient had a diagnosis of acute SC and the chorea lasted 2 or more years 
regardless of the use of neuroleptics and/or valproic acid. A cardiac assessment, including 
ECG was performed in all patients with SC. Evidence of active carditis was present in 
34/48 of the acute SC patients, 2/24 of the persistent SC patients and all of the rheumatic 
fever controls.
PANDAS
The diagnosis of PANDAS was made by a paediatric neurologist, Dr. Russell Dale,
(Great Ormond Street Hospital) according to clinical criteria (Swedo et al., 1998).
Clotted blood samples were taken from patients and controls and centrifuged within one 
hour to collect serum. All samples were stored at -20°C until required. Throat swabs were 
also collected for GABHS or other bacterial identification. Each patient was also 
thoroughly investigated for alternative causes for their disorder which included laboratory 
investigations for: anti-nuclear antibodies, acanthocytes, amino acid disorders, copper 
and caeruloplasmin and, where appropriate genetic screening.
Tourette’s syndrome
All TS patients were diagnosed by Prof. Mary Robertson using standardised instruments 
including the National Hospital Interview Schedule (Robertson MM et al., 1996), the 
Diagnostic Interview Schedule (Robertson et al., 1999) and the Yale Global Tic Severity 
Rating Scale (Leckman et al., 1989). In order to make a diagnosis of TS, patients had to 
satisfy DSM-IV-TR (APA 2000) and ICD-10 (WHO 1992) criteria. Thus, patients had to 
have multiple motor and 1 or more vocal tics, with symptoms lasting longer than 1 year.
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2.3 Samples
The control groups for the SC study were community matched healthy controls. None of 
the SC patients or control groups was or had been on corticosteroids or other 
immunosuppressive treatment regimes. All patients and controls signed consent for the 
study, which was authorised by the local ethics committee (Brazil and United Kingdom). 
Whole (clotted) blood samples from patients with clinically definite acute, persistent SC 
and controls were taken during the same time period 1999-2000. The blood samples 
where centrifuged within 1 hour to separate sera which were pipetted into 200pi aliquots 
and stored at -80°C prior to being couriered to the laboratory on dry ice where they were 
placed in a -80°C freezer until required (Table 2-1).
Table 2-1 Sydenham’s chorea sample demographics (all Brazilian samples)
Group Number Mean age years (range) Sex M/F
Acute SC 34 11.3 (4-20) 8/26
Persistent SC 24 14.4(11-21) 7/17
Rheumatic Fever 20 16.4(13-17) 4/16
Normal controls 40 15.3 (12-17) 18/22
2.3.1 Paired cerebrospinal fluid and serum cohort o f Sydenham’s chorea 
patients from Brazil
To investigate systemic and intrathecal immunological abnormalities in SC, a second 
cohort of patients was recruited (Table 2-2). Paired serum and cerebrospinal fluid (CSF)
samples were taken on the same day and snap-frozen immediately after collection in 
liquid nitrogen and stored at -80 °c until use. All the SC samples were snap-frozen within 
10 minutes of collection and stored at -80°c until the samples were couriered on dry ice to 
the laboratory. No control data for normal CSF cytokine levels had been recorded; 10 
patients with a diagnosis of non-inflammatory, neurological diseases were recruited from 
Great Ormond Street Hospital as controls. These patients were undergoing CSF and 
serum collection as part of their routine investigations and gave consent for the study, 
again authorised by a local ethics committee. The final clinical diagnoses of these 
patients were. Epilepsy (n=2), neurodegenerative disease with dystonia (n=4), benign 
intracranial hypertension (n=2) and dopamine responsive dystonia (n=2). These samples 
were taken during the same time-course (2001-2002) and in the same way as the SC 
patients. The SC and control demographics are presented in table 2-2.
Table 2-2 Sydenham’s chorea: Cerebrospinal fluid and control sample 
demographics
Group Number Sex (M/F) Mean age years (range)
Acute SC 14 2/12 10.2 (4-17)
Persistent SC 4 1/3 13.8(11-21)
Controls 10 4/6 9.8 (2-16)
2.3.2 Patients with Sydenham ’s chorea from the United Kingdom 
Thirteen children with a diagnosis of acute and four with persistent SC were identified 
and recruited from the UK during 1999-2003 to assess whether differences in population 
and access to health care differences influenced streptococcal serology, ABGA positivity
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and clinical outcomes. Other causes of chorea were excluded through careful clinical 
assessment (Neurology, Great Ormond Street Hospital). The patients were diagnosed 
according to the modified Jones criteria (Jones., 1945; Special Writing Group of the 
Committee of Rheumatic Fever., 1992). The patients had an acute onset of a movement 
disorder (chorea) with a clinical history of GABHS infection and/or RHF.
Laboratory testing was performed in each case to exclude other diseases such as SLE, 
vascular or metabolic disease. MRI was performed where clinically appropriate. In each 
case the patient and family signed consent (local ethics permission for the study was 
given) and were assessed and diagnosed by a paediatric neurologist, RCD. Serum was 
stored at -20°c for testing ABGA and streptococcal serology. In addition a throat swab 
was obtained and cultured to detect GABHS or other bacteria. CSF was not obtained 
from any patient.
2.3.3 Control groups used fo r  PANDAS and Tourette ’s studies in children 
For control data, 30 UK children with a diagnosis of development delay were recruited 
from Great Ormond Street Hospital. To investigate ABGA and streptococcal serology in 
other streptococcal autoimmune syndromes; 49 UK children with a clinical diagnosis of 
streptococcal autoimmune diseases (non-neurological disease) were recruited. The 
streptococcal patients had a clinical diagnosis which was supported by laboratory 
findings (throat swab, raised ASOT and DNAse B, exclusion of alternative pathogenesis). 
The clinical phenotypes were: PSGN (n=14 patients), post-streptococcal arthritis (n=15 
patients), vasculitis including; Henoch schonlein purpura (n=5 patients), Kawasaki’s 
syndrome (n=10 patients) and rheumatic fever (n=5 patients). This study was authorised
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by the local ethics committee and controls were recruited during the same time period as 
the SC patients (1999-2003). Twenty millilitres of whole (clotted) blood was taken from 
each patient and control and the serum separated and stored at -80°c until use.
2.3.4 Paediatric autoimmune neuropsychiatric disorders associated with 
streptococcus
UK patients with a diagnosis of PANDAS that conformed to the clinical diagnostic 
criteria (Swedo et al., 1998) were recruited. Patients were recruited by Dr. Russell Dale, 
paediatric neurologist at Great Ormond Street Hospital using the Swedo criteria for a 
diagnosis of PANDAS (Swedo et al., 1998). Patients with chorea or other neurological 
diagnosis were excluded also according to the Swedo criteria (Swedo et al., 1998).
Several control groups were also recruited (Tables 2-3 and 2-4). All patients were 
recruited from the Neurology department at Great Ormond Street Hospital, London. UK. 
All patients and controls signed consent for this study, which was authorised by the local 
ethics committee.
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Table 2-3 Neurology controls for Tourette’s and PANDAS
Dystonic (n=32)
Encephalitis
• Invasive n=5 (HSV, EBV, VZV)
• Inflammatory n=4 (Aicardi Goutiere 
and Coats disease)
• Rasmussen’s encephalitis (n=2)
• SSPE (n=l)
Vascular • Basal ganglia stroke (n=6)
• Vasculitis (n=l)
Metabolic
• Kernicterus, mitochondrial cytopathy, 
Batten’s disease, Lesch Nyhan, 
SanFillipo, Glutaric aciduria type 1 
(n=l each)
Other
• Status dystonicus (n=2), nvCJD, basal 
ganglia tumour, athetoid cerebral palsy, 
drug-induced rigidity, juvenile 
Parkinson’s (n=l each)
Encephalitis with 
no extrapyramidal 
features (n=17)
Invasive • Unidentified organism (n=12), HSV 
(n=2), mycoplasma (n=l), adenoviral 
(n=l), neurocysticosis (n=l)
Immune-mediated 
CNS disorders 
(n=45)
Demyelinating
disorders
• Acute disseminated encephalomyelitis 
(non-streptococcal) (n=16)
• Multiphasic disseminated 
encephalomyelitis (n=2)
• Multiple sclerosis (n=4)
• Optic neuritis (n=3)
‘Autoimmune
disorders’
• Dancing eyes syndrome (n=9)
• Post-infectious ataxia/cerebellitis (n=7)
• Chronic infantile neurological 
cutaneous articular syndrome (CINCA) 
(n=3)
Other neurology 
controls (n=6)
• Epilepsy (n=3), myasthenia gravis 
(n=l), metachromatic leukodystrophy 
(n=l), Bell’s palsy (n=l)
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Table 2-4 Autoimmune controls without apparent neurological complications (n=70)
Clinical phenotype Number Age (range) Sex (M/F)
Rheumatic fever no chorea N=16 9.8(6-15) 5/11
Post-streptococcal glomerulonephritis N=14 11.8(9-16) 8/6
Post-streptococcal vasculitis N=8 13.4(10-17) 3/5
Erythema nodosum N=4 12.4 (9-15) 2/2
Post-streptococcal arthritis N=T5 16.2(11-17) 7/8
Post-streptococcal uveitis N=4 9.9(8-10) 2/2
Juvenile idiopathic arthritis N=4 14.3 (12-16) 3/1
Henoch Schonlein purpura N=3 11.9(10-13) 2/1
Systemic lupus erythematosus, N=2 each 15.6(9-17) 2/6
Kawasaki’s disease, polyarteritis nodosa
and Cogan’s syndrome
2.3.5 Patients with Tourette’s syndrome 
I decided to investigate the hypothesis that some patients with Tourette’s syndrome may 
fulfill the criteria for PANDAS. Children and adults with TS were recruited to investigate 
differences in evidence for a PANDAS-like pathogenesis in different TS age groups. A 
large cohort of patients was screened to assess the proportion with evidence of 
streptococcal infection, by measuring ASOT compared to controls. ABGA was also 
assessed by ELISA, Western immunoblotting and IF. Ethics permission was obtained for 
the cross-sectional study from the National Hospital for Neurology and Neurosurgery and 
the Institute of Neurology’s local ethics committee. The TS patient and control patient 
demographics are presented in Table 2-5.
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Seven TS patients were also recruited for a follow-up study after primary testing. A 
whole blood sample was taken 3 months after the initial blood sample and the serum was 
retested for ABGA and streptococcal serology. This was because the intensity of tics and 
neuropsychiatric symptoms waxes and wanes in TS as it does in PANDAS (Swedo et al., 
1998). It was hypothesised that the exacerbations in TS were related to the presence or 
absence of streptococcal infection(s) which could cause an increase or production of 
ABGA leading to neuronal dysfunction with worsening of TS symptoms.
Table 2-5 Tourette’s syndrome patient and control demographics
Group Number Mean age years (range) Sex (M/F)
Child Tourette’s Syndrome 56 12.8(8-17) 40/16
Adult Tourette’s Syndrome 44 37.8(18-61) 32/12
Child streptococcal infection 50 9.8 (2-15) 25/15
controls
Child neurological controls 50 7.6(0.5-18) 24/26
Adult healthy controls 50 35.6 (19-57) 25/25
Adult neurological controls 50 41.1 (19-70) 30/20
A number of control groups (adults and children) were recruited to assess sensitivity and 
specificity of ABGA and streptococcal serology in the TS study. Recruitment of controls 
occurred during the same time period and samples were stored in the same manner. The 
demographics and clinical definitions of each control group are presented in Tables 2-6, 
2-7, 2-8 and 2-9.
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Table 2-6 Neurological control groups (children) for Tourette and PANDAS
Group Diagnosis Number Mean age in 
years (range)
Sex
(M/F)
Inflammatory 12 10.9(3-13) 5/7
Vascular 6 11.2(5-12) 2/4
Dystonic Metabolic 6 8.9(2-11) 4/2
Genetic 2 7.0 (6-8) 2/0
Encephalitis HSV, VZV, EBV 
and unknown ‘viral’
20 12.2(5-13) 12/8
Other Variant CJD, basal 1 each 10.5 (7-11) 2/2
ganglia tumour, 
cerebral palsy, 
juvenile Parkinson’s 
disease
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Table 2-7 Streptococcal infections (childhood) controls for the PANDAS and SC 
Study__________________________________________________________________
Group Number
GABHS pharyngitis 45
GABHS skin 5
Mean age in years 
(range)
13.8(3-16)
9.9(2-13)
Sex (M/F)
20/25
3/2
infections
Table 2-8 Neurological disease controls (adults) for the Tourette’s study
Group Number Mean age in 
years (range)
Sex (M
Multiple Sclerosis 12 38 (30-52) 2/10
Encephalitis 20 28.9 (19-36) 11/9
Dementia 7 63.6 (55-74) 4/3
Paraneoplastic 3 60 (59-63) 2/1
syndrome
Autoimmune 3 32.5 (29-34) 1/2
Neuropathy
Cerebellitis 3 42 (40-43) 1/2
Other 2 41 (40-42) 1/1
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Table 2-9 Healthy adults recruited from staff in the laboratory staff and the Great 
Ormond Street Hospital for the Tourette’s study
Group Number Mean age in years Sex (M/F)
(range)
Healthy adults 50 35.6(19-57) 25/25
2.3.6 Adult onset movement disorders 
Adult patients with an acute onset movement disorder were recruited from the movement 
disorder clinics at the National Hospital of Neurology and Neurosurgery, London. All 
patients were being routinely investigated for the cause of their movement disorder and 
ethical permission was obtained to investigate the presence of ABGA and streptococcal 
serology. The patient demographics are presented in table 2-10.
Table 2-10 Adult movement disorders: sample demographics
Diagnosis Number Sex (M/F) Age years
(range years)
Primary blepharospasm 7 2/5 38.7 (25-52)
DYT1 positive dystonia 10 4/6 41 (35-45)
Idiopathic dystonia 20 10/10 34 (26-40)
Huntington’s disease 3 2/1 45.6 (35-50)
Tourettism 5 5/0 39.9 (26-45)
To answer the question as to whether ABGA are associated with an autoimmune basal 
ganglia syndrome such as the proposed pathogenesis of SC, adults with a range of 
movement disorders were also investigated. Patients with genetic disorders such as 
Huntington’s disease and DYT (gene) positive dystonia were studied to see if ABGA 
might be epiphenomena to secondary basal ganglia pathogenesis. Primary blepharospasm 
can be associated with autoimmunity in 26% of patients (Jankovic et al., 1993). The 
presence of an inflammatory pathogenesis in these patients may have led to the 
production of autoantibodies against brain tissue such as the basal ganglia so, was also 
investigated. Idiopathic dystonia and adult-onset “Tourettism” were also investigated as 
the range of movement disorders associated with streptococcal infection and ABGA may 
be wider than previously thought.
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2.4 Basic laboratory testing of samples: immunoglobulin measurements
Serum IgG levels were measured by routine rate nephelometry in the SC patients to 
assess whether an increase in polyclonal IgG as a consequence of past streptococcal 
infection may lead to false positive binding to the basal ganglia tissue and lead to 
aberrant results in the ABGA ELISA method. Samples were also tested for ASOT and 
anti-DNAse B.
2.5 In d ire c t  im m u n o flu o rescen ce
2.5.1 Commercial sections 
Sagittal brain sections from rat were purchased from Novagen, Germany. Monkey 
sections were purchased from The Binding Site, UK. Control tissue sections containing 
monkey myocardium (The Binding Site FS215), cerebellum, cerebrum and mouse 
stomach (The Binding Site FS224.A) and mouse liver, kidney and stomach (The Binding 
Site FS313) were purchased commercially. Sections were formalin fixed and prepared for 
IF using standard techniques.
Basic method
• Sera was diluted 1/50 and 1/500 in 0.9% saline and incubated for 30 minutes
• Sections were washed in 0.9% saline for 20 minutes
• Sections were incubated with anti-human IgG conjugated with FITC (Dako) 
diluted according to manufacturers instructions
• Sections were washed in 0.9% saline for 20 minutes
• Sections were mounted in permanent mounting fluid (Dako)
• Sections were screened using a fluorescence microscope (Leitz) the same day
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2.5.2 Human sections 
A tissue block containing human dissected caudate and putamen from the Queen Square 
Neurological Diseases Brain Bank, University College London, was snap-frozen in iso- 
pentane (Fisher Scientific P/1030) and frozen carbon dioxide pellets. A commercial 
preparation of tissue embedding medium, tissue-tek OCT (Sakura Finetek) was used to 
create a tissue block for microtome sectioning. The block was held in place with tissue- 
tek and placed in the freezing iso-pentane to form a frozen tissue block by attaching the 
frozen tissue to a metal chuck which was used to cut sections on a freezing microtome. 
The chuck was kept at -80°C until use and then transferred to the microtome which was 
kept at -20°C to facilitate cutting. The chuck was left for 30 mins to equilibrate and then 
excess tissue tek medium was trimmed from the block using the microtome to reveal the 
longitudinal or transverse section of caudate/putamen or globus pallidus. Briefly, 10 pm 
thick frozen sections were cut from the block and a glass slide was gently placed onto the 
section which was attached to the surface of the slide. The slides were labelled and were 
immediately stored at -80°c.
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2.6 Basic method of indirect immunofluorescence to detect anti-basal
ganglia antibodies 
Basic method
• Tissue sections were allowed to defrost at room temperature for 30 mins before 
use.
• The sections were blocked with 10% normal rabbit serum (Sigma R9133) in 
saline (Sigma P4417), (blocks exposed proteins thereby reducing false positive 
staining) for 30 mins in a damp chamber at room temperature to prevent drying.
• The sections were gently washed and placed in a slide tray containing the same 
PBS wash solution to soak for 20 mins to remove unbound blocking solution.
• The slides were removed from the bath and excess fluid was wiped from around 
the edges of the sections to prevent additional dilutions of sample and detector 
reagents.
• During the blocking step, patient and control serum samples were diluted with 
PBS containing 0.1% rabbit serum. The 1/50, 1/500 diluted samples (200pL) 
were carefully pipetted onto each slide and allowed to incubate for 30 mins in a 
damp chamber
• The serum was gently washed off with PBS and the slide washed with PBS to 
remove excess sera. After 20 mins each slide was removed from the bath and 
excess fluid carefully wiped from around the edges of the section, ensuring the 
section did not dry out.
100
• Rabbit anti-human IgG secondary antibody conjugated with fluorescein 
isothiocynate (FITC), (Dako F0315) was diluted 1/30 with PBS/0.1% rabbit 
serum and applied to each slide to detect antibody binding.
• The sections were washed as previously described. Sections were mounted (see 
appendix) and kept at +4°C in the dark until screened (the same day) using a 
fluorescence microscope (Leitz, UK).
• Sections were assessed for apple-green staining of neurons (Husby et al., 1976) 
and photographs of typical findings from controls and SC patients were taken 
using an attached camera (Olympus, UK).
2.6.1 Identification o f individual cell types 
Differentiation of the cell types on the IF staining patterns such as glial cell population 
(neuronal supporting cells) were identified by testing the same tissue sections with a 
diluted (1/500) monoclonal antibody specific for glial fibrillary acid protein (GFAP), 
(Sternberg Monoclonals Inc). The neurons were identified (stained) by using a diluted 
monoclonal antibody (1/500) specific for neuron-specific enolase (NSE), (Santa Cruz 
biotechnology sc-21737). The staining of neurones and accessory cells was carried out by 
comparing the pattern of fluorescence (FITC secondary detector). The staining pattern 
obtained using the GFAP and NSE monoclonal antibody was compared to that of patient 
serum (IgG) from SC, and PANDAS.
2.6.2 Comparison with previous published immunofluorescence results 
The IF method previous published (Husby et al., 1976; Kotby et al., 1998) was applied to 
the detection of ABGA in SC patients and controls by testing samples from acute SC and 
normal controls undiluted or diluted 1/2 on basal ganglia sections. The sections were then 
assessed by counting the number of stained neurones and grading the intensity of staining 
in both SC and controls as previously proposed (Husby et al., 1976; Kotby et al., 1998). 
To improve on this IF method (background and false positive staining) the standard 
dilution of serum was changed to improve assessment of positivity by enabling the 
differences between positive and negative to be clear through the presence or absence of 
neuronal staining. Serial dilutions of SC and control samples were prepared (1/2, 1/10, 
1/20 and 1/100) in PBS. The optimum serum dilution for testing SC samples by IF was 
assessed as the serum dilution which resulted in the ideal signal to noise ratio of stained 
neurons with low background and the absence of non-specific binding or background 
auto-fluorescence. Positive staining was interpreted as apple-green staining of the basal 
ganglia neurons with sparing of accessory glial cells.
2.7 Systemic (non-brain) autoantibodies 
Rat tissue sections of liver, kidney and stomach (RLS) were used for antibody binding 
with IF to detect systemic autoantibodies. These included anti-nuclear, smooth muscle, 
parietal cell, liver-kidney microsomes, reticulin, mitochondrial and ribosomal antibodies. 
Any positive reactivity or titre was recorded for each patient and control sample tested.
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2.7.I Indirect Immunofluorescence against rat tissue 
Snap-frozen RLS tissue sections (The Binding Site FS313) were used 
Basic method
• SC and controls which were diluted 1/10 and 1/25, pipetted on to each section and 
incubated for 30 mins at room temperature.
• Diluted serum was washed off with PBS and sections were placed in a bath 
containing PBS for 20 minutes.
• Rabbit anti-human IgG conjugated with FITC (Dako P0315) was diluted 1/20 and 
carefully pipetted onto each slide and incubated for 30 mins.
• Sections were washed in PBS and left in fresh PBS for a further 20 mins.
• Sections were mounted and specific binding was assessed using a fluorescence 
microscope (Letiz) the same day.
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2.8 Human brain tissue for ELISA and Western blotting 
Introduction
Human brain tissue was used rather than rat or rabbit brain because the original 
reports of ABGA were all carried out using human brain. This was available for 
use. Rat brain was also being investigated as a source of antigen in PANDAS sera by 
Dr Russell Dale in the same laboratory, therefore this was not duplicated.
Whole human striatum, containing caudate, putamen and globus pallidus, was obtained 
from the Queen Square Neurological Diseases Brain Bank, University College London, 
from a cadaver that had no clinical or histological evidence of neurological disease. This 
was authorised by the local ethics committee at the National Hospital for Neurology and 
Neurosurgery, Queen Square, London. Human cerebellum, cerebral cortex, myelin and 
spinal cord were also obtained from the Queen Square Neurological Diseases Brain Bank 
and used as control tissue for autoantibody determination in patients and controls. The 
preparation of tissue to provide antigen homogenates for antibody assays was carried out 
using the same methods as those for the basal ganglia homogenates. The tissue had been 
dissected from the brain by a qualified brain pathologist and flash-frozen 24 hours after 
death. The dissected tissue was stored at -80°C prior to further preparation for anti-basal 
ganglia antibody assays.
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2.9 Homogenisation of brain tissue with saline
A block of brain tissue was defrosted at room temperature 
Basic method
• Tissue was weighed and cut into 10mm pieces using a sterile scalpel
• The tissue pieces were placed in a glass homogenizer tube (Fisher scientific) 
which had been stored on water ice for 30 mins to cool
• Add protease inhibitor cocktail was immediately added to the tube (Sigma P- 
8340) in a concentration of 500pL per 2g of tissue
• The tissue was mechanically homogenised with a small volume of sterile saline 
0.5mL/g until all visible aggregates of tissue had disappeared.
• The resulting homogenate was pipetted into sterile tubes and centrifuged at 
10,000 rpm for 30 mins to remove large particles and insoluble material.
• The resulting supernatant was carefully pipetted off and stored at -80 °c until 
required (Soluble SI protein fraction), Figure 2-1.
• The insoluble cell debris at the bottom of the centrifuged tube was also stored, 
(fraction pellet PI).
Figure 2-1 flow diagram showing protein preparation protocol
Brain
Centrifuge
H om ogenisation  with 
T -per
H om ogenate
Centrifuge
H om ogenisation  with 
saline
Fractions
• S1
• P1
Centrifuge 10,000 rpm for 30 minutes, fractions stored at -80°c.
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2.10 Homogenisation with commercial detergents 
Homogenisation of striatum was also carried out using a commercial non-ionic detergent 
cocktail, tissue protein extraction reagent, T-per (Perbio 78510), (appendix), which was 
added to the homogeniser tube instead of saline. The addition of T-per is reported to 
increase the efficiency of protein recovery from tissue by gently breaking down cell 
membranes and increasing the release of proteins into the supernatant (see appendix). 
However, T-per is probably no better than the addition of non-ionic detergents such as 
Triton X or CHAPS in improving solubilisation but is reproducible and free of 
contaminants.
The T-per reagent was compatible with most assays, including Western Immunoblotting 
and ELISA and was capable of being dialysed. Reactivity to commercial antibodies was 
assessed using T-per and saline fractions to investigate its use. The method for T-per 
protein homogenisation was as the same as that for saline. The resulting supernatant and 
pellets were pipetted into fresh tubes. The fractions were stored at -80°C until used.
2.10.1 Demyelinated fractions 
The antibodies against basal ganglia are thought to bind to neurones (Husby et al, 1976). 
However, it had not been shown whether this antibody binding was specific to a 
particular neuron type, or indeed was directed against the myelin sheath of neurones. As 
antibody responses against myelin sheath components have been shown previously in a 
number of neurological diseases, including MS and encephalitis, it was essential to 
investigate whether antibodies from patients with SC and PANDAS reacted against the
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myelin components of neurones or neuronal proteins. The myelin containing fraction of 
the prepared supernatants was separated to allow antibody activity against myelin and 
neuronal proteins to be assessed separately.
Myelin was removed as followed:
• 2 mL aliquot of basal ganglia homogenate was pipetted into a glass tube and 
500pL of the solvent, di-iso-propyl-ether (BDH 28268) was added.
• The tube was sealed with a glass stopper, mixed thoroughly and centrifuged 
(Whatman Force 712) at 10,000 rpm for 15 mins in a sealed centrifuge bucket.
• The protein fraction was carefully pipetted from the protein/lipid interface using 
a sterile spinal needle and syringe.
• The protein fraction was transferred into another tube and centrifuged again to 
remove any remaining lipid which had been pipetted from the surface.
• The lipid fraction was then pipetted from the tube avoiding contamination with 
the solvent.
• The protein concentrations were determined and the fractions stored at -80°c.
2.10.2 Antibody reactivity in T-per and saline producedfractions 
Commercial antibodies against neurone-specific enolase (Autogen Bioclear), pyruvate 
kinase and Aldolase C (AbCam) were diluted 1/5000 and tested against Western blots of 
saline and T-per produced fractions to ascertain if T-per might affect antigen reactivity.
2.10.3 Protein assay
All the homogenised tissue was assayed for protein concentration by using a 
commercially available kit based on the Lowry method (Biorad 500-0114). Standards
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containing a known concentration of protein were prepared (0, 0.1, 0.25, 0.5, 0.75, 1.0,
1.5 and 2.0 mg/mL) along with a reagent blank (distilled water)
Basic method
• Standards and controls and sample were pipetted in duplicate into a 96 well 
microtitre plate (BDH 402200432)
• A series of doubling dilutions of each homogenate was prepared (1/2-1/64). lOpL 
of neat and diluted homogenates was pipetted in duplicate into the microtitre plate
• 25 pL of reagent A was added followed by 200pL of reagent B. The plate was left 
for 15 mins to develop at room temperature
• Absorbances were read on a plate reader (Wallac) at 790nm with a reference filter 
of 492nm
• The mean absorbance for duplicate wells was calculated for each standard and 
homogenate dilution
• The standard curve was plotted using excel software (Microsoft)
• The protein concentration for the neat homogenate and dilutions was extrapolated 
from the curve and recorded. Dilutions were used when the neat protein 
concentration was above the highest protein standard
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2.11 Anti-basal ganglia antibodies: enzyme-linked 
immunoabsorbant method
2.12 Method development
An enzyme-linked immunoabsorbant assay (ELISA) to detect ABGA was designed to 
allow the screening of large numbers of serum samples simultaneously. The results from 
the ELISA method also enabled statistical analysis of data of controls and post­
streptococcal neurological disease patients. The differences in the ELISA results obtained 
using antigen derived from: 1). Soluble SI fraction of the whole basal ganglia 
homogenate; 2) The SI fraction treated to remove lipid; 3) The insoluble PI fraction. The 
ELISA assay was developed from 16 ABGA IF positive stained samples. Normal and 
neurological disease controls were used to develop a cut-off value of absorbance (the 
upper limit of normal) to assess the percentage of patients and controls with raised 
ABGA ELISA results.
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2.12.1 Antigen dilutions and method development 
Initially, aliquots of each basal ganglia antigen were defrosted and diluted with 0.5M 
carbonate buffer to produce aliquots containing: 5pg/mL, 2.5pg/mL, 1.25pg/mL, 
l.Opg/mL and 0.5pg/mL of total protein.
Basic method
• Microtitre plates (BDH maxisorb 402200432) were coated with lOOpL of each 
antigen using 0.05M carbonate buffer (see appendix) as a coating medium.
• Plates were covered with Clingfilm and left overnight (maximum of 14 hours) at 
+4°C.
• The plates were allowed to come to room temperature and washed four times with 
0.2% bovine serum albumin (BSA), (Sigma A7906) diluted in PBS containing
0 05% Tween 20 (Sigma P7949) using a commercial plate washer (Biorad).
• Plates were blocked with 2% BSA/PBS and incubated for 1 hour at room 
temperature with gentle shaking.
• The microtitre plates were washed 4 times with 0.2% BSA/PBS, 0.05% Tween 20 
(Sigma P7949) to remove excess blocking reagent.
• Serum samples from the controls and acute SC patients (IF positive) were initially 
diluted 1/100 in 0.2% BSA/PBS with lOOpL pipetted into each well in duplicate.
• Two wells were used as a reagent blank by pipetting lOOpL of 0.2% BSA/PBS 
without serum into duplicate wells.
• The plates were incubated at room temperature for 1 hour with gentle shaking on 
a plate shaker (Denley, UK) and washed as previously described.
I l l
• Freshly prepared 1/1000 diluted anti-human IgG secondary antibody conjugated 
with horseradish peroxidase (Dako P-0406) was added to each well and incubated 
for 1 hour at room temperature.
• The plates were again washed as previously described. Colour reagent O- 
phenylenediamine (see appendix) was added to each well and the colour reaction 
was allowed to develop in the dark for 15 mins.
• The colour change was stopped with the addition of 1M HCL (BDH) to each well 
and the absorbances were read on a plate reader at 492 nm wavelength with a 
reference filter of 405 nm (Wallac multi-label counter).
The mean ELISA absorbance for the duplicate wells of blanks, control and IF-positive 
SC samples was calculated and the results produced from testing different antigen 
concentrations were compared. The antigen concentrations which gave the best signal to 
noise ratio (blank wells <0.1 absorbance and normal controls <0.5 absorbance) were used 
to assess the appropriate antigens for use in the ELISA. The optimum dilutions for testing 
serum samples and the detector secondary antibodies were analysed by setting up a 
chequerboard of dilutions against each of the antigen concentrations. The samples tested 
in each case were the same samples with a moderately high absorbance SC patient (IF 
positive) identified from the first experiments and a normal control which was IF 
negative.
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2.12.2 Optimum serum dilutions
To investigate the optimum serum dilution for ELISA a chequerboard of dilutions was 
tested.
Method
• 16 SC IF positive samples were diluted as follows: 1/50, 1/150, 1/300, 1/500 and 
1/ 1000.
• Samples were tested against lpg/mL of the soluble SI fraction of basal ganglia
• The mean absorbance was calculated for each of the duplicate wells and plotted 
against the serum dilutions.
The results were compared against the same samples with different concentrations of the 
detecting secondary HRP-conjugated antibody.
2.12.3 Optimum dilution o f secondary antibody
The anti-Human IgG, HRP conjugated secondary antibody was diluted according to 
manufacturers instructions 1/2000.
2.12.4 ELISA using protein and myelin containing fractions
The difference in the ELISA results using either lipid extracted antigen preparations or 
lipid containing homogenates were assessed by running 16 IF positive patients and 16 
normal controls against the same protein concentrations of whole basal ganglia 
homogenate, or the homogenate treated to remove the lipid fraction. The plates were set 
up at the same time, using the same aliquot of diluted samples. All samples were tested in 
duplicate with blank reagent wells on each plate. The absorbances were calculated and
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the mean results of the negative controls and acute SC patients were compared to assess 
differences in absorbances between antigens containing purified protein or crude 
homogenates with lipid. This was repeated using the insoluble fraction.
2.12.5 Basal ganglia antibodies: cut-off value for upper limit o f normal 
absorbances
A statistical cut-off value for assessing the upper limit of normal for absorbances was 
initially calculated by testing 30 acute SC patients and 30 normal controls against a basal 
ganglia ELISA with the optimum antigen concentration, serum sample and secondary 
antibody dilutions. To produce the cut-off value, the mean ELISA absorbance and SD of 
all the normal controls was calculated and 2 standard deviations (of the control data) 
added. All patients with SC from the Brazilian cohort and the patients with SC from the 
UK were analysed and mean absorbances recorded and compared to the cut-off value so 
that the percentage of patient and controls with raised ELISA results could be assessed.
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2.13 Anti-basal ganglia antibodies: Western immunoblotting 
Introduction
Lithium dodecyl sulphate (LDS) sample buffer (Invitrogen NP0002) was used in place of 
the typical sodium dodecyl sulphate (SDS) detergent. Whilst SDS is the usual method, 
LDS was available to use in the laboratory and is the routine method in use by the 
Neuroimmunology laboratory, UCL NHS trust for detecting anti-neuronal antibodies by 
Western blot for the diagnosis of paraneoplastic disease. There were no funds left from 
my grants to investigate the difference in results obtained from LDS or SDS which is of 
course a criticism of this Study.
To prevent disulfide bonds forming between cysteine residues a reducing reagent, 
dithiothreitol (DTT), (Sigma D9163) was added to all the sample preparations. The thiol 
reagent had the effect of increasing band sharpness by aiding protein separation and 
reproducibility of the polyacrylamide gel electrophoresis (PAGE).
Conclusion
Therefore in conclusion Western blotting was carried out using the Invitrogen mini-gel, 
Nu-PAGE system with LDS buffer under reducing conditions and blotting using a semi­
dry electro-transfer onto supported nitrocellulose membranes. This was the most studied 
and expensive part of the thesis and the UCL central research grant paid for it.
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2.14 Basic poly-acrylamide gel electrophoresis method
• The basal ganglia homogenate was prepared by adding 250pL of LDS (x 4 
concentrate) to 500pL of basal ganglia homogenate.
• In addition lOOpL of 0.5M concentration DTT (Sigma) was added to provide a 
reducing agent of a final concentration of 0.05M. Finally 150pL of ultra-pure, 
double-distilled water was added and the tube was vortexed to mix sample 
components thoroughly.
• The tube was then placed into a pre-heated water bath (Grant, UK) at 65°C for 15 
mins to denature the proteins. The homogenates were allowed to cool and 
vortexed again to ensure thorough mixing of proteins. This was used as a stock 
solution to optimise the protein concentration.
A pre-stained molecular weight marker (Invitrogen, LC2626) was run in one well of 
each gel. A commercial buffer tank, electrode and power pack (Invitrogen) was used to 
run the gels with MES running buffer (Invitrogen NP00002) which gave the optimum 
separation of small and medium size proteins. The gels were run for 39 mins at room 
temperature using the following electrophoretic conditions: 200V, 120mA and 25 W.
Once the electrophoresis was finished, a gel was either transferred into fixative solution 
(see appendix) for staining with Commassie Brilliant Blue to visualise the separated 
proteins or was electro-blotted, to transfer basal ganglia proteins onto a nitrocellulose 
membrane (Sartorius WPHY320F2). Nitrocellulose provided a permanent support for 
investigating protein separation and allowed probing with antibodies. This enabled serum
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from patients and controls to be tested against a nitrocellulose strip containing a range of 
separated basal ganglia proteins (2-200 kDa).
2.14.1 Basic method o f electro-blotting o f proteins onto nitrocellulose 
Transfer of proteins was carried out using electro-blotting, which increased the efficiency 
of protein transfer on to the nitrocellulose membrane. The procedure uses a semi-dry 
system and a blotting cassette (Invitrogen E l9051). A commercial protein transfer buffer 
(Invitrogen NP0006), (see appendix) and 20% methanol were used to increase the 
efficiency of protein transfer.
Basic method
• An electrophoresed gel was removed from its plastic supporting cassette and the 
gel overlaid with a nitrocellulose membrane which had been pre-soaked in 
transfer buffer.
• The gel and nitrocellulose was placed on a plastic blotting cassette on top of 2 
sponges which had been soaked in transfer buffer.
• A piece of blotting paper soaked in buffer was placed on top of the sponges and 
the gel placed on top.
• Two sheets of transfer buffer soaked filter paper were placed on top of the 
nitrocellulose membrane.
• The ‘sandwich’ was finished by adding 2 transfer buffer soaked sponges and the 
top of blotting cassette.
• The blotting cassette was placed in the electrophoresis tank (Invitrogen E l0001).
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• The outer core of the tank contained distilled water to provide heat exchange as 
the electrophoretic transfer produces heat which could interfere with efficient 
protein transfer.
• The proteins were electro-blotted onto the nitrocellulose membrane for 2 hours 
using the following electrophoretic conditions: 25 V, 160mA and 17W at room 
temperature.
The blotted nitrocellulose membrane was carefully removed from the gel and placed into 
a blocking solution containing 2% skimmed milk powder diluted in 0.9% saline with 
gentle rocking for 2 hours. This reduces background staining through blocking unbound 
protein sites with milk proteins. The blocking solution was rinsed off with 0.9% saline.
2.14.2 Basic method o f testing samples against Western blots
• The nitrocellulose membrane was placed into a ten well plastic incubation 
manifold (Amersham Pharmacia 80-6087-98) which allows up to 9 samples to be 
tested against a lane of separated proteins.
• The incubation manifold was left covered in Clingfilm with gentle rocking 
overnight at +4°C. The diluted serum in each well was discarded
• The nitrocellulose was washed with water 10 times and then washed with 0.2% 
milk in saline containing 0.05% Tween 20 (Sigma P-1379) 10 times with 10 min 
intervals between washes to remove unbound antibody.
• Anti-Human IgG conjugated with HRP (Dako, P-0406) was diluted 1/1000 in 
50ml 0.2% milk in saline and left with gentle rocking for 2 hours at room 
temperature.
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• The nitrocellulose was washed as previously described.
• Identification of antibody reactivity was carried out using 4-chloro-l-napthol 
(Sigma chemical C8890) and hydrogen peroxide as the enzyme substrate.
• The substrate was added to the nitrocellulose membrane and left to develop for 20 
minutes at room temperature with gentle rocking.
• The molecular weights of any resulting bands were recorded and the 
nitrocellulose was scanned using a scanning densitometer (Biorad GS 690) for 
future analysis.
2.14.3 Optimising Western immunoblotting method 
The optimum antigen concentration was assessed by testing basal ganglia homogenates 
diluted (1/2, 1/3, 1/4, 1/8, 1/10, 1/12, 1/15, 1/20 and 1/40) of whole, de-lipidated and 
insoluble basal ganglia homogenates SI and PI fractions (0.1-100pg/mL).
• 16pL of the prepared dilutions were pipetted into 4-12% Bis-Tris PAGE gel 
(Invitrogen) with a 10 well configuration and electrophoresed.
• One gel was stained with Commassie Brilliant blue to assess protein separation.
• Duplicate gels were electroblotted onto nitrocellulose and used to test 10 ABGA 
IF positive samples and 10 neurological controls (1/300) against the antigen 
dilutions.
• The optimum signal to noise ratio was the antigen concentration which produced 
bands in SC samples without homogenous staining of the background.
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Once protein concentration had been optimised a gel with a 2-D configuration (1 well for 
MW marker, 1 large well for homogenate) was set up.
• IF positive SC patients and control samples were diluted in 0.2% milk in saline 
(1/00, 1/200, 1/300, 1/400, 1,500 and 1/1000) and tested using an incubation 
manifold which allowed 10 dilutions to be tested against one coated membrane.
• The reproducibility of results and stability of the antigens was also determined.
• Five IF positive samples from patients with acute SC were tested against 5 
separate Western blots made using the same antigen aliquot. The molecular 
weight of any reactivity (bands) was recorded and was used to assess 
reproducibility of band patterns.
2.14.4 Antigen stability for Western blotting 
The stability of the antigen source was determined by producing 2 aliquots of basal 
ganglia homogenates and storing one at +4°c and another at -80°C. Four Western blots 
were made each week using both aliquots and the same 4 positive (SC) and 4 negative 
samples tested each time. The molecular weights of reactivity were recorded as was the 
condition of the results (high background and loss/increase in the number of bands). This 
information was used to ascertain the optimum storage conditions of the prepared antigen 
samples and degradation of proteins over time.
120
2.15 Polyacrylamide gel staining methods
To assess protein separation, band intensity and aid protein identification, PAGE gels 
were stained to reveal the protein separated into bands using either colloidal blue stain or 
the more sensitive silver stain.
2.15.1 Colloidal blue stain
The PAGE gel was fixed (appendix) for 10 minutes at room temperature with gentle 
shaking. The colloidal blue stain was obtained from a commercial source (Invitrogen 
LC6025), (see appendix). The gels were left in staining solution overnight (8 hours) and 
the background cleared by several changes of distilled water for at least 7 hours at room 
temperature.
2.15.2 Silver staining
Silver staining of PAGE gels enabled the staining of proteins down to a nanogram range 
of concentration, which was up to 100 times more sensitive than blue colloidal staining.
A commercial kit was used in all silver staining (Amersham-Pharmacia 17-1150-01) of 
PAGE gels.
Basic method
• A mini-gel or large SDS gel (Amersham Pharmacia 80-6002-21) was fixed (see 
appendix) for 30 mins.
• A sensitising solution was added to the gel consisting of 75mL ethanol, lOmL 
sodium thiosulphate, 17g sodium acetate and 165mL of distilled water and left for 
30 minutes.
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• After washing in water the silver solution, containing 25mL silver nitrate and 
125mL of distilled water, was added with lOOpL of formaldehyde (37% w/v) 
added at the last minute.
• The gel was left for 20 minutes before washing in water and the addition of 
developing solution which consisted of 250mL distilled water, 6.3g sodium 
carbonate and 50pL of formaldehyde (37% w/v).
• After 5 mins or once protein ‘spots’ were visible with clear background, a stop 
solution containing 250mL distilled water and 3.7g of sodium EDTA was added 
and left for 10 minutes.
2.15.3 Gel storage
Stained gels for analysis of bands by proteomics and mass spectroscopy were stored in 
distilled water at 4°C for a maximum of 1 week. For permanent storage stained gels were 
dried. The PAGE mini gels were dried using a commercial gel-drying system (Invitrogen 
N12387). A gel was soaked in gel-dry solution for a maximum of 5 minutes and then 
sandwiched between cellophane which had also been soaked for 10 minutes in gel-dry 
solution. The gels were left at room temperature away from sunlight for 48 hours to dry. 
Large SDS gels were soaked for 20 mins in a preserving solution (see appendix). 
Permanent storage of gels was carried out by wrapping the gel in one sheet of cellophane 
(Amersham Pharmacia 80-6117-81) and leaving to dry for 48 hours at room temperature 
away from direct sunlight.
2.15.4 Gel imaging
Where possible pictures were taken using a Sony, Cybershot DSC-VI 5 mega pixel 
camera, no software manipulation of images was carried out. A Biorad, scanning 
densitometer was used for older images; no software manipulation of images was carried 
out.
2.16 Anti-neuronal antibodies against other brain areas
2.16.1 Indirect Immunofluorescence 
Monkey cerebellum and cerebrum sections were purchased commercially (The Binding 
Site, FS224. A). Acute SC patients with positive ABGA were tested at 1/25 and 1/50 
against the section to ascertain whether ABGA were specific to striatum.
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2.17 Streptococcal serology
Evidence of prior streptococcal exposure was made using 2 independent serological tests 
(ASOT and DNAse B) when possible. The normal ranges were in accordance with WHO 
guidelines. A reduction in titre during recovery was necessary to determine the 
significance of raised streptococcal serology in addition to a clinical determination of 
likely infections such as pharyngitis or skin infection. Serum ASOT and DNAse B were 
measured in the controls, SC and PANDAS cohorts to assess whether there were any 
differences in streptococcal serology suggestive of differences in disease latency or 
presence of persistent infection.
2.17.1 Anti-streptolysin-0 litres (ASOT)
A commercial nephelometry kit was used to measure anti-streptolysin O titre (ASOT), 
(The Binding Site ZK189.L.R).
Basic method
• Serum or kit controls (normal and raised) were diluted 1/40 and 30pL was 
pipetted into a cuvette containing a stirring bar.
• Using an electronic pipette 400pL of ASO buffer and 40pL of reaction reagent 
was pipetted into the cuvette.
• After 2 mins the ASOT result was produced as IU/mL (International units per 
millilitre).
The upper limit of normal was 200 IU/mL which is in accordance to WHO guidelines 
(Spaun etal., 1961).
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2.17.2 Anti-DNAse B titre 
A Dade Behring BN 11 nephelometer and reagent kit (Behring) was used to measure 
Anti-DNAse B using commercial antiserum and reagents. The upper limit of normal for 
Anti-DNAse B antibody results was 300 IU/ml (in house laboratory cut-off). This assay 
was not available for the TS study. This assay was kindly carried out by the Microbiology 
Department at Great Ormond Street Hospital.
2.18 Cytokine assays 
Two Thl cytokines (interfer'on-gamma and interleukin-12), (and two Th2 cytokines 
(interleukin-4 and interleukin-10) were measured using commercial ELISA (Amersham 
Pharmacia, RPN2783 IL-4, RPN2785 IL-10, RPN2787 5-INF, RPN2752 IL-12). The 
method used an antibody specific for the individual cytokine coated onto a microtitre 
plate.
Basic method
• Test samples standards of known cytokine concentrations and controls were 
pipetted into duplicate wells and allowed to incubate at room temperature for 1 
hour.
• The excess serum or CSF was washed off with several changes of buffer and a 
biotinylated antibody was then added which binds to the specific cytokine from 
the incubated sample bound to the microtitre plate.
• An amplification reagent was then added to increase sensitivity and once washed 
thoroughly to remove unbound antibody
• enzyme substrate TMB was added and the plate allowed to develop for 15 mins.
125
• The colour reaction was stopped with sulphuric acid and the absorbances of each 
well read on a plate reader (Wallac) at 450nm with a reference filter of 405nm.
All samples were assayed in’ duplicate on the same plate with a standard curve, blanks 
and low and high controls. All standards were within acceptable limits. The normal levels 
of serum cytokines accepted were <1.5pg/mL (IFN-y), <4.6pg/mL (IL-4), (IL-10) and 
(IL-12), (ALmersham Pharmacia cut-off values). The upper limit of normal for the CSF 
cytokines was calculated as the mean of the neurological disease controls plus 2 standard 
deviations. The cut-off levels of normal CSF cytokines was <0.6pg/mL (IFN-y), 
<1.5pg/mL (IL-4), <0.5pgmL (EL-10) and <1.5pg/mL (IL-12) in this study.
2.19 Oligoclonal IgG bands 
Isoelectric focusing can be used to separate proteins, such as immunoglobulins, according 
to the isoelectric points of the proteins. The isoelectric point is the specific pH at which a 
protein has zero net charge and is thus static at a particular point (focused). Protein 
separation occurs within a pH gradient which is generated by an electrophoretic field and 
is stabilised by using zwitterionic ampholytes. The ampholytes are soluble carrier 
molecules with a high buffering capacity. Resolution is controlled by the slope of the pH 
gradient which is produced by anodic and cathodic buffers.
The separated proteins were passively transferred on to a nitrocellulose membrane by 
placing a 1 kg weight on the top of the nitrocellulose membrane which had been placed 
on to the surface of the gel. Unoccupied protein binding sites are blocked with 2% milk 
proteins. Separated IgG clones were identified by incubating the blotted nitrocellulose
with diluted goat anti-human IgG antibody (Diasorin 80261). The presence of IgG clones 
which were polyclonal, monoclonal or oligoclonal were detected by the addition of a 
HRP conjugated anti-goat antibody (Dako P0406). Visualisation of the IgG pattern was 
carried out using an enzymatic detection method with the addition of the enzyme 
substrate, 3-amino-9-ethyl-carbazole (Sigma A5760) and hydrogen peroxide. Oligoclonal 
bands were assessed visually by comparing serum and CSF lanes (paired samples) and 
counting the number of bands in each lane (>2 bands=oligoclonal or homogeneous 
smear=poly clonal).
2.20 Cross-reactivity between anti-basal ganglia antibodies and streptococcus 
To re-examine Husby et al hypothesis that ABGA reactivity could be removed by 
incubating with streptococcus I aimed to see if the antibody responses against GABHS 
isolated from a SC patient could be removed by incubating with brain tissue.
2.20.1 Streptococcal cultures 
A UK patient with acute SC was throat swabbed and a Ml GABHS serotype cultured. A 
bacterial homogenate from this Ml serotype and a control streptococcal strain (M5) from 
a patient with PSGN were prepared for Western blotting by lysing the cell walls with 
bugbuster (CN biotechnology 70584) and preparing a homogenate. The streptococcal 
homogenates were incubated with LDS sample buffer and DTT using the same method as 
that for basal ganglia Western immunoblotting. The homogenates were run on a 2-D well 
4-12% Nu-Page gel (Invtrogen NP0321) with a MW marker. The proteins were blotted 
onto nitrocellulose and probed using a 10 well plastic manifold.
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2.20.2 Absorption experiments 
The serum from the SC patient was investigated to ascertain if there was any specific 
antibody reactivity against the Ml serotype grown from the throat. The M5 serotype was 
used as a control. The serum was diluted 1/300 and incubating against both M l and M5 
overnight, after washing, 1/1000 diluted anti-human IgG conjugated with HRP was used 
to detect any antibody reactivity against the 2 streptococcal serotypes.
In a separate experiment, the 1/300 diluted SC patient’s serum was pre-incubated with 
lOOpg of: 1) basal ganglia homogenate and 2) human cerebellum homogenate in separate 
tubes at 37 °c for 1 hour. The final dilution of the serum was 1/300 in all instances. The 
tubes were centrifuged at 10,000rpm for 10 mins to precipitate immune complexes. The 
resulting supernatant was tested against Western immunoblots of the Ml and M5 
serotypes. This was to examine if reactivity against the streptococcal proteins were 
absorbed out by incubating the serum with basal ganglia or cerebellum homogenates.
2.21 Identification of candidate antigens by two-dimensional 
protein electrophoresis
The basal ganglia homogenates underwent IEF and PAGE using 2 methods, and protein
‘spots’ were identified by staining the gel with either a silver stain. Electro-blotting on to
nitrocellulose was used to allow for the probing of separated proteins in ABGA positive
samples (SC, PANDAS and TS) and controls. Antibody binding to the 2-D gels was
detected colorimetrically using 4-Chloro-l-Naphthol (Sigma chemicals C8890) or with a
chemiluminescence kit (Perbio 34080). Any reactivity of ABGA against protein(s) on the
nitrocellulose was used to identify the position of the protein in a stained gel (run at the
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same time). Candidate protein ‘spots’ were cut out from the stained gels, enzymatically 
digested and the sequence identified by mass spectroscopy (MALDI-TOF) and searching 
a protein database such as Swiss-prot. The digestion of protein candidates and mass- 
spectroscopy was carried out by Dr Robin Wait at the Kennedy Institute of 
Rheumatology, Imperial College University, London.
2.21.1 Two-dimensional electrophoresis method: mini-gel system 
Basal ganglia SI fraction was diluted 1/2 with IEF sample buffer (Invitrogen LC5311) 
leaving a final concentration the same as that used in the basic Western immunoblotting 
methods, although this was adjusted if a higher or lower concentration was required to 
increase resolution of the gels and to avoid streaking.
First phase
• The anode and cathode buffer for the wet chamber was prepared and allowed to 
stand to remove air bubbles.
• 10-well IEF gel was placed into the inner portion of the tank and secured with 
wedges, the anode buffer was used to fill up the outside chamber.
• The prepared sample was pipetted into each well using 15pL, apart from well 1 
which was filled with an IEF coloured marker (Invitrogen 39212-01).
• The gel was run for a total of 2 and 1/2 hours in a step gradient: 1 hour at 100V, 
18mA and 2W; 1 hour at 200V, 18mA and 3.5W with 30 mins at 500V, 18mA 
and 9W.
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• The gel was placed in fixing solution (TCA/SSA), (see appendix) for 30 mins to 
fix proteins and wash out pharmalytes which could give false signals on a stained 
gel.
• The gel was then briefly stained in Commassie and de-stained until clear (see 
appendix). The gel was then left for 1 hour in 20% ethanol to remove the acetic 
acid and shrink the gel slightly.
• A vertical strip was cut from the gel containing 1 column of proteins and placed 
in LDS and 25% ethanol for between 5 and 10 minuets.
Second phase
• A 2-D Nu-PAGE gel (Invitrogen NP0326) was prepared and the slice of gel was 
placed horizontally in the well and electrophoresed as previously described.
• The gel was either stained to reveal proteins or electro-blotted on to nitrocellulose 
to allow probing of the bound proteins by patient serum or monoclonal antibodies. 
The advantages of the mini-gel 2-D gels system is that small volumes of samples 
could be tested although at a cost of reduced separation capacity due to the size of 
the gel and the available pH ranges.
2.21.2 Two-dimension electrophoresis: immobiline gel system 
The limitation of the mini-gel system was that only one pH range could be used in the 
first dimension (pH 3-10) and the size of the gels meant that separation between protein 
‘spots’ was not always complete. An immobiline gel strip system such as a pH 3-10 range 
(Amersham Pharmacia 17-1234-01) was used to increase protein separation due to the 
larger size of the strips (18xJ8cm IEF gel strips) and overlapping pH gradients were
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available to increase focusing (i.e.; 3-10, 9-11 and 3-5). The basal ganglia homogenate 
was first diluted in solubilisation buffer (see appendix). The immobiline buffer (pH range 
dependant on gel used) was then added (Amersham Pharmacia 17-6000-87 for pH 3-10) 
and the sample thoroughly mixed.
First phase
• The basal ganglia proteins, diluted in solubilisation buffer were used to 
reconstitute the immobiline strips of the appropriate pH range (stored at -20° C).
• The IEF strips were placed in a dry strip holder (Amersham Pharmacia 80-6371- 
84) and 350pL of the basal ganglia solution was pipetted on to each strip which 
was covered with mineral oil (Amersham Pharmacia 17-1335-01) to prevent 
evaporation and contamination.
• The strips were left overnight to reconstitute.
• Each strip was aligned in the multiphor II electrophoresis system (Amersham 
Pharmacia 18-1018-06).
• The strips were electrophoresed under mineral oil to prevent drying (Amersham 
Pharmacia 17-1335-01) using the following conditions: 1 min at 500V, 2mA, 5W; 
1 hour 30 mins at 3500V, 2mA, 5W and 8 hours at 3500V, 2mA and 5W.
• After the run the strips were laid on blotting paper to remove excess moisture and 
prepared for the second SDS-PAGE separation.
• The strips were equilibrated in two buffers (see appendix) and left for 5 mins with 
gentle rocking. After a gentle rinse in double distilled water the strips were placed 
in the same stock solution for 5 mins. This contained iodoacetamide (Sigma I-
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1149) which alkylates thiol groups, lessening streaking of proteins during the 
second phase of electrophoresis.
Second Phase
• An equilibrated IEF strip was placed horizontally, face-down onto an 18x18 cm 
SDS gel (Pharmacia 80-6002-21) with an additional strip on the left hand side of 
the gel soaked in molecular weight marker (Invitrogen LC5925).
• The anodic buffer strip (Amersham Pharmacia 17-1342-01) was positioned 1 cm 
in from the edge of the SDS gel near the positive electrode. The cathode buffer 
strip (Amersham Pharmacia 17-1342-01) was placed 1 cm from the edge of the 
gel near the negative electrode.
• To prevent water from ‘streaking’ the proteins, squares of blotting paper were 
placed underneath both ends of the IEF strip to allow water to move away from 
the region of protein separation.
• The electrodes were aligned with the buffer strips and the lid placed on the 
electrophoresis tank (Amersham Pharmacia 18-1018-06).
• The gel was run in 2 steps: 120V, 20mA, 30W for 40 mins, after which the IEF 
strip was removed. Step 2 was 600V, 50mA, 30W and 1 hour or until the 
bromophenol blue (Amersham Pharmacia 17-1329-01) front reached the anodic 
buffer strip.
• The gel was either stained in Commassie or electro-blotted on to nitrocellulose 
membrane (SartoriuS WP4HY320F2).
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2.22 Immunoprecipitation 
In experiments to purify out the most common basal ganglia antigens (40, 45, 60 and 98 
kDa) recognised using Western immunoblotting, a Mammalian cell immunoprecipitation 
kit was purchased (Perbio 45225). The system is designed to utilise small concentrations 
of antibody and antigen source and is carried out in microcentrifuge tubes (2ml) 
containing a spin cup (semi-permeable membrane), (Perbio 45225).
Basic method
• Immobilised protein G, gel slurry (50% with buffer) was pipetted (0.4mL) into a 
microcentrifuge tube containing the spin cup and was centrifuged at 10,000 rpm 
for 1 min to remove excess buffer and leave protein G gel in the cup.
• The protein G gel was washed with binding buffer for 2 mins by inverting the 
tube and centrifuged at 10,000 rpm for 1 min to remove excess buffer.
• Purified IgG (500 pg) from a patient with acute SC (ABGA positive) was pipetted 
into the tube and left to incubate with gentle rocking at 4°C overnight to allow 
antibody to bind to the immobilised protein G gel.
• The tube was allowed to reach room temperature and was centrifuged at 10,000 
rpm for 1 min to remove unbound antibody. The flow-through was collected and 
its protein concentration determined to calculate the relative amount of antibody 
binding.
• An antibody cross-linker (disuccinimidyl suberate) was dissolved in dimethyl 
sulfoxide (DMSO), (Sigma D2650) and pipetted immediately into the spin cup. 
The antibody linker avoids immunoglobulin contamination (from the bound 
antibody) in the final elutes and preserve the bound antibody for future
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immunoprecipitation. The linker was incubated with the protein G, gel for 1 hour 
at room temperature with gentle mixing.
• The tube was then centrifuged at 10,000 rpm for 1 min to remove excess fluid and 
washed 4 times with quenching buffer to remove DMSO.
• Elution buffer (500 pL) was then added and the tube gently mixed by inverting 10 
times. The tube was centrifuged and the liquid flow-through collected. The 
elution step was repeated 4 times and the liquid collected into numbered tubes. 
This step removed the excess antibody linker and any contaminants, leaving 
behind the protein G-bound antibody.
• Human basal ganglia homogenate was mixed with an equal volume of binding 
buffer and 500 pL of this solution was added to the washed spin cup containing 
the protein G, gel. The homogenate was incubated in the cup overnight at 4°C 
with gentle rocking.
• The tube was then allowed to come to room temperature and centrifuged at 
10,000 rpm for 1 min and the liquid (unbound homogenate) removed.
• Washing buffer was added and the gel washed by inverting the tube 10 times, 
centrifuging at 10,000 rpm for 1 min and collecting the flow through. This was 
repeated twice to wash off unbound antigen.
• The elution buffer (Perbio 45225) was then added (190 pL) to the tube and mixed 
with the protein G, gel by inverting the tube 10 times.
• The tube was centrifuged at 10,000 rpm for 1 min and the liquid flow-through 
collected. This elution step was repeated a further 4 times and the flow through
134
collected. The spin cup was washed with buffer several times and left in 500pL of 
washing buffer with 0.1% sodium azide and stored at 4°C for future use.
• The protein concentrations of the flow-through from antibody, antibody cross­
linker, antigen binding and final protein elutions were calculated.
PAGE gel of eluted protein
The final elutes were prepared for PAGE analysis by adding LDS buffer containing 
0.05M DTT and heated to 65°C. The elutes were electrophoresed in a 10 well 4-12% bis- 
tris gel (Invitrogen NP0321) gel to assess the antigen(s) collected from the 
immunoprecipitation method. The gels were stained with silver and the pattern and 
number of bands (if any) recorded for each elute. The subsequent Western blots were 
probed with ABGA positive antibodies (40, 45, 60, 98 kDa) to assess whether the 
reactive antigen was immunopreciptated from the crude basal ganglia homogenate and 
was present in a particular elute. Specific binding to the eluted antigens was compared to 
that from Western blotting and antibody probing of crude basal ganglia homogenate. Any 
reactive antigens were cut out of the gel and identified using mass spectroscopy. Separate 
immunoprecipitation was carried out for each of the known basal ganglia antigens 
(positive sera with reactivity against one of the antigens alone 40, 45, 60 and 98 kDa).
As the recovered protein from immunoprecipitation or 2-D electrophoresis may have 
been too low for peptide identification. A commercial centrifugal filter device (YM-100, 
Milipore 42412) was used with a membrane specific for a particular molecular weight 
cut-off. This stopped the loss of proteins with molecular weights >10,000 kDa. Recovery 
of proteins after concentration was reported to be 95% (Millipore, 42412) with a
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concentration factor as high as 100% depending on how long centrifugation was required 
and the volume of buffer used to re-suspend the protein.
Briefly, a Microcon sample reservoir was inserted into a 1.5mL microcentrifuge tube. A 
maximum of 0.5mL of sample was pipetted into the sample reservoir and centrifuged at 
14,000g for 10 mins in a microcentrifuge (Whatman Force-7). The sample reservoir was 
then removed and placed upside down into a fresh microcentrifuge tube. The tube was 
then centrifuged at 10,000g to transfer the concentrate into the bottom of the new 
microcentrifuge tube. The sample reservoir was then removed and the concentrated 
sample was ready for use or storage. The recovered proteins were compatible with PAGE 
and mass-spectroscopy
2.23 Anti-human neuron-specific enolase in controls and acute Sydenham’s 
chorea
To assess neuron-specific enolase (NSE) as a candidate autoantigen in post-streptococcal 
movement disorder syndromes, neurone-specific enolase antigen was purchased 
commercially (Sigma N-4773). The antigen was prepared for Western immunoblotting 
using the same procedure used for basal ganglia homogenates. Due to the cost of this 
antigen a total of 5pg of protein was loaded per well (approx 0.5pg per lane).
Six controls with movement disorders and streptococcal disease were used as controls the 
diagnosis were: DYT1 positive dystonia; Huntington’s chorea; “idiopathic” Parkinson’s 
disease; PSGN; Streptococcal pharyngitis and Multiple sclerosis. Samples from 6 patients
with acute SC who had not been tested previously for ABGA were kindly provided by 
Dr. F. Cardoso, Federal University of Minas Gerais, Brazil. All samples were diluted 
1/300 and tested using the same method used for the basal ganglia homogenate Western 
immunoblotting method. For positive control, a commercial antibody (goat polyclonal) 
specific for human NSE (C-terminus specific), (Santa Cruz, sc-7455) was tested at a 
1/1000 dilution on Western immunoblotting and detected using a rabbit anti-goat HRP- 
labelled secondary antibody (Dako, P-0449).
2.24 Functional effect of ABGA on enolase enzymatic activity 
This investigation was designed to see whether the antibodies could alter the normal 
glycolytic enzyme activity of enolase. As enolase is one of the glycolytic enzymes 
(conversion of pyruvate to lactate) the production of NAD+ from NADH+ was used to 
assess the glycolytic NSE activity in the presence of purified IgG from subjects with 
ABGA and IgG from neurological controls (Parkinson’s disease).
2.24.1 Enolase and IgG purification 
Enolase was purified from human brain using ammonium sulphate and Fluid Phase 
Chromatography (FPLC) and was kindly provided by Dr Russell Dale, Institute of Child 
Health, Great Ormond Street, London. Serum samples were run through a protein A 
column using FPLC to purify IgG (Amersham Pharmacia 17-042-03), (see appendix).
2.24.2 Alterations in enolase activity with anti-enolase and control IgG 
The enolase activity was determined by measuring the transformation of NADH+to 
NAD+, a method previously described (Pancholi et al., 1998). The enzyme reaction was 
performed using purified NSE from rat brain, kindly provided by Dr Russell Dale,
Institute of Child Health and Neurology, Great Ormond Street Hospital. The enzyme 
activity assay took place in a microtitre plate, by first adding NSE to the reaction 
substrate (see appendix). The activity of the enzyme was measured by adding 100 pL of 
NSE and recording the change in absorbance at 340nm (conversion of NADH+ to NAD+) 
using a plate reader (Wallac multi-label counter). This was carried out by taking an 
absorbance reading in 30 second intervals until no change in absorbance could be 
detected. The decrease in extinction at 340nm was due to the increase in production of 
NAD+ from NADfT and the results plotted onto an Excel (Microsoft) spreadsheet for 
further analysis.
Anti-NSE positive serum was put through a protein A column to purify IgG. The effect of 
anti-NSE positive IgG was analysed by incubating it with NSE using the same antigen 
and antibody dilutions as used for analysis of ABGA (1/300 serum dilution and 30 pg of 
protein). The IgG was incubated with NSE using gentle rocking at room temperature. 
Every hour, lOOpL of the incubated NSE was pipetted from the stock solution and the 
NSE activity measured. This was carried out until a maximum of 12 hours incubation had 
occurred. Alterations in the enzyme activity were assessed by recording the effect of the 
antibody incubations on the decrease in absorbance at 340nm compared to baseline 
enzyme measurement (without IgG). To control the study and to study any deterioration
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in the NSE activity over time, 5 IgG control samples from patients with idiopathic 
Parkinson’s disease were tested. A control sample was tested in parallel using the same 
antigen source and at the same time as the anti-NSE antibody experiment.
2.25 Statistical analysis
All statistical analyses were done using SAS software (SAS Institute, Inc., Cary, North 
Carolina, USA). Streptococcal serology (ASOT and DNAse B) and ABGA, cytokine 
ELISA absorbance data were compared using the non-parametric 2 sample exact 
Wilcoxon rank-sum test (Mann-Whitney). Comparison of the numbers of samples with 
raised streptococcal serology was carried out using the Fisher’s exact test. Positive 
ABGA Western immunoblotting was compared in each subgroup using Chi-square tests. 
All confidence intervals quoted refer to 95%.
2.26 Conclusions
ELISA, Western immunoblotting and IF was used to detect ABGA in serum samples 
from patients with SC, PANDAS and TS. Streptococcal infection was determined by 
surrogate serology and clinical presentation. A proteomic method was chosen to identify 
putative autoantigens in these syndromes.
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3 Results of Indirect immunofluorescence
3.1 Indirect Immunofluorescence 
Introduction
The Indirect Immunofluorescence work in this thesis was carried out with the kind 
assistance of Neuropathology, although, routine requirements of the laboratory 
meant access to microscopes and other equipment was limited. 
Immunohistochemistry could also have been performed as this is a standard method 
for detecting anti-neuronal antibodies.
Unfortunately, no grant monies were secured for conducting a large histopathological 
study of anti-basal ganglia antibodies. Therefore only these pilot studies using indirect 
immunofluorescence were performed. However, the aim of this thesis was to attempt to 
identify and characterise the antigens using proteomics. A separate series of studies is 
required to investigate antibody binding by histochemistry.
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3.2 Sagittal rat brain sections 
Introduction
Frozen sections of rat brain sagittal sections were purchased from Novagen, Germany. 
Four patients with Sydenham’s chorea and 4 normal controls were diluted 1/50 and 1/500 
and tested by IF in accordance with a commercial suggestion for detected anti-neuronal 
antibodies in paraneoplastic disease using indirect immunofluorescence (The Binding 
Site, UK), for routine diagnostic purposes (Figure 3-1).
A commercial monoclonal antibody which recognised grey matter (basal ganglia areas), 
dopamine D2 receptor (Autogen Bioclear), (Secondary antibody FITC labelled rabbit 
anti-goat immunoglobulins, Dako) was tested. Cerebellum was identified by testing just 1 
paraneoplastic Hu sera from a patient with SCLC and neurological disease.
IgG binding to the section was identified using FITC labelled anti-Human IgG (Dako). 
This was to assess grey matter area staining of SC samples in comparison to the D2 
receptor identified area and cerebellum in comparison to one Hu positive serum.
More samples were not tested due to the expense of these sections and the negative 
results of SC samples tested (Figure 3-1).
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Results from sagittal sections
Normal controls (Figure 3-la) did not bind specifically to any brain structure. Secondary 
antibody against Human IgG (fab) FITC labelled (Dako) did not bind to any brain 
structure. Photograph of this had low contrast and brightness and did not print adequately 
which is why they are not shown.
In comparison the D2 receptor antibody (Figure 3-lb) identified deep grey matter 
neurones. The commercial anti-enolase monoclonal antibody bound to neurones within 
this area, but, there was neuronal staining across the section with this enolase antibody 
(Figure 3-2b) and was not confined to the D2 stained area. There was no staining of the 
D2 area with the 4 SC samples tested either at 1/50 or 1/500.
A patient with PNS and Hu positive serum bound to Purkinje cells within the cerebellum 
as expected (Figure 3-lc). There was no other neuronal or glial staining evident. The 4 
patients with SC did not appear to bind at either 1/50 or 1/500 to Purkinje cells (Figure 3- 
id).
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Figure 3-1 Sagittal Rat Brain slices of 4 normal controls, 1 commercial D2 receptor, 
1 Hu antibody positive and 4 Sydenham’s chorea samples against cerebellum and 
grey matter areas
amm
A: Normal (non-diseased) control diluted 1/50, 
IgG did not stain any structure mag x200
B: Commercial dopamine D2 receptor antibodies 
1/500 identified grey matter neurones in sagittal 
Section, mag x200
C: Hu sample diluted 1/500 had 
Positive staining o f  
Cerebellum Purkinje cells (arrow) 
mag x200
Key: Yellow bar 5p.m
D: Sydenham’s chorea sample diluted 1/50 
did not bind to Purkinje cells 
mag x200
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3.3 Results of sagittal section stained with four Sydenham’s chorea
samples and four normal controls to assess neuronal staining within 
the cerebral cortex.
Introduction
Husby’s original report of basal ganglia antibodies suggested that the antibodies also 
bound to the cerebral cortex (Husby et al., 1976).
The same batch of slides were also incubated with 4 acute Sydenham’s chorea samples 
and 4 normal controls which were diluted 1/50 and 1/500 in 0.9% saline and incubated 
with the section for 30 minutes. IgG binding to the section was identified using FITC 
labelled anti-Human IgG (Dako).
Results
Sydenham’s samples diluted 1/500 were all negative (4 samples). There was no binding 
to neurones or anything else. Patients with Sydenham’s chorea only bound weakly to 
neurones at a dilution of 1/50 (Figure 3-2c). The 1/50 binding was similar to that seen 
with the commercial enolase antibody which was axonal, cytoplasmic staining (Figure 3- 
2b). Neuronal staining was weak and distributed throughout the brain rather than in one 
distinct area.
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Figure 3-2 Commercial anti-neuron specific enolase antibody diluted 1/500 and 
tested against rat cerebral cortex and ten patients with Sydenham’s chorea and 10 
normal controls diluted 1/50
A: Normal control diluted 1/50 against rat brain section. 
There is no obvious staining, mag x200
B Commercial NSE P-2 antibody diluted 1/500 C: Sydenham’s chorea serum diluted 1/50 against
against rat brain sagittal section sagittal section binds only weakly to
Identified neurones, mag x400 isolated neurones in the cortex, mag xlOO
Key: Yellow bar 5jim
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Conclusions
Sydenham’s chorea samples only had weak IgG binding to neurones, unlike, 
paraneoplastic antibodies there was no Purkinje cell staining and the concentration of 
antibody was significantly lower than that expected in paraneoplastic syndromes (1/500- 
1/5000). This means that anti-neuronal antibodies in SC are weak and possibly of no 
significance. There was no obvious staining like that seen with the D2 receptor, although 
it was assumed that this antibody recognised the basal ganglia area in rats which may not 
be the case. Neuronal-like staining was only diffuse rather than to one distinct area. 
Therfore basal ganglia antibodies do not appear to be specific to the basal ganglia in rats.
However, these negative results might be influenced by species differences in antigen 
concentration, localisation and presentation. The original publications of basal 
ganglia antibodies used human tissue (Husby etal,  1976). Therefore primate and 
human brain were studied.
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3.4 Indirect immunofluorescence against monkey cerebellum, cerebrum 
and mouse stomach
Introduction
As most accepted anti-neuro'nal antibodies bind to cerebellar neurones the post­
streptococcal neurological disease patients were tested for the typical paraneoplastic 
antibodies. A typical, routine method was used with primate (monkey) tissue containing 
cerebellum, cerebrum and mouse stomach (The Binding site, UK). This is a method 
commonly used for detecting anti-neuronal antibodies by EF in paraneoplastic syndromes 
(PNS), (The Binding Site, UK). One patient positive for Hu and 1 with Yo were used for 
controls, (Figure 3-3c and e).
Ten acute SC and 5 normal controls were diluted both 1/50 and 1/500 (dilutions 
suggested by manufacturer, The Binding Site, UK) and tested against cerebellum, 
Cerebrum and mouse stomach sections (The Binding Site, UK).
Results
None of the SC patients had IgG binding to the cytoplasm of monkey Purkinje cells, 
although one patient had nuclear binding (Figure 3-3f). All patients were negative for 
paraneoplastic antibodies against cerebellum. The known positive Hu and Yo samples 
gave expected staining of cerebellar Purkinje cells (Figure 3-3c and e). None of the 
normal controls had any neuronal staining the background fluorescence was not different 
from that of sections incubated with just secondary antibody alone (Figure 3-3a and b).
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There was staining of neurones in the cerebellar granule layer, this neuronal staining was 
identified by testing the same sections with a commercial anti-NSE antibody. The pattern 
of the staining was cytoplasmic and appeared to be similar with anti-NSE antibody 
(Figure 3-4a) and SC samples (Figure 3-4 b and c). This staining was weak and confined 
to scant neurones only.
There was scattered staining of neurones with axonal like pattern in the cerebral cortex of 
monkey section with all ten SC samples at a dilution of 1/50. Only 2/10 (20%) had weak 
staining of neurones at a serum dilution of 1/500. The pattern of IgG staining was similar to 
that seen with commercial NSE antibody suggesting the antibodies bind to axonal 
cytoplasm. There was no evidence of membranous staining, although, this could be 
masked by cytoplasmic staining.
Double staining a section with a SC serum diluted 1/50 with anti-human IgG FITC and a 
commercial glial fibrillary acid protein (GFAP) monoclonal antibody, (Sternberg 
Monoclonals) with anti-mouse TRITC identified glial cells (Figure 3-4c and d). The SC 
samples clearly had different staining to the GFAP antibody. The anti-neuronal staining 
in SC was similar to that seen with the commercial anti-NSE antibody showing that SC 
IgG binds to neurones albeit at low titre.
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Figure 3-3 Monkey Cerebellar and mouse stomach sections
A: 2nd antibody only anti-Human IgG against 
monkey cerebellum. Background staining 
only, mag x200
B: Normal control diluted 1/50 and tested 
against monkey cerebellum. Background staining 
only, mag x200
C: Hu antibody diluted 1/500 with positive 
Purkinje cells and granular neurones 
Nuclear staining, mag x200
D: Hu antibody also stains neurones (arrow) in 
mouse stomach myenteric plexus, mag x200
E: Yo antibody diluted 1/500 with positive 
Granular staining o f  Purkinje cells, (arrow) 
Mag x200, Key: Yellow bar 5pm
F: Sydenham’s chorea sample diluted 1/500 
showing some staining o f  Purkinje cells nuceli 
mag x200
Monkey cerebellum stained with commercial Monkey cerebellum stained with
NSE antibody (P-2) diluted 1/500 showing SC sample diluted 1/500 showing
predominant cytoplasmic localisation (arrows) similar pattern to NSE with weak
o f staining in the granular layer, mag x400 cytoplasmic localisation (arrow) o f  staining in the
granular layer, mag x400
Same section double stained with SC and GFAP antibodies to assess neuronal specifier
Monkey Cerebrum with Sydenham’s chorea 
Sample diluted 1/50 showing weak 
Axonal Staining, mag x400
Monkey Cerebrum with anti-GFAP antibody 
diluted 1/1000 showing glial cell staining in 
the same section, mag x400 Key: Yellow bar 5pm
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3.5 Tourette’s syndrome and patients with PANDAS have a similar anti­
neuronal like staining pattern using monkey tissue but only at 1/50 
dilution
Five patients with Tourette’s and PANDAS were tested against the same sections as SC 
studies (Figure 3-5). The five patients had been identified as possible positive samples 
using Western immunoblotting.
Results
There was a similar pattern of neuronal staining with axonal, cytoplasmic predominance. 
The optimum staining was again only at a dilution of 1/50.
Figure 3-5 Tourette’s syndrome and PANDAS patients tested against monkey 
sections
Monkey Cerebellum with Tourette’syndrome 
Sample diluted 1/50 Showing neuronal (axonal) 
mag x400
Key: Yellow bar 5pm
Monkey Cerebellum with PANDAS sample 
diluted 1/50 Showing neuronal staining 
mag x400
Conclusion
Antibodies in SC were proposed to be basal ganglia specific (Husby et al, 1976) although 
the authors suggested weaker staining in the cortex. Therefore these results are consistent 
with Husby’s reported findings (Husby et al., 1976). However, neuronal staining was also 
present in the cerebellar granular layer, these cells are easily cultured so live cells assays 
could be performed using IgG from SC patients to investigate whether these antibodies 
have any functional effects. Repeating Husby’s original study using human basal ganglia 
sections was also done.
There appears to be low titre anti-neuronal like staining in post-streptococcal 
movement disorders. However, the staining is cytoplasmic and therefore unlikely to 
constitute a functional autoantibody disorder as no membranous distribution is 
evident. The antigen(s) are likely to be soluble and might be of little consequence. 
However, in the absence of control positivity, these antibodies might be a marker of 
disease. For example most anti-neuronal antibodies are non-functional but, are very 
useful for the diagnosis of autoimmune disorders mediated by other processes such 
as aberrant T-cells.
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3.6 Husby’s method to detect anti-basal ganglia antibodies against 
human tissue by indirect immunofluorescence in 4 Sydenham’s 
chorea samples
Introduction
The suggested method for detecting ABGA (Husby et al., 1976) was by counting and 
grading positive stained neurones in human basal ganglia using Vi diluted sera Husby et 
al, 1976. Sections from 3 different normal striatums were tested in SC, PANDAS and TS, 
normal controls and secondary antibody only was set up to investigate if artefact staining 
of neurones was present.
I repeated the published method of Husby, (Tables 3-1 and 3-2), using 4 samples of 
patients with acute SC. All the experiments were carried out using the same block of non­
diseased human basal ganglia. These sections were kindly cut by Linda Kilford, Queen’s 
square Brain bank for Neurological diseases.
Results
I repeated the method of Husby exactly, but, grading the intensity of fluorescence as a 
method of assessing positivity was very unreliable. It was very difficult to see the 
difference between positive neuronal staining and background.
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Conclusion
This method is too unreliable to interpret results. Kiessling et al used grading of 
fluorescence to investigate ABGA so I repeated this next, for methodological and 
comparison purposes.
3.7 Grading of indirect Immunofluorescence results in 4 Sydenham’s 
chorea samples diluted 1/2 using Husby’s method
Four acute SC samples were tested in triplicate and the following scheme was used to 
grade the neuronal staining: Neg (negative), + (weak positive), ++ (positive), +++ (strong 
positive). This method of assessment produced inconsistent results (Table 3-1). This 
method proved difficult due to high background fluorescence.
Table 3-1 Grading of indirect immunofluorescence of samples diluted 1/2
Sample Test Test Test
Sample 1 + ++ +
Sample 2 +++ + +
Sample 3 ++ + ++
Sample 4 + • + Neg
Positive neurones were counted in 1 microscopy field at low power (original 
magnification x200) in the middle of the caudate head using the same ABGA positive 
sample. This resulted in differences (mean difference 30.3 neurones (range 28-33) in the
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numbers of positive neurones counted in 1 field (Table 3-2). Testing tissue sections from 
different blocks of striatum with the same sera also produced different positive neuron 
counts (mean difference 30.5 neurones (range 17-49)), despite testing the same SC serum 
(Table 3-3). This appeared to be due to variations in section quality, since the samples 
were tested in an identical fashion.
Table 3-2 Duplicate positive neurones counted in one microscope field
Sample Counted Counted Counted Counted Mean neurone
positive positive positive positive count (range)
neurones neurones neurones neurones
Sample 1 40 33 59 28 40 (28-59)
Sample 2 15 39 29 48 32.8 (15-48)
Sample 3 40 51 45 69 51.3 (40-69)
Sample 4 51 42 68 40 50.3 (40-68)
Table 3-3 Testing the same sample against sections from different blocks
Sample Counted No of Counted No of Percentage
positive positive difference
neurones neurones counts
(Block 1) (Block 2)
Sample 1 39 70 56%
Sample 2 25 50 50%
Sample 3 40 89 45%
Sample 4 51 68 75%
Conclusion
Grading and counting neurones was unreliable and neat or XA dilutions of serum gave 
high background. Therefore a higher dilutions of sera: 1/25, 1/50 and 1/500 were 
investigated, to allow any discrimination between positive or negative sample to be better 
defined.
Serial dilutions other than 1/50 and 1/500 preparations of each sample was not done 
routinely due to limitations in numbers of tissue sections and the variations in section 
quality (Tables 3-2 and 3-3). Poor tissue preservation might be a cause for the variability 
in results, itself influenced by time of storage of brain tissue post death.
Serial titrations would of course show the average expected titre of ABGA.
However, from earlier experiments, staining is not present at dilutions of only 1/500, 
so ABGA were assumed to be of low concentration. However, titrating samples to 
endpoint could be done as some patients might have high titre antibodies which 
influence clinical presentation or outcome.
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3.8 Altered method using a 1/50 dilution of serum improved
immunofluorescence results in 10 normal and 10 rheumatic fever 
controls 
Introduction
I found that diluting the serum 1/50 produced clearer results compared to Husby’s 
methods as background fluorescence was reduced (Figure 3-6).
Results
Background fluorescence such as lipofuschin granules was present in secondary antibody 
tested against the basal ganglia section without serum, but there was no obvious anti­
neuronal staining (Figure 3-6a).
It was found that 10 normal control samples tested did not produce any specific staining 
of neurones or accessory cells at a dilution of 1/50 (Figure 3-6b-d).One of the RHF 
controls (10%) was positive for weak axonal-like staining (Figure 3-e).
Conclusion
Therefore neuronal-like staining might be present in some cases of RHF without obvious 
chorea. Normal controls did not appear to have neuronal-like staining.
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Figure 3-6 Typical results from control sample from a control with post­
streptococcal glomerulonephritis tested 1/50 against human caudate and putamen 
section
A: 2nd antibody diluted 1/30 and tested B: Normal control sample diluted
against Human basal ganglia section 1/50 and tested against human basal ganglia
No specific staining. Lipofuschin section. High background but no specific staining,
granules, mag x200 Lipofuschin granules, mag x200
C: Normal control diluted 1/50 and tested D: RHF control diluted 1/50 and tested,
against human basal ganglia. No specific staining, against human basal ganglia. No specific staining
Lipofuschin granules, mag x200 Lipofuschin granules, mag x200
E*
t
E: RHF control diluted 1/50 and tested against 
against human basal ganglia. Weak specific staining, 
(arrows), mag x200 
Key: Yellow bar 5p.m
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3.9 Anti-basal ganglia antibody results in a large Sydenham’s chorea 
cohort using indirect immunofluorescence and 1/50, single point 
dilution of sera
Introduction
Using the developed IF method (1/50 dilution of serum) described earlier 34 SC, 24 
persistent SC, 20 normal controls and 20 RHF samples were diluted 1/50 and tested 
against human basal ganglia.
Results
No normal control showed any specific binding (Figure 3-7a). Eighteen of the 20 RHF 
cases had no specific binding (Figure 3-7b), but 2 of the RHF controls had axonal-like 
staining (Figure 3-6e).
In acute SC 97% (33/34) had IgG binding to axons (Figure 3-7 b-e and Figure 3-8). 
Binding dropped to 63% (15/24) in persistent SC, but the staining pattern was similar to 
acute SC (Figure 3-7f). The acute SC and persistent SC groups both had increased IF 
positivity compared to both RHF (p=<0.01) and normal controls (p=<0.01). There was a 
higher percentage of positivity in acute compared to persistent SC (p=<0.01).
Conclusion
The binding appeared to be predominantly cytoplasmic though it was difficult to establish 
whether membranes were also stained. There were some yellow precipitates of 
lipofuschin which is not uncommon when using IF methods on human tissue (Figure 3-6 
and 3-7).
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Figure 3-7 Indirect Immunofluoresence of Sydenham’s chorea, rheumatic fever and 
normal controls diluted 1/50 and tested against human basal ganglia
A: Normal control diluted 1/50 and tested 
Against human basal ganglia tissue.
No specific staining, mag x200
B: RHF control diluted 1/50 and tested against 
Human basal ganglia. No specific staining, 
magx200
C: SC sample diluted 1/50 and tested against 
Human basal ganglia tissue. Weak staining 
o f axons (arrow), mag x200
D: SC sample diluted 1/50 and tested against 
human basal ganglia tissue. Strong staining 
o f axons (arrow), mag x200
E: SC sample diluted 1/50 and tested against 
Human basal ganglia. Strong staining (arrow) 
o f axons, mag x200 
Key: Yellow bar 5pm
F: Persistent SC sample diluted 1/50 and 
tested against human basal ganglia. Staining 
o f axons (arrows), mag x200
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Figure 3-8 Detailed figure of a typical indirect immunofluorescence staining pattern 
in a patient with acute Sydenham’s chorea using 1/50 diluted serum
A: Neuron specific staining; predominant in axons with sparing o f  the nucleus; B: Lipofuschin granules; C: 
Low background fluorescence (original magnification x200).
Key: Yellow bar 5pm
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3.10 Indirect immunofluorescence of Putamen using 5 Sydenham’s 
chorea samples
Introduction
To assess differences in caudate/putamen staining, 5 SC samples were tested at 1/25 and 
1/50 against human putamen sections.
Results
ABGA staining was only scantly present in putamen (Figure 3-9) and only at dilutions of 
1/25, but appeared to be specific to the cytoplasm. High magnification appeared to show 
cytoplasmic and not membranous neuronal-like staining (Figure 3-10).
Figure 3-9 Typical Indirect Immunofluorescence staining pattern in the putamen 
from one patient with acute Sydenham’s chorea using 1/25 diluted serum
A: Neuronal staining is present but positive neurones are sparser than seen in the caudate (original 
magnification x200). Key: Yellow bar 5pm
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Figure 3-10 High power magnification of the same SC sample showing cytoplasmic 
staining of neuronal-like cell
stronger in caudate than putamen, the numbers of samples tested was small, n=20. 
Characterisation of neurones was crude, but, if glial cells were stained the numbers of 
positive stained cells would be far greater than that seen (Figure 3-9). As basal ganglia 
neurones express very similar receptors so an in-situ hybridisation method would be 
required to diffentiate neurones rather than just double staining with antibodies. The 
neurones appear to be large, 5pm in length.
However, using commercial antibodies to prove neuronal, rather than glial 
specificity of this low titre staining is required. Examining a larger cohort for 
sensitivity and specificity of IF is also require^ if AB(*A are a diagnostic tool.
A: Neuronal-like staining o f cytoplasm (original magnification x400). 
Key: Yellow bar 5pm
Conclusions
SC samples had an anti-neuronal like positive staining but only at 1/50 dilutions, this was
3.11 Anti-basal ganglia antibodies: neuronal specificity in 
human basal ganglia
Introduction
The cells that stained with ABGA were also stained with a coomercial, neurone-specific 
enolase antibody. To assess the distribution of this staining, i.e. if staining is just 
cytoplasmic or there is any indication of membranous staining, human sections were 
tested. (Figure 3-11 and 12). Transverse sections were also tested as this was how Husby 
et al presented ABGA in their original paper (Husby et al., 1976). Therefore an attempt 
was made to repeat this study and try and show if the cytoplasm of neurones were stained 
by IgG (Husby et al., 1976).
Results
Commercial antibody against neurone specific enolase (NSE), which is a specific 
antibody against a protein found on and within neurones (Figures 3-11). Patients with SC 
had similar staining (Figure 3-7 and 3-8). Transverse section showed C-19 antibody 
stained neuronal cytoplasm (Figure 3-12). One patient with SC also had similar staining 
to the NSE antibody (Figure 3-13). There was no obvious membranous staining.
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Figure 3-11 Longitudinal section of human basal ganglia stained with anti-enolase 
commercial antibody (C-19) diluted 1/500 to visualise axonal staining
A: Enolase NSE-P2 antibody diluted 1/500 B: Sydenham’s chorea sample diluted 1/50 binds to
binds to axons (arrow). axons (arrow)
Granules, mag x400 Ubiqutous lipofuschin granules
mag x400
Key: Yellow bar=5pm
Figure 3-12Transverse section of human striatum stained with anti-enolase 
commercial antibody (C-19) diluted 1/500 to visualise neurones
A: Anti-enolase antibody staining o f  transverse section showing granular cytoplasmic staining o f  neurone; 
B: Lipofuschin ganule (appears green due to filter used), (Original magnification x800).
Key: Yellow bar 5pm
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Figure 3-13 Transverse section of human striatum stained with anti-basal ganglia 
positive antibody to visualise neurones
A: Sydenham’s chorea anti-basal ganglia antibody staining o f longitudinal section showing cytoplasmic 
staining o f neurone; B: Lipofuschin granule (appears green due to filter used), (Original magnification 
x800). Key: Yellow bar 5pm
Conclusion
These results appear to show a axonal distribution of IgG binding from patients with SC 
but more samples should be tested. Commercial controls of ubiquitous neuronal proteins 
should also be tested such as neurofilaments, tubulin and 14-3-3. Live cell assays with 
primary striatal cultures are also necessary to prove this hypothesis.
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3.12 Anti-basal ganglia antibodies in cerebrospinal fluid detected using 
indirect immunofluorescence
The volume of CSF from 2 acute SC patients was sufficient for ABGA testing, and this 
resulted in the same neuronal staining pattern as seen in the parallel serum samples. The 
ABGA positivity was the same as that found in the first SC cohort with cytoplasmic 
staining of medium-large neurones which were confined to neuronal tracts predominantly 
in the caudate head. However, the numbers tested are too small to draw any meaningful 
conclusions and SC patients are unlikely to undergo routine lumbar puncture.
3.13 False positive indirect immunofluorescence in a patient with chorea 
One UK patient with a diagnosis of persistent SC was later diagnosed as having a 
vascular basal ganglia pathogenesis rather than SC. The IF pattern was consistent with 
that seen in SC and there was reactivity to several antigens on Western immunoblotting. 
The ABGA positive result may have been an example of a false positive result in a 
patient with suspected persistent SC, or the patient may have had a dual pathogenesis, 
having had clinically defined SC 2 years previously. In view of the specificity of ABGA 
the latter seems more likely.
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3.14 Recrudescent (late recurrent) Sydenham’s chorea 
None of the 5 patients with recrudescent chorea was ABGA positive using IF, ELISA or 
Western immunoblotting. The mean ASOT level was 190 IU/mL (50-210 IU/mL). One 
patient (1/5, 20%) had a raised ASOT level of 210 IU/mL. The mean ant-DNAse B was 
255 IU/mL (50-290IU/mL). No patient had a raised anti-DNAse B. One patient (1/5, 
20%) was subsequently diagnosed with Coeliac disease and was placed on a gluten free 
diet. This improved the choreic symptoms but it is uncertain whether the improvement 
was a spontaneous improvement or related to the removal of gluten.
168
3.15 Ten Tourette’s syndrome patients tested against basal ganglia
Introduction
IF was only performed in this study on 10 TS patients (5 paediatric and 5 adult) who 
were positive on Western immunoblotting. Ten, neurological disease controls were 
tested. All patients had the same binding pattern, with IgG binding to large basal ganglia 
neuronal-like cells.
Results
IgG from all the TS patients studied had staining of axons with a similar pattern to SC 
(Figure 3-14 and Figure 3-15). None of the 10 controls tested reacted against any cellular 
component of the basal ganglia (Figure 3-14a).
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Figure 3-14 Indirect Immunofluorescence against human basal ganglia in Tourette’s 
syndrome
A: Neurological disease control diluted 1/50 and tested 
against human Basal ganglia tissue. High background but 
no specific neuronal-like staining
mag x200
B: Child with TS diluted 1/50 and tested against 
Human basal ganglia. Axonal staining 
Present, mag x200 
Key: Yellow bar 5pm
C: Child with TS diluted 1/50 and tested against 
Human basal ganglia. Axonal staining present 
showing cytoplasmic predominance at high 
Magnification, x400
Conclusions
IF was only used to investigate a small number of TS patients with positive streptococcal 
serology. A large histological study is required so this is pilot data only.
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Figure 3-15 Detailed figure of indirect immunofluorescence of a sample from a 
patient with Tourette’s syndrome tested at a 1/50 dilution against human caudate 
and putamen section
A: IgG staining o f  neuronal-like cells predominately localised to the cytoplasm; B: Lipofuschin granules; 
(Original magnification x400). Key: Yellow bar 5pm
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3.16 Sixteen patients with Paediatric autoimmune neuropsychiatric
disorders associated with streptococcal infections tested against human basal 
ganglia
Introduction
Indirect immunofluorescence was performed in 16 patients with PANDAS and 10 with 
streptococcal infection controls
Results
In the control group 1/10 streptococcal infection controls had similar binding to SC and 
TS at 1/50 (Figure 3-16), the remaining 9 were negative. The same IgG binding to 
neuronal-like cells was seen in 14/16 of PANDAS patients. The binding pattern appeared 
to be cytoplasmic and axonal if these cells are neurones (Figure 3-17).
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Figure 3-16 Post-streptococcal nephritis control diluted 1/50 and tested against 
human basal ganglia showing neuronal-like binding
Axonal-like staining (arrows), mag x200, Key: yellow bar 5pm
Figure 3-17 1/50 dilution of sera from a UK PANDAS patient, tested with a section 
of human caudate and putamen tissue
A: IgG staining o f  the axons o f large striatal neurones with the same pattern as that seen in the Brazilian SC 
patients. (Original magnification x400).
Key: Yellow bar 5pm
Conclusion
Whilst the similar staining in PANDAS to SC is interesting only a small number of 
samples were tested. This is pilot data only due to the small numbers of samples tested
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3.17 The presence of other autoantibodies in Sydenham’s chorea 
Introduction
All SC patients and controls were tested for the presence of systemic autoantibodies 
using a general indirect immunofluorescence screen against rat liver, kidney and stomach 
tissue (The Binding site FS313).
Results
Few systemic autoantibodies (anti-nuclear antibodies etc) were detected in SC, RHF and 
controls (Table 3-4).
Conclusion
There was no difference in the number and percentage of positive systemic 
autoantibodies detected using IF in SC and controls.
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Table 3-4 Other autoantibodies in Sydenham’s chorea using indirect 
immunofluorescence
Autoantibody Acute SC Persistent SC RHF Normal
controls
Nuclear 3/34(10%)* 0/24 (0%) 3/20 (15%) 1/40 (3%)
antibodies
Smooth muscle 2/34 (6%) 0/24 (0%) 3/20(15%) 0/40 (0%)
antibodies
Mitochondrial 0/34 (0%) 0/24 (0%) 0/20 (0%) 1/40 (3%)
Reticulin 0/34 (0%) 0/24 (0%) 0/20 (0%) 0/40 (0%)
Liver Kidney 0/34 (0%) 0/24 (0%) 0/20 (0%) 0/40 (0%)
Microsomes
Ribosomal 0/34 (0%) 0/24 (0%) 0/20 (0%) 0/40 (0%)
P=n/s Fisher’s exact test (2 tailed).* All 3 ANA positive patients were negative for dsDNA and extractable
nuclear antigen autoantibodies.
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Conclusions
Testing SC samples against rat brain sections did not result in any obvious staining of 
brain at a dilution of 1/500. There was only weak neuronal-like staining at 1/50 dilutions. 
The area of the brain with deep grey matter/basal ganglia like structure was identified 
with staining the section with a commercial monoclonal D2 receptor antibody. This 
stained a small portion of the section. There was no obvious staining of this area with SC 
samples compared to the rest of the brain. However, too few samples were tested and a 
more appropriate study would be at least 100 samples and 100 controls and to use 
histochemistry against whole rat brain with multiple monoclonal anti-neuronal antibodies 
to define cell populations.
As ABGA was originally reported using human brain (Husby et al., 1976). Antigen 
localisation, presentation and presence might be dependant on species and may have 
accounted for the negative findings. Primate and human sections were also studied as 
previous published peer reviewed work of basal-ganglia antibodies used human tissue, so 
it appeared logical to at least attempt to replicate these frequently cited studies.
There was no staining of Purkinje cells with 1/50 diluted SC, TS or PANDAS samples in 
monkey sections. There was staining of neurone-like cells in the cerebellar granule layer 
of monkey brain. There was also neuronal-like staining in human basal ganglia. 
Commercial antibodies suggested this staining as neuronal rather than glial, although this 
is just a basic method. Techniques such as in situ hybridisation are required to 
characterise these neurones, this has not been done. Double staining sections with
176
antibodies against tubulin, neurofilaments and SI00b could have been done to 
differentiate between neurones and glia. Further staining with commercial antibodies 
could not be done due to cost although more samples and controls must be investigated.
Human basal ganglia appeared to give the best staining of neuronal-like antibodies in SC, 
TS and PANDAS. Staining of neurones in other areas of the brain, notably the cerebellar 
granular layer means that these antibodies are not basal ganglia specific. However the 
antigens may be enriched in mammalian basal ganglia as the human sections gave a clear 
anti-neuronal staining pattern. The problem with this tissue source is high background 
fluorescence and problem of availability. Although controls were negative, presence of 
donor IgG might have caused false positive staining, so human tissue is not ideal for 
study.
Further studies are required to investigate the specificity of anti-neuronal antibodies in 
SC. Additional techniques could include immunohistochemistry and live cell assays 
using primary striatal cultures. One potential method is using cultured cerebellar granule 
cells which appeared to be bound by IgG from SC patients according to Dale et al (Dale 
et al., 2006). An ELISA screening test for ABGA was developed for screening multiple 
samples to identify samples for proteomics and putative antigen identification.
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4 Results of the Enzyme linked immunoabsorbant
assay
4.1 Anti-basal ganglia antibodies in Sydenham’s chorea 
detected by ELISA; method development for a screening 
assay
Introduction
Indirect immunofluorescence appeared to suggest cytoplasmic, rather than membranous 
distribution of weak (1/50) IgG binding from patients with Sydenham’s chorea,
PANDAS and a small group of patients with Tourette’s. This may suggest that the 
antigen(s) responsible for this staining are cytosolic and therefore possible soluble. It was 
hypothesised that a soluble fraction obtained from basal ganglia tissue might be an ideal 
antigen for an ELISA to detect these antibodies in large numbers of samples. The ELISA 
technique has the advantage of cheaper cost and availability of tissue from animal 
sources if the assay was discriminatory between SC, PANDAS and controls.
A box-and-whisker plot, incorporating a scatter plot of individual data points is 
used to show all ELISA data. The bar represents the median, rather than mean 
absorbance and the whisker is the range of results.
178
4.2 Comparison of basal ganglia preparations for ELISA; whole 
homogenate, de-lipidated soluble and insoluble fractions 
The influence of different antigen preparations on the ELISA results was investigated. 
Duplicate microtitre plates were prepared using the same concentration of either (1) 
soluble basal ganglia homogenate SI (2) The SI fraction treated to remove excess lipid 
(delipidated); (3) Insoluble fraction PI (solublised with 6M urea), (Figure 4.1). Each 
plate was incubated with the same samples (20 acute SC and 20 normal controls).
Results
The soluble whole homogenate ELISA had high blank wells (mean 0.1 absorbance, SD 
0.08). There were also high absorbances (>0.35) in four normal controls (Figure 4-1).
The presence of myelin-lipids in the homogenate could have caused these results and 
removal of lipids reduced these raised results in controls (Figure 4-1).
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Figure 4-1 Results from twenty Sydenham’s chorea samples and twenty normal 
controls diluted 1/100 showing ABGA ELISA absorbances plotted against different 
antigen preparations with error bars showing the range of results
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Sl=soluble human basal ganglia fraction; SI delip= Slfiaction delipidated; PI fraction=solublised 
remaining pellet after initial homogenisation and removal of soluble proteins. All samples were tested in 
duplicate.
The insoluble fraction PI did not produce any differences in SC patients compared to 
controls (p=n/s in all instances). The SI fraction was treated to remove lipid and 
investigated for use as an ELISA antigen to detect anti-brain antibodies in SC, PANDAS, 
TS and controls.
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4.3 The optimum fraction for performing an ELISA to detect anti-basal 
ganglia antibodies in 20 Sydenham’s chorea and 20 normal controls
The results showed that the best signal-to-noise result of the 20 SC samples compared to 
controls and lowest blanks, was from the soluble fraction of basal ganglia SI (caudate 
and putamen), prepared using T-per but, treated with Di-iso-propyl-ether (BDH) to 
remove excess lipid (Figure 4.1).
Results
Reagent blanks of SI antigen typically had a mean absorbance of 0.05 (SD 0.03). 
However, there was no significant difference (p=n/s) in ABGA results when comparing 
mean SC results from the SI fraction (mean absorbance 0.78, SD 0.06) compared to the 
de-lipidated SI fraction (mean absorbance 0.64, SD 0.09), (Figure 4.1). Therefore the de- 
lipidated SI fraction was used for all ELISA.
Conclusion
The potential auto-antigens that patients with SC react to are soluble proteins rather than 
lipids, or membrane proteins and are cytosolic. Therefore ABGA are probably just a 
marker of disease rather than functional on the basis of these results with the IF findings.
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4.4 Optimisation of ELISA method using SI soluble fraction of human basal
ganglia 
Introduction
The antigen concentration for the ABGA ELISA method (standard serum dilutions and 
dilution of the detecting secondary antibody) was obtained from the chequerboard of 
dilutions using 16 SC and 16 normal controls (Figure 4.2). The optimum components of 
the ELISA:
• Concentration of antigen which gave the best signal-to-noise ratio with low 
absorbance of the reagent blanks (<0.10).
• Serum and secondary antibody dilutions that gave the best signal-to-noise ratio
• The ELISA was designed to give ideal discrimination between absorbances from 
IF negative and positive samples so that it could be used as a screening assay.
Results
The ELISA antigen concentration used was lpg/mL of human basal ganglia soluble 
fraction which was delipidated (Figure 4-2). However, the mid-point of the concentration 
chquerboard was 1.25pg/mL (Figure 4-2) which could also be used. Using lpg/mL the 
mean absorbance of normal controls was under 0.5 which is the cut-off for a screening 
ELISA used routinely by the Neuroimmunology department, UCL NHS trust, CPA 
accredited, to detect anti-ganglioside antibodies in GBS. This concentration appeared to 
allow discrimination between SC patients which had a mean absorbance in these 16 
patients of over 0.5 and the normal controls (Figure 4-2).
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Figure 4-2 Results of sixteen normal controls and acute Sydenham’s chorea samples 
diluted 1/100 and tested against soluble SI basal ganglia ELISA antigen 
concentration chequerboard
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4.5 Optimum serum dilution for ELISA
A series of serum doubling dilutions of 16 SC samples resulted in a 1/300 dilution of 
serum giving the optimum signal-to-noise ratio between controls and positive samples 
(Figure 4.3). Additionally, a typical double dilution of 1 SC samples is presented in 
Figure 4.4. This was also a similar dilution (1/250) used by Singer et aVs group for their 
basal ganglia ELISA method (Singer et al., 1998 and 2003).
Figure 4-3 Serial serum dilutions to ascertain optimum dilution for anti-basal 
ganglia ELISA using sixteen Sydenham’s chorea samples
Box and whisker showing sixteen Sydenham's chorea samples tested against 1 ug/mL 
antigen, increasing dilutions
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Figure 4-4 Titration result from 1 patient with error bars showing percentage 
difference in absorbances after testing 3 times
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4.6 Optimum dilution of secondary anti-Human IgG HRP conjugated 
antibody
The optimum dilution of the secondary detector antibody was obtained through following 
guidance of the manufacturer for antibody (Dako). A dilution of 1/2000 of the secondary 
antibody was used.
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4.7 Intra-assay variation of the basal ganglia ELISA
Introduction
Three SC samples and three normal controls were tested on the same plate using 1 pg/mL 
of soluble SI fraction and 1/300 dilution of serum to assess intra-assay variation of the 
ELISA.
Results
The results are summarised in Table 4-1.
Table 4-1 Summary of the results of intra-assay variation for the basal ganglia 
ELISA
Group Mean SD Standard
absorbance error
Acute SC 0.63 0.14 0.04
0.55 0.14 0.05
0.68 0.11 0.03
Normal 0.19 0.06 0.02
controls 0.17 0.08 0.03
0.25 0.06 0.02
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4.8 Inter-assay variation of the basal ganglia antibody ELISA
One SC sample and 1 normal control were tested in duplicate wells on 10 different plates 
to assess inter-assay variation (Figure 4.5). The statistics revealed that the assay was 
relatively reproducible (Table 4-2).
Figure 4-5 Low and high positive ELISA sera tested on 10 separate ELISA plates to 
assess inter-assay variation of the ELISA
Inter- assay variation
0.8 
0.7 - 
0.6 — SC positive 
Normal control
OD
Replicate measurements
Table 4-2 Statistical analysis of inter-assay variation
Group Mean SD CV Standard error
absorbance
Acute SC 0.85 0.07 0.08 0.02
Normal control 0.21 0.07 0.34 0.02
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4.9 Summary of how the antigen was prepared for the ELISA
used in all the following results
Defrost caudate/putamen block at room temperature, weigh and cut into small pieces with 
a sterile scalpel. Transfer into homogenisation tube, add protease inhibitor cocktail (100 
pi per 2g tissue), (Sigma chemicals). Add T-per, tissue extraction reagent (Peirce), (lmL 
per gram of tissue). Place tube in wet ice and homogenise tissue until there are no clear 
precipitates. Transfer into a fresh tube and centrifuge at 10,000rpm for 15 minutes.
Collect supernatant, mix with 25% volumes of di-iso-propyl-ether, centrifuge, 10,000rpm 
for 15 minutes. Using a spinal needle, or long glass pipette, collect the protein fraction 
from the solvent/protein phase and store in a fresh tube. All the ABGA ELISA results 
were obtained using lpg/mL of basal ganglia homogenate and all samples were tested in 
duplicate at 1/300 dilution of serum. Measure total protein; adjust concentration to 
lpg/mL in 0.025M carbonate buffer. Pipette 100 pi into duplicate well of a Nunc, 
maxisorb microtitre plate, cover with film and leave at +4°C overnight (12 hours). Rinse 
with PBS and proceed with ELISA run.
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4.10 IgG levels in 30 Sydenham’s chorea samples and 50 controls 
Introduction
To assess non-specific binding, IgG concentration was measured. However, the normal 
ranges of IgG are dependant on age and will influence the importance of these results. 
Therefore individual patients and controls will naturally have higher of lower IgG levels 
than older or younger children. This is a potential source of inaccuracy in the ELISA 
method and is a major critism of this assay. A better method would be to dilute all the 
samples to the same concentration of IgG but this was not practical for large numbers of 
samples and expensive.
Results
There appears to be no significant differences in mean IgG results between SC and 
controls (Figure 4-6). No variation in IgG concentration in age ranges was taken into 
account.
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Figure 4-6 Serum IgG levels in 30 acute, 20 persistent Sydenham’s chorea patients 
and 30 rheumatic fever and 20 normal controls measured by standard rate 
nephelemetry
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4.11 Analysis of the basal ganglia ELISA results of 60 controls and 58 
Sydenham’s chorea samples
Introduction
Using the optimum basal ganglia ELISA method 60 controls and 58 SC samples (Table 
4-3) were tested 1/300 against ELISA of soluble SI fraction.
Results
The mean absorbance in SC was increased compared to normal controls (p=<0.001) and 
patients with RHF (p=<0.001), (Wilcoxon rank-sum test), (Figure 4-7, Figure 4-8 and 
Table 4-3). There was no significant binding of IgG to just the microtitre plate, a method 
suggested by examiners (Figure 4-7 and Figure 4-8).
Subgroup analysis showed patients with acute SC had a higher mean ABGA absorbance 
than patients with persistent SC (p=0.03) or controls (p=<0.001). Patients with persistent 
SC also had significantly higher mean ABGA levels than normal (p=0.002) and RHF 
controls (p=0.003), (Figure 4-7, Figure 4-8 and Table 4-3).
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Figure 4-7 Box and whisker plot of basal ganglia antibody ELISA absorbances of 
twenty acute and persistent Sydenham’s chorea samples diluted 1/300 with 
individual blanks (no antigen) for each sample
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p=<0.001 refers to acute SC versus blanks and versus persistent SC; Wilcoxon rank-sum test (Mann- 
Whitney). There was a significant increase in ABGA ELISA in acute SC compared to persistent SC
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Figure 4-8 Box and whisker plot of basal ganglia antibody ELISA absorbances of 
twenty Rheumatic fever and forty normal controls samples diluted 1/300 with 
individual blanks (no antigen) for each sample
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p=n/s; Wilcoxon rank-sum test (Mann-Whitney). There was no significant difference between Rheumatic 
fever and normal controls. The mean absorbance of blank wells (no antigen) was 0.127. There were 14/40 
patients who had blank wells above the mean blank although only 1 patients had a blank result above a 
statistical cut off value 0.33 absorbance units.
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Table 4-3 Summary of ELISA results of Sydenham’s chorea patients
Group Number Mean absorbance SD
at 492nm
Acute SC 34 0.62* 0.2
Persistent SC 24 0.40** 0.15
Rheumatic fever 20 0.23 0.11
Normal controls 40 0.21 0.06
*p=<0.01, **p=0.03, (versus normal and rheumatic fever controls). Wilcoxon rank-sum test (Mann- 
Whitney).
4.11.1 Basal ganglia ELISA results using transformed data 
Normalising the absorbance data, using a simple logarithmic transformation resulted in 
acute and persistent SC ELISA results significantly elevated compared to a range of 
normal, streptococcal and neurological disease controls (Figure 4-9). This confirms that 
an anti-basal ganglia screening ELISA detected significant elevations in IgG binding in 
Sydenham’s chorea compared to a range of normal and disease controls.
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Figure 4-9 Log transformed plot of anti-basal ganglia antibody ELISA in 20 acute, 6 
persistent Sydenham’s chorea patients and 30 normal, 10 demyelinating 
neurological and 25 streptococcal immune mediated disease controls.
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4.12 Basal ganglia ELISA utilising an upper limit of normal cut-off value 
Introduction
The number and percentage of individuals in each group with ELISA results above 
normal was calculated. To assess raised ABGA ELISA results a cut-off value for normal 
limits was calculated, (mean of controls plus 2 standard deviations, 95% percentile).
Results
This produced a cut-off value of 0.33 absorbance units. A higher cut-off value, (control 
mean plus 3 standard deviations, 99% percentile) was also calculated. This produced a 
cut-off value of 0.39 absorbance units. Using these cut-off values the number and 
percentage of raised ABGA ELISA results in each group was calculated (Table 4-4). A 
cut-off value of 0.33 was found to give the best ABGA positive discrimination of SC 
patients from controls.
4.12.1 Positivity o f Sydenham's chorea patients compared to ELISA cut-off 
Using the cut-off value (0.33 absorbance units), 91% (31/34) of the acute SC group, 58% 
(14/24) of the persistent SC group, and 78% (45/58) of the entire SC cohort, 10% (2/20) 
of RHF and 0% (0/40) of normal controls had an elevated ABGA (Table 4-4). 
Cerebrospinal fluid could not be tested due to insufficient sample volume.
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Table 4-4 Anti-basal ganglia antibodies in Sydenham’s chorea using ELISA cut-off
Group Number >0.33 Number >0.39
(Percentage) (Percentage)
Acute SC 31/34(91%)** 18/34 (53%)*
Persistent SC 14/24 (58%)* 8/24 (33%)*
Rheumatic fever 2/20 (10%) 1/20 (5%)
Normal controls 0/40 (0%) 0/40 (0%)
*p=<0.01; ** p=<0.001, Fisher’s exact test (2 tailed), Acute and persistent SC versus controls.
4.12.2 Anti-basal ganglia antibodies in a patient with Sydenham *s chorea: 
ELISA results over time 
One patient with a diagnosis of acute Sydenham’s chorea was admitted to hospital and 
ABGA measured at 1 week intervals for 3 weeks. Two further samples were tested in the 
convalescent phase. The level of ABGA measured by ELISA was highest at week 2 when 
the chorea was at its worse (Figure 4-10). The level of ELISA absorbance fell over time 
and appeared to mirror that of the clinical recovery (personal correspondence from Dr 
Russell Dale, Great Ormond Street Hospital).
Figure 4-10 Anti-basal ganglia antibodies in one patient with acute Sydenham’s 
chorea during acute disease and clinical recovery
Anti-basal ganglia ELISA absorbance over time in a 
patient with Sydenham's chorea
0.8
Time weeks
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4.13 Anti-basal ganglia antibodies: ELISA results in Sydenham’s chorea 
patients and controls from the UK
Introduction
Where possible serum was analysed for IgG concentration 
Results
There was no difference in serum IgG between SC and controls (Figure 4-11) and the 
mean ABGA ELISA results were similar between all controls groups.
Figure 4-11 Serum IgG levels in 12 UK patients with acute SC, 5 with persistent SC 
compared to 20 UK development delay controls and 15 Streptococcal infection 
controls
p=n/s
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p=n/s; Wilcoxon rank-sum test (Mann-Whitney).
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Results of the basal ganglia ELISA
In the acute SC group the mean ABGA ELISA was raised compared to any control 
groups (P=<0.01 in all comparisons), (Wilcoxon rank-sum test). In the persistent SC 
group the mean ABGA ELISA was not different from any control and was lower than the 
acute SC group (P=<0.001), (Table 4-5). In the acute SC group, as in the Brazilian SC 
cohorts, ABGA was raised (>0.33) in 83% of patients (10/12) unlike any control group 
(P=<0.001 in all instances). The mean ABGA ELISA in the persistent SC group was not 
different from controls although the number tested was small. The number of persistent 
SC patients with ELISA results above the cut-off (>0.33) was higher (p=<0.001) than 
controls though 33% (1/3) and consistent with the findings from the Brazilian SC cohort 
(Tables 4-4 and 4-5). In the control groups 0-21% of the UK streptococcal-associated 
autoimmune disease controls had raised ELISA results (>0.33) which was higher than the 
Brazilian normal controls or the UK developmental delay controls (Table 4-5).
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Table 4-5 Summary of Sydenham’s chorea anti-basal ganglia antibody results (UK)
Samples Number (sex ELISA ABGA P value
M:F) mean (Normal
<0.33 absorbance 
units)
Developmental 30(15/15) 0.210(0/30,0%) P=<0.0001
delay controls
Post-streptococcal 15 (8/7) 0.231 (1/15,6%) P=<0.0001
arthritis
Post-streptococcal 14(5/9) 0.261 (3/14,21%) P=0.0048
glomerulonephritis
Post-streptococcal 15 (5/10) 0.201 (0/15,0%) P=<0.0001
vasculitides
Rheumatic fever 5 (1/4) 0.305 (0/5, 0%) P=<0.0001
Acute Sydenham’s 12 (2/10) 0.565 (10/12,83%)
chorea
Persistent 3 (1/2) 0.286 (1/3,33%)
Sydenham’s
chorea
P value; Fisher’s exact test (2 tailed), Acute SC versus controls.
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4.14 Anti-basal ganglia antibodies detected by ELISA in patients with 
PANDAS
Introduction
Serum IgG was not tested routinely as there was no ethical approval for this test which is 
a recognised weakness and criticism of this study.
Results of basal ganglia ELISA
The mean ABGA ELISA absorbance was elevated in the PANDAS group compared to 
the neurological, streptococcal, autoimmune and normal controls (<0.001 in all 
comparisons), (Wilcoxon rank-sum test), (Figure 4-12). However, there was 47/220 
(21%) of controls above the cut-off value for this ELISA so ELISA had a sensitivity of 
75% (12/16 PANDAS positive) and specificity of 79% (47/220 positive control groups).
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Figure 4-12 Box and whisker plot of basal ganglia antibodies in 16 children with 
PANDAS and 40 neurological, streptococcal autoimmune, uncomplicated 
streptococcal infection and 30 healthy controls
B asa l ganglia ELISA  in PA N DA S and controls
Ia
CQ
1.4
1.2
1.0
0.8
0.6
0 .4
0.2
0.0
p=<0.01
8 ®Oo ■
S
O PANDAS 
H Child neuro 
A Strep immune
♦ Uncom strep
•  Healthy control
G roup
There was a significant difference between mean absorbance in the PANDAS groups and controls using a 
Wilcoxon test. There was 47/220 (21%) of controls above the cut-off value for this ELISA (all data not 
shown as several data points overlapped). Therefore the specificity of the ELISA test was poor for 
PANDAS diagnosis although the sensitivity was adequate (83%). Statistics used were the Wilcoxon rank- 
sum test (Mann-Whitney), statistics summarised in table 4-6.
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Table 4-6 Summary of PANDAS ELISA results
Group Number Mean Confidence intervals
absorbance
PANDAS 16 . 0.410 0.341-0.471
Neurology 100 0.229 0.207-0.251
controls
Uncomplicated 40 0.189 0.171-0.207
strep
Strep 50 0.251 0.200-0.302
autoimmune
Normal controls 30 0.230 0.130-0.330
P value
p=<0.001
p=<0.001
p=<0.01
p=<0.001
p=value; Wilcoxon rank-sum test (Mann-Whitney), PANDAS versus controls.
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4.15 Results of anti-basal ganglia ELISA in Tourette’s syndrome 
Introduction
Serum IgG was not tested as there was no ethical approval for this test which is a 
weakness of this study.
Results
The mean ABGA, ELISA result in the child TS groups was not different from the 
neurological and streptococcal infection controls (Figure 4-13). The mean ABGA, ELISA 
results in the adult TS group compared to the adult neurological disease and healthy 
controls was also not different (p=ns), (Figure 4-13).
Using the ELISA cut-off value (<0.33), an elevated ABGA ELISA result was only 
present in 16% (9/56) of the child TS cohort, 4% (2/50) of the neurology control group 
and 5% (2/40) of the streptococcal control group. There was no difference between 
groups (ns; p=0.09, p=0.08 respectively).
Using an ELISA cut-off of two standard deviations above the mean of both adult control 
groups (<0.43), an elevated ABGA ELISA was present in 11% (5/44) of adult TS, 2% 
(1/50) of adult neurological disease and 4% (2/50) of healthy controls, which gave no 
difference between groups (ns; p= 0.08, p=0.2), (Table 4-7). ELISA did not discriminate 
TS from control groups, (Table 4-7).
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Figure 4-13 Box and whisker of 56 child and 44 adult Tourette’s samples and 200 
age matched controls
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Table 4-7 Summary of Tourette’s syndrome anti-basal ganglia antibodies ELISA
results
Group Number Mean ABGA SD Confidence P value
ELISA intervals
Child TS 56 0.230 0.2 0.19-0.262 N/s
Child neurological 50 0.229 0.05 0.197-0.261 N/S
disease controls
Child streptococcal 50 0.189 0.07 0.171-0.207 N/s
infection controls
Adult TS 44 0.312 0.4 0.259-0.365 N/s
Adult neurological 50 0.224 0.06 0.197-0.251 N/s
controls
Adult normal controls 50 0.282 0.02 0.259-0.305 N/s
P=n/s (not significant); Wilcoxon rank-sum test (Mann-Whitney), TS versus controls.
4.16 Absorbances in Sydenham’s chorea, PANDAS and TS
Whilst a significant difference in ELISA was present in SC and PANDAS compared to 
controls the range of absorbances showed that ABGA is of low concentration (titre). This 
is because from the box and whisker plots, very few samples had absorbances over 1.0. 
Therefore like the IF results, ABGA ELISA show IgG responses are of low concentration 
in the blood.
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4.17 Conclusions
The ABGA ELISA was designed to allow for comparison of IgG binding to basal ganglia 
antigens in large numbers of samples with SC, PANDAS and Tourette’s and control 
groups. It was shown that highest ELISA results came from the ELISA prepared using a 
soluble SI extract of basal ganglia homogenate. Background reactivity was lessened by 
removing lipids. Elevated IgG was not shown to be responsible for higher ELISA results 
in SC compared to controls. IgG was not measured in PANDAS or TS which is a major 
criticism.
Results are summarised in table 4-8. There was a significant difference in the mean 
ABGA ELISA in acute SC compared to control groups, although this was not the case 
with persistent SC where 40% were negative according to a numerical cut-off value. 
However, 95% of acute SC patients, using the same cut-off value had raised results 
compared to 5% of controls. Significant differences may imply a higher autoantibody or 
more likely a higher polyspecific antibody response in certain post-infectious groups 
which happen to have neurological sequeale.
There was a similar pattern of ELISA results in patients with PANDAS which are 
patients with acute onset, post-streptococcal tic disorder. However, antibody reactivity 
was higher in control patients with non-neurological, immune complications of 
streptococcal infection e.g. Nephritis, arthritis and rheumatic fever. Results raised above 
cut-off were present in 21% of all controls. This suggests that ABGA are common to 
post-streptococcal immune mediated disorders and are just a marker of disease, rather
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than involved in pathology. Alternatively raised ELISA results may reflect binding to 
different epitopes in each group.
There was no significant difference in the mean ABGA ELISA results in either children 
or adults with TS compared to controls. This could mean that ABGA are not commonly 
present in TS or alternatively only a small subgroup is positive. Alternatively, as TS is a 
chronic disorder ABGA may only be a transitory phenonomen, present in the early stages 
of an inflammatory movement disorder perhaps only following recent infection. This 
probably suggests that anti-basal ganglia antibodies are just a marker of post­
streptococcal neurology.
The ELISA might have been a useful screening test in acute onset post-streptococcal 
disorders SC and PANDAS but is of no use in Tourette’s syndrome. The assay gave 
no indication of what the antigen was except for a soluble protein. A cytoplasmic 
antigen was suggested from IF studies which ELISA results support. Other 
autoantibodies may give false positive results. Contaminating factors such as 
heterophile antibodies may give false positive results. Whilst ELISA results in 
controls were below statistical cut-off from Brazilian controls this was not the case 
with UK controls groups, in the PANDAS study up to 21% of controls had raised 
results, although, this was mainly the streptococcal autoimmune patients without 
neurological signs.
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In conclusion this assay is not recommended for the measurement of IgG auto­
reactive antibodies against basal ganglia. Antibodies against a channel would also 
not be detected using this method so ELISA was not used further.
Table 4-8 Summary of ELISA results in post-streptococcal movement disorders
Group Number Mean Number over cut­
absorbance off (%) positive
Acute SC 34 0.62* 31/34 (91%) **
Persistent SC 24 0.40* 14/24 (58%) **
PANDAS 16 0.41* 12/16 (75%) **
Tourette’s 56 0.23 9/56 (16%)
Normal 40 0.21 0/40 (0%)
control
Neurological 50 0.23 2/50 (4%)
controls
Rheumatic 20 0.21 2/20 (10%)
fever
Streptococcal 40 0.19 2/40 (5%)
infection
Streptococcal 50 0.25 5/50 (10%)
autoimmune
disease
*p—<0.01, Wilcoxon rank-sum test (Mann-Whitney), SC, PANDAS and TS versus controls 
**p=<0.01, Fisher’s exact test (2 tailed), Acute SC, PANDAS and TS versus controls.
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5 Results of Western immunoblotting
5.1 Development of a method to detect anti-basal ganglia antibodies 
using Western immunoblotting
Introduction
Five separate striatum tissue blocks were used for this method. The first tissue used 
was optimised for detecting IgG responses in IF and ELISA positive samples. 
However, each tissue block was individually checked for optimum antigen dilution 
using 4 known positive and 4 negative samples detected using previous tissue. This 
was carried out using a 10 well PAGE gel containing double diluted antigen 1/2- 
1/128. Serum was diluted 1/300 and tested against Western blot. The antigen 
concentration which gave expected positive results without loss of reactivity seen 
with higher dilutions was used. The protein concentration on each blot was 
measured using a commercial kit (Biorad) and was between 30 pg and 50 pg of 
protein per gel, although less protein was on each blot.
Two basal ganglia fractions were tested SI and PI, although from ELISA and IF results 
the SI fraction was likely to contain any reactive antigens. As T-per was used, 
membranous proteins would be present in this fraction as well. However, the remaining 
pellet PI fraction was also studied. It is important to note that while the PI fraction 
contained membranous proteins, denaturing the proteins for Western blotting could have 
damaged (denatured) any possible channel that might be a candidate antigen for ABGA.
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5.2 Fractions tested for Western blotting
Prior to antigen concentration optimisation, fractions of human basal ganglia were tested 
by double dilutions of each fraction on a 10 well gel and stained. The first soluble 
fraction obtained from the crude homogenate S1 was collected as per ELISA antigen.
This fraction was also treated by solvent extraction to remove lipid. The remaining pellet 
PI was washed with Tris-HCL buffer and solublised using LDS sample buffer and heated 
at 65°C for 15 minutes. All fractions were double diluted (e.g. 1/2, 1/4, 1/8, 1/16) and 
PAGE was performed. The resulting Commassie stained gels are shown below (Figure 5-
i).
Results: Page gel showing double dilution of the soluble SI and remaining pellet P lof 
human basal ganglia. Multiple bands are present in the S1 fractions. The streaking in the 
SI and PI fractions is probably due to lipid and insoluble cell debris. Lipids were shown 
to be a problem in ELISA assay for ABGA. Therfore lipid was removed, gel was stained 
with high sensitivity Colloidal blue (commassie based) staining kit (Invitrogen) to show 
bands clearly (Figure 5-1 SI del).
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Figure 5-1 Comassie stained gels SI and PI showing basal ganglia double diluted 
fractions and SI delipidated gel stained with high sensitivity colloidal blue stain
SI fraction, soluble cytosolic proteins, S2; PI fraction remaining insoluble proteins and cell debris, all 
fractions were double diluted 1/2, 1/4, 1/8, 1/16 etc and 16pl loaded into each well. SI del=soluble SI 
fraction solvent extracted to remove lipid; stained with colloidal blue stain so bands can be seen in detail.
5.3 Influence of homogenisation methods on Western blots
5.3.1 Protein recovery 
The addition of T-per is thought aid the disruption of cell membranes, thereby increasing 
protein recovery (Perbio). However, many homogenisation methods include non-ionic 
detergents such as CHAPS, so T-per is just a commercial homogenisation reagent with 
the benefit of being reproducible. To assess whether T-per (Perbio) influenced results 2 
tissue blocks were homogenised in saline or T-per. The supernatant was diluted (1/4- 
1/32), electrophoresed in a 10 well PAGE gel and stained with Commassie blue (Figure 
5-2).
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Results
There were more bands present in each doubling dilution with the T-per treated sample 
than those produced with saline (Figure 5-2).
Figure 5-2 Scanned, commassie stained PAGE gel of basal ganglia tissue 
homogenised with saline or T-per and doubling diluted showing increase protein 
recovery with T-per
MW Saline MW T-per
Soluble SI fraction was obtained by homogenisation with saline or T-per, the results suggest T-per 
increases protein recovery
5.3.2 The influence o f homogenisation on antibody reactivity 
Introduction
To ensure that reactivity of protein was not affected by the addition of T-per, commercial 
antibodies against neuronal enzymes: Neuron-specific enolase, (ENO), (Autogen 
Bioclear), Pyruvate Kinase (PYK), (AbCam) and Aldolase C (ALDO), (AbCam) were 
diluted 1/5000 and tested against a 10 lane Western blot of soluble SI fraction containing 
double dilution of antigens prepared with saline and T-per (Figure 5-3).
Results
There was no loss of antibody reactivity in the homogenate produced using T-per 
compared to saline (Figure 5-3).
Figure 5-3 Reactivity of commercial monoclonal antibodies against basal ganglia 
homogenates prepared using saline and T-per, showing no loss or change of 
reactivity with T-per
PYK "
ENO "' ^
ALDO
MW T-per dilutions MW Saline dilutions
Commercial antibodies were tested against double diluted (1/2-1/16) SI soluble fraction from basal 
ganglia, there was no difference in reactivity between saline and T-per fractions. T-per fractions appeared 
to give a stronger signal perhaps suggesting greater protein yield.
5.3.3 Antibody binding: colorimetric and chemiluminescence methods 
Introduction
Visualisation of antibody binding was carried out using enhanced chemiluminescence 
(ECL), (Perbio, 34080) and colorimetric substrate: 4-chloro-l-naphthol (Sigma C8890), 
(Figure 5-4),
Results
ECL produced an array of bands in controls and patients with high (polyclonal) 
background, making analysis of specific responses difficult (Figure 5-4). The number of 
bands and extent of high background staining also depended on how long the
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nitrocellulose was left developing with photographic paper, making timing very critical 
for the quality of results.
Colour development was more controllable and the stain less sensitive. This meant that 
weak affinity or low antibody concentration against brain tissue was less likely to result 
in multiple weak bands. Colour development of the Western blot was optimum at 15 
mins. Longer development resulted in discolouration of the nitrocellulose making 
resolution of bands poor and scanning of the blots difficult. However, this method is less 
sensitive than ECL so weak reactivity may not be seen which a criticism of this method.
Figure 5-4 Sensitivity of basal ganglia antibodies developed using colorimetric or 
chemiluminescent techniques
I’ M  ! ! !
<-D
A: colorimetric B: chemiluminescent
+  m  : ~
1/300 diluted normal control samples tested; A: Secondary antibody 1/1000 for colorimetric; B: 1/5000 for 
ECL; C: Only one normal healthy control has a weak band on colorimetric development; D: 
Chemiluminescent development reveals multiple bands not present on colorimetric detection.
5.3.4 Stability o f Western blotting homogenate
The prepared basal ganglia samples were stable (no loss of reactivity) for 48 hours at 
+4°C and 2 two weeks stored at -80°c. This was assessed by testing a positive SC sample 
known to be positive against a 60kDa band. The 60 kDa positivity appeared to be the 
same with the antigen source stored at +4°C for 2 days. The third day showed a decrease 
in reactivity and seven days later the band was barely visible. The activity of the 60 kDa 
band appeared to be unaffected by freeze-thawing as the LDS-treated sample kept for up 
to 2 weeks.
5.3.5 Dilution o f secondary antibody
IgG binding was detected using rabbit anti-Human IgG (fab) conjugated with HRP 
(Dako). The secondary antibody was diluted in 0.9% saline, containing 0.1% fat free milk 
powder. The dilution of this antibody was always 1/1000; this is the recommended 
dilution for Western immunoblotting from the manufacturer (Dako). A 1/1000 dilution is 
also the standard dilution used by the Neuroimmunology Department, UCL NHS trust for 
the detection of anti-neuronal antibodies by Western blotting of brain tissue.
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5.4 Antigen concentration of Western blotting of human basal ganglia 
Introduction
Four SC, ELISA and IF positive samples (2 weak and 2 strong) and 4 normal (no 
reactivity) controls were diluted 1/300 and tested against double dilutions o f  SI and PI 
fraction o f  human basal ganglia.
Results
None o f  the controls was positive, all four SC patients were positive against basal ganglia 
proteins. None o f  the SC patients o f  controls had any reactivity against the PI fraction.
Thirty micrograms o f  protein 1/8 dilution (Figure 5-5) was the dilution o f  antigen used 
that gave positive results 60 and 98 kDa bands (Figure 5-5) without loss o f  bands present 
in higher concentrations in this experiment. As human tissue was used donor IgG was 
always present and tested by diluting secondary antibody 1/1000 and testing against the 
same blot as figure 5-5, 1 band at 50-55 kDa was commonly present (Figure 5-5).
Figure 5-5 Commassie stained gel and Western blot of titrated SI fraction of human 
basal ganglia probed with positive Sydenham’s chorea sample diluted 1/300 to 
assess protein concentration for Western blotting
<—98 kDa
<—60 kDa
- I g G
4 5 6 7 8 1 2 3 4 5 6 7 8
Key: 1=1/4; 2=1/8; 3=1/16; 4=1/32; 5=1/64
The 1/8 dilution was used for all the following blots=30 gg protein per blot
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Conclusions
Five tissue blocks from different cases were used for Western blotting previous 
Western blot positives from the last tissue block used were tested on a chequerboard 
of antigen dilutions (Figure 5-5) neat-1/128 to re-asses optimum antigen dilutions. 
This was always between 30 and 50 pg of protein per blot.
An important criticism is that it was assumed that any reactive antigens would be in 
first soluble SI fraction because it contains detergent. However, a functional 
autoantibody would be likely directed against a channel. Whilst the membranous 
proteins are in both SI and PI fractions any channel reactivity is not usually 
apparent using Western blot. This method does not show that membranous proteins 
are not candidate antigens for antibodies in SC and PANDAS.
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5.5 Optimum serum dilutions for Western blotting 
Introduction
The results from both IF and ELISA showed that the expected titre of ABGA, or anti­
neuronal antibodies is considerably lower than that of PNS anti-neuronal antibodies. 
Results
Samples were not routinely titrated, instead a single point titration was used to analyse 
the presence of reactive proteins of the same molecular weights. In the 
Neuroimmunology laboratory sera are diluted 1/500 or 1/1000 for Western blotting and 
1/500 for immunohistochemistry (Neuropathology department) for the detection of anti­
neuronal antibodies for routine diagnosis of PNS. The optimum dilution of serum for the 
ABGA ELISA chequerboard was 1/300 and this same dilution was used throughout for 
Western blotting to compare the methods. Singer et al also used 1/250 dilution in both 
ELISA and Western blotting of human putamen and caudate (Singer et al., 1998 and 
Singer et al., 2003).
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5.6 IgG reactivity using Western immunoblotting of SI and PI fractions 
of human basal ganglia in 14 patients with Sydenham’s chorea and 
14 normal controls
Introduction
Using colorimetric development of Western blot reactivity of 15 Sydenham’s chorea and 
14 normal controls to the SI and PI fraction of human basal ganglia was assessed.
Results
There was no reactivity in SC patients and controls against the PI fraction of basal 
ganglia. (Number tested 14 in each group).
There was reactivity from SC samples to a number of bands in the SI fraction (Figure 5- 
7), which was expected from the ELISA and IF results, as antigens appeared to be 
cytoplasmic and therefore likely soluble. Bands were absent in controls (Figure 5-6). 
Conclusion
The SI fraction was used to test basal ganglia antibodies as the PI fraction gave no 
binding. The soluble nature of the antigens means a membranous antigen is unlikely. This 
makes a functional effect of anti-basal ganglia antibodies unlikely as functional 
antibodies are considered to be only reactive against membrane proteins such as in LEMS 
or Myaesthenia Gravis. ABGA might still be a marker of disease though.
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5.7 Western blot results in Sydenham’s chorea and controls 
using 30 jag of soluble SI fraction of basal ganglia and 
1/300 dilution of serum
Introduction
Using the optimum Western immunoblotting method of SI fraction and 1/300 dilution of 
serum 58 SC, 20 RHF and 40 normal controls were tested.
Results
97% (33/34) of acute SC, 63% (15/24) of persistent SC, 83% (48/58) of the entire SC 
cohort and 10% (2/20) of RHF controls reacted against at least 1 basal ganglia protein 
(Table 5-1). None of the healthy controls 0% (0/40) had any binding (Figure 5-6 and 5- 
7). There was reactivity to a number of basal ganglia antigens with molecular weights of: 
35 kDa (n=2), 40 kDa (n=15), 45 kDa (n=13), 60 kDa (n=7), 80 kDa (n=2) and 98 kDa 
(n=3).
The most common antigens were 40, 45 and 60 kDa. In the acute SC group only 15% 
(3/20) did not react with any of the 3 common basal ganglia antigens (Figure 5-8). The 
most common antigens in the persistent SC group were also 40 kDa (n=6), 45 kDa (n=5) 
and 60 kDa (n=6). All of the positive persistent SC reacted to at least 1 of these antigens 
(Figure 5-8).
Two patients with RHF who were ELISA and IF positive reacted to a 40 kDa antigen 
(Figure 5-6). Native IgG from the human tissue donor was detected in the basal ganglia 
homogenate (Figures 5-6, 5-7 and 5-8), (Table 5-1).
Figure 5-6 Western immunoblotting of 6 control samples tested against basal 
ganglia protein
t
mw con
Mw=molecular weight marker, con=positive control
lanes 1, 2 and 3 normal controls,
lanes 4, 5 and 6 RHF, lane 5 40 kDa band 9arrow)
Figure 5-7 Detailed Western blot showing no binding of 3 normal controls and 2 
rheumatic fever controls to 40, 45 or 60 kDa bands
B
60 kDa !gG
1
\ - -1
45 kDa 
40 kDa
A B
B: Detailed figure o f normal controls tested against a soluble SI fraction og human basal ganglia showing 
no reactivity except IgG from donor. A: 2nd antibody Rabbit anti-Human IgG HRP conjugated only; B, C 
and D: Normal control with no specific bands; E, F: Rheumatic fever control with no specific bands
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Figure 5-8 Western immunoblotting of 6 Sydenham’s chorea patient tested against
basal ganglia proteins
A
98 kDa —
60 kDa -> *****
IgG--*
45 kDa —*• ...  .......
Blank SC SC SC SC SC RHF
A: Results show strong staining against a 60 kDa protein in all patients with weaker responses to 45 kDa 
antigen in 3 patients. The first patient had multiple bands against two antigens at approximately 40 kDa, 
and 1 weak band against 60 kDa and one at 98 kDa. The reactivity of the IgG detector antibody against 
donor IgG is present in all wells, as expected. Rheumatic fever control was negative.
B *
98 kDa - •
-  > a . i  ii i i r K w H
i i i i l  igG
45 kD a—*
• ^ -40 kDa
SC SC SC sc
B: Four SC patients with multiple bands of reactivity, but with common 40, 45, 60 and 98 kDa 
The reactivity of the IgG detector antibody against donor IgG is present in all wells, as expected.
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Table 5-1 Summary of Western immunoblotting results in the Sydenham’s chorea 
cohort
Group Positive/ P value Basal ganglia antigens (molecular weights) 
number
Acute SC 33/34 - 30 kDa (n=l), 35 kDa (n=2), 40 kDa
(n=15),
45 kDa (n=13), 50 kDa (n=l),
60 kDa (n=7), 80 kDa (n=2),
95 kD a (n=l), 98 kD a (n=3) 
Persistent 15/24 0.0009 40  kD a (n=6), 45 kD a (n=5), 50 kD a (n=2),
SC 60 kD a (n=6), 80 kD a (n=3), 90 kD a (n=l),
95 kDa (n=2), 100 kDa (n=l) 
Rheumatic 2/20 <0.0001 40 kDa (n=2), 95 kDa (n=l)
Fever
Normal 0/30 <0.0001 No binding
controls
P value; Fisher’s exact test (2 tailed), Acute SC versus controls and persistent SC. Persistent SC versus 
RHF p= 0.0005 and normal controls p=<0.001.
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5.8 Sydenham’s chorea cerebrospinal fluid anti-basal ganglia antibodies by 
Western immunoblotting
Introduction
Neat CSF of 6 acute and 5 persistent SC patients was of sufficient volume to be tested for 
ABGA.
Results
In acute SC, 83% (5/6) and persistent SC 100% (5/5) had IgG reactivity against basal 
ganglia antigens. The basal ganglia antigens recognised by ABGA were the same in CSF 
as serum for each patient tested. The antigens common to CSF and serum IgG in acute 
SC were 35 kDa (n=l), 40 kDa (n=5), 45 kDa (n=3), 60 kDa (n=5), and 80 kDa (n=l). 
The persistent SC CSF and serum responses were 45 kDa (n=3), 60 kDa (n=4), 80 kDa 
(n=l), and 95 kDa (n=l), (figure 5-9).
Figure 5-9 Serum diluted 1/300 and neat cerebrospinal fluid from 1 patient with SC 
tested against 30 pg of SI fraction of human basal ganglia
CSF seram
SC CSF and serum binds to the same 45 kDa protein
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5.9 Sydenham’s chorea patients from the UK, Western immunoblotting 
results
of anti-basal ganglia antibodies
In the acute SC group recruited from the UK, 92% (11/12) of patients had positive 
reactivity to at least 1 of the common Brazilian SC antigens (40, 45, 60, 98 kDa), (Table 
24). Reactivity to the same antigens was present in both the UK and Brazilian, SC 
cohorts. In addition, reactivity against 38, 80 and 95 kDa basal ganglia proteins was seen 
in 4 acute SC patients. These additional responses were unusual and inconsistent. One 
acute SC patient had no reactivity against any Western immunoblotting protein and was 
also IF negative. In the persistent SC patients, 33% (1/3) reacted to antigens at 40kDa 
(n=l), 60 kDa (n=2) and 98 kDa (n=l), (Table 5-2). The persistent SC samples did not 
bind to any other basal ganglia proteins, although the numbers tested were small since SC 
is a rare condition in the UK.
Western immunoblotting of basal ganglia produced a specific 60 kDa band in 1 control 
with post-streptococcal arthritis. This patient had no evidence of RHF or movement 
disorder, although no psychiatric assessment was performed. Two controls with post­
streptococcal glomerulonephritis reacted against antigens of 20 and 55 kDa in 1 patient, 
and 60 kDa in the other. There was no evidence of a movement disorder although the 
psychiatric history was not assessed in detail. None of the patients with post­
streptococcal vasculitides had reactivity to basal ganglia but 1 patient from the RHF 
group bound to a 40 kDa antigen, although again the number of patients tested was small
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Table 5-2 UK Sydenham’s chorea and controls Western blot results
Samples Number (sex
M:F)
Developmental 30(15/15) 
delay controls 
Post-streptococcal 15 '(8/7)
arthritis
Post-streptococcal 14 (5/9)
glomerulonephritis 
Post-streptococcal 15 (5/10)
vasculitides 
Rheumatic fever 5 (1/4)
Acute Sydenham’s 12 (2/10)
chorea
Persistent 3 (1/2)
Sydenham’s 
chorea
Western blot P value 
Positive/negative
<%)
0/30, (0% ) P=<0.0001
1/15, (6% ) P=<0.0001
2/14, (14% ) P=0.0002
0/15, (0% ) P=<0.0001
1/5, (20% ) P=0.0099
11 /12 ,(93% )
2/3, (66% )
Fisher’s exact test (2 tailed), Acute SC versus controls. No statistics were performed on the persistent SC 
group as the numbers tested were too small for meaningful comparison
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5.10 Titration of four strongly positive Sydenham’s chorea samples 
against 30 micrograms of SI fraction of human basal ganglia
Introduction
Forty positive SC samples diluted 1/300 were visually assessed for reactivity on Western 
blot.
Results
Only 4 samples from 40 (10%) were considered to have strong binding and these samples 
were serially diluted 1/300, 1/500, 1/1000 and tested against a Western blot o f  human 
basal ganglia (Figure 5-10). Three samples had binding at 1/500, and 1 at 1/1000.
Figure 5-10 Western blots showing serial dilution of strong positive post­
streptococcal movement disorder patients
60 kDa
98 kDa— ►
40 kDa
cont 1 2 3 4 5 6 cont 1 2 3 4 5 6 blk
con: control, 1: 1/300, 2: 1/500, 3: 1/1000 
blk: blank, 6:1 /300 ,5:1 /500 ,4:1 /1000
Conclusions
In accordance with IF and ELISA only a minority o f  patients have reactivity at titres 
greater than 1/500.
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5.11 Western immunoblotting results in 16 PANDAS patients and 220
controls 
Introduction
Western immunoblotting demonstrated antibody reactivity to specific basal ganglia
antigens in the PANDAS patients rather than a polyspecific response
Results
Reactivity against any basal ganglia antigen was significantly more prevalent in the 
PANDAS patients compared to any of the controls (p<0.0005), (Fisher’s exact test), 
(Figures 5-11 and 5-12). Analysis of the patients and controls found that reactivity to 
basal ganglia protein was present in 94% (15/16) of the PANDAS patients compared to 
5% (11/220) of all the control groups combined. This method derived a sensitivity of 
94% and specificity of 95% in detecting patients with a potential diagnosis of PANDAS 
(Table 5-3).
The three most common basal ganglia antigens detected in the PANDAS patients had 
molecular weights of 40, 45 and 60 kDa (Figure 5-12). Analysis of the PANDAS results 
revealed that the 45 kDa and 60 kDa antigens were present in 50% (8/16). In contrast, 
reactivity to the 40 kDa antigen was present in 62.5% (10/16) of the PANDAS group 
(Table 5-3).
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Figure 5-11 Fourteen neurological disease controls tested 1/300 against Western 
blots of SI fraction of human basal ganglia
M w pos
A: No reactivity in 7 controls expect 
Donor IgG reactivity as expected 
Mw: molecular weight marker 
Pos: positive control 40 ,45 and 60 kDa
M w pos
B: No reactivity in 7 controls except donor 
IgG reactivity as expected 
Mw: molecular weight marker 
Pos: positive control to 40 ,45  and 60 kDa
Figure 5-12 Antibody binding of four PANDAS sera and three normal controls on a 
Western immunoblot of SI fraction of human basal ganglia
98 kDa
60 kDa
Ig G —►
45 kDa
40 kDa
MW PANDAS Normal controls
Western blot showing 4/4 PANDAS patients with antibody to a 60 kDa protein, 1 with 40 kDa binding, 2 
with 45 kDa, 2 with 98 kDa. Common bands were present due to reactivity o f  the secondary antibody with 
IgG from the donor tissue. Normal controls showed no reactivity.
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Table 5-3 Summary of PANDAS and control Western blotting results
Result PANDAS Neurology Uncomplicated
control streptococcal
Fisher’s exact 
test
Streptococcal
autoimmune
controls
Number
(Percentage)
positive
Mw:
15/16
(94%)
4/100 (4%) 1/40 (2%) 5/50 (10%)
40 kDa 8/16 (50%) 1/1 0 0 (1%) 0/40 (0%) 2/50 (4%)
45 kDa 7/16 (44%) 0/100 (0%) 0/40 (0%) 0/50 (0%)
50 kDa 0/16 (0%) 0/100 (0%) 0/40 (0%) 0/50 (0%)
60 kDa 7/16 (44%) 1/100 (1%) 1/40 (2%) 1/50 (2%)
80 kDa 4/16 (25%) 0/100 (0%) 0/40 (0%) 0/50 (0%)
other mw 30, 35, 42, 
62, 98 kDa
42,43,95 kDa 35 kDa 35, 50 kDa
P value, _ <0.01 <0.01 <0.01
Normal
controls
1/30 (3%)
0/30 (0%) 
0/30 (0%) 
1/30 (3%) 
0/30 (0%) 
0/30 (0%) 
50 kDa
<0.01
5.11.1 Results o f Western blots in control groups 
Four percent (4/100) of the neurological control group were ABGA positive with 
Western immunoblotting. The clinical presentation of the ABGA positive patients were: 
Status dystonicus (n=l), encephalitis (n=l), ataxia (n=l) and leukodystrophy (n=l). Only 
the sample from the patient with encephalitis bound to the common 40 and 60 kDa 
antigens seen in SC and PANDAS. The other patient samples, bound to a number of 
different antigens (42, 43, 95 kDa). Two percent (1/40) of the uncomplicated 
streptococcal infection controls were ABGA positive and bound to 35 and 60 kDa 
antigens. Three percent (1/30) of the normal controls was also positive and bound to a 50 
kDa antigen. Ten percent (5/50) of the autoimmune were also positive (Table 5-3). Two 
patients had RHF: one reacted to a 50 kDa basal ganglia antigen whilst the other reacted 
to a 40 and 60 kDa antigen. Two patients with glomerulonephritis reacted to 35 and 40 
kDa antigens and 1 patient had arthritis and also reacted to a 40 kDa antigen. All the 
ABGA positive autoimmune controls had post-streptococcal autoimmune diseases (Table
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5.12 Western blotting results in 100 patients with Tourette’s syndrome 
and 100 controls
5.13 Results from paediatric Tourette’s syndrome
Common bands of reactivity were seen in the TS group rather than polyspecific binding.
Results
Twenty percent (12/56) of the paediatric TS group had positive Western immunoblotting, 
compared to 4% (1/50) of the neurological controls and 2% (1/40) of the streptococcal 
controls. This was significantly different in the TS group compared to both control 
groups (p<0.05 and p<0.05 respectively), (Fisher’s exact test). The most common 
response was to 60 kDa (n=6), 40 kDa (n=4), 45 kDa (n=3), 67 kDa (n=2), 80 kDa (n=2 ) 
and 95 kDa (n=l) antigens (Figure 5-13). The positive neurological controls bound to a 
40 kDa (n=l) and 43 kDa (n=l) antigen. The positive streptococcal control bound to a 60 
kDa antigen.
5.13.1 Results from adult Tourette ’s syndrome 
Twenty seven percent (12/44) of the adult TS group had positive Western 
immunoblotting which was higher when compared to 2% (1/50) of neurological controls 
and 4% (2/50) of healthy controls, (p<0.005 and p<0.005 respectively), (Fisher’s exact 
test). The common antibody binding was also to 60 kDa (n=7), 40 kDa (n=5), 45 kDa 
(n=2), 80 kDa (n=2), 67 kDa (n=l) and 98 kDa (n=l) antigens. The positive neurology 
control bound to a 40 kDa antigen. The positive healthy controls both bound to a 55 kDa
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antigen. In all paediatric and adult TS patients the most common basal ganglia 
autoantigens detected were to a 60 kDa protein (n=13) followed by 40 kDa (n=9).
Figure 5-13 Three positive samples from Tourette’s syndrome patients tested 
against the SI fraction of human basal ganglia
60 kDa 
IgG—* 
45 kDa
40 kDa
Blank TS TS TS
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5.14 Homogenised guinea pig brain as a source of antigen for Western 
blotting to identify anti-neuronal antibodies in post-streptococcal 
movement disorder patients
Introduction
Guinea pig homogenate is used by the Neuroimmunology department, University College 
Hospital NHS Trust, London to perform Western blotting for the identification of 
paraneoplastic anti-neuronal antibodies. Therfore to confirm the 40, 45 and 60 kDa 
reactivity in SC and PANDAS, Western blots of 50 pg SI fraction of homogenised 
guinea pig brain was tested using 7 normal, 14 neurological disease controls, and 3 
strongly positive Sydenham’ and 2 PANDAS samples. All sera were diluted 1/300.
Results
Results from controls, SC and PANDAS are shown in Figure 5-14. One control with 
cerebellar ataxia was positive to a 60 kDa band. All SC samples were positive to a 60 
kDa band which was found on human basal ganglia; however 1 patient only had very 
weak binding which was difficult to show on an image. One PANDAS patient was 
positive and 1 was negative.
Conclusion
These results only show a point of principal that animal brain might be used to detect IgG 
reactivity against the bands common to SC and PANDAS. A large number of samples 
need to be tested. Not all of the strong positive IgG binding against human basal ganglia 
proteins was reflected in the results from guinea pig brain. This might reflect antigen
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concentration, localisation and source. However, reactivity to 45 and 60 kDa proteins 
were present so whole animal brain could be used as an antigen source but requires 
methological assessment.
Figure 5-14 Western blot of a soluble fraction of guinea pig brain probed with 7 
neurological disease control samples and 7 psychiatric disease control was diluted 
1/300
A B
Pos
60
kDa
1
mw cont 1 2 3 4 5 6 7 mw cont 1 2 6 7
A: mw= molecular weight marker 
Cont: 40, 45 and 60 kDa positive 
7 normal controls with no binding
]
B: mw= molecular weight marker 
cont=40, 45 and 60 kDa positive 
6 neurological controls negative, 1 positive to 60 kDa 
with cerebellar ataxia
mw cont 1 2 3 4 5 6 7 a  mw cont 1 2 3 4 5 6 7
31 f t
C: 1-5 & 7 neurological controls with no binding. D: 1 SC 60 kDa; 2 PANDAS neg; 3 PANDAS
6 Neurological control with 80 kDa band, 45 kDa; 4 SC 35 & 60 kDa; 5 SC trace 60 kDa;
7. Blank
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5.15 Identification of the dominant immunoglobulin type and IgG subclass 
specificity of ABGA binding using Western immunoblotting in 7 SC 
patients
Serum from 5 acute SC patients and 2 , persistent SC patients had the same pattern of 
binding to basal ganglia antigens on Western immunoblotting (40, 45 and 60 kDa), when 
staining for different IgG subclass binding. None of these samples had abnormal 
immunoglobulin levels above the ranges appropriate for their ages, measured using 
standard rate nephelometry.
Results
There were no significant responses against basal ganglia proteins with Western 
immunoblotting when investigating serum IgA or IgM binding from either acute or 
persistent SC patients. The dominant IgG subclass reactivity against basal ganglia 
proteins was IgGi or IgG3 in both acute and persistent SC (Figure 5-15). None of the 
patients tested had any reactivity when using IgG2 or IgG4 antiserum against Western 
immunoblots of human basal ganglia proteins.
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Figure 5-15 IgG subclass responses from a patient with Sydenham’s chorea against
basal ganglia proteins
M kDa-
45 kDa
MW IgG l; IgG2 IgG3 IgG4
V i - x ; ; : : . ; ; : - : :
5.16 Adult movement disorders: UK study 
The results from this study showed that patients with known genetic movement disorders 
(dystonia) were negative for ABGA and had no evidence of raised streptococcal 
serology. In patients with primary blepharospasm, which has been reported to be 
associated with autoimmunity, were included in this study (Jankovic e ta l 1993). 
Evidence of ABGA was also not found, but 1 patient had raised ASOT (10% 1/7), (Table 
5-4). This is in accordance with the expected incidence of raised ASOT in an adult 
healthy population as seen in these adult TS studies.
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In comparison, 25% of patients with idiopathic dystonia were ABGA positive by IF and 
Western immunoblotting, but only 4 had a raised ASOT. Unfortunately anti-DNAse B 
was not measured in these patients as the assay was not available at the time. 
Interestingly, 60% of patients with adult onset tics or “Tourettism” were also ABGA 
positive. ASOTs were raised in all of these patients.
Table 5-4 Results in patients serum from adult movement disorders
Diagnosis Number ABGA IF ABGA WB ABGA ELISA
% positive % positive Mean (% > 0.33)
Primary 
blepharospasm 
DYT1 positive 
dystonia 
Idiopathic 
dystonia 
Huntington’s 
disease 
Tourettism
10
0% (0/10) 0% (0/10) 0.213 (0%)
0% (0/10) 0% (0/10) 0.199 (0%)
20 25% (5/20) 25% (5/25) 0.38 (30%, 6/30)
0% (0/3) 0% (0/3) 0.299 (33%, 1/3)
60% (3/5) 40% (2/5) 0.30 (20%, 1/5)
ASOT 
Mean 
(% >200 
IU/ml)
152 IU/mL 
( 10%, 1/ 10) 
135 IU/mL 
(0%, 0/ 10) 
230 IU/mL 
(20%, 4/20) 
96 IU/mL 
(0%, 0/3) 
200 IU/mL 
(40%, 2/5)
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5.17 The sensitivity and specificity of the anti-basal ganglia antibody 
assays in Sydenham’s chorea
Results of Western blotting are summarised in table 5-5.
Results
The sensitivity and specificity of the ABGA IF method was calculated in all the SC 
samples tested (Brazilian and UK) and found to be 96% (44/46) in acute and 63% (17/27) 
in persistent SC. The specificity of IF in SC was 96% (5 positive controls from 139 
tested). The sensitivity of the ABGA ELISA was 89% (41/46) in acute and 55% (15/27) 
in persistent SC. The specificity of the ELISA was 95% (6 positive controls in 139 
tested). The sensitivity of the ABGA Western Immunoblotting was 96% (44/46) in acute 
and 59% (16/27) in persistent SC. The specificity of Western immunoblotting was 95%
(6  positive controls from 139 controls). The majority of controls were ABGA negative 
(non-diseased or patients with development delay (70/139).
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Table 5-5 Summary of Western blotting results
Group
Acute SC 
Persistent SC
PANDAS
TS
Normal control 
Neurological 
controls 
Rheumatic fever 
Streptococcal 
infection 
Streptococcal 
autoimmune 
disease
Number Common bands
46 40, 45, 60, 98 kDa
27 40, 45, 60, 98 kDa
16 35, 40, 45, 60, 80 kDa
56 40, 45, 60, 67, 80, 95 kDa
40
100 40, 42, 43, 60, 95 kDa
20 40, 95 kDa
40 • 35, 60 kDa
44 20, 55, 60
Number positive 
(%)
44/46 (96 %) ** 
16/27 (59%) **
15/16(94%)** 
12/56 (20%) ** 
0/40 (0%) 
4/100 (4%)
2/20 (10%) 
1/40 (2%)
5/50 (10%)
Most common 
band
45 kDa 
40, 60 kDa
40 kDa 
60 kDa
40 kDa 
35 kDa
55 kDa
**p=<0 .0 1 , Fisher’s exact test (2-tailed). Acute, persistent SC, PANDAS and TS versus 
controls
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5.18 Diagnostic utility of anti-basal ganglia antibodies in 
idiopathic movement disorders
As Western immunoblotting was highly sensitive and specific in post-streptococcal 
movement disorders, the method was evaluated as a diagnostic tool in children with new 
onset, otherwise ‘idiopathic’ tic disorders. Those patients with a clinical diagnosis of 
post-streptococcal tics (n=16) and chorea (n=20) were compared with a dystonic, 
neurological disease control group (n=32). The diagnostic sensitivity of ABGA was 93% 
and specificity 97%. The positive predictive value was 97% (likelihood ratio for a 
positive test = 31), and the negative predictive value was 91% (likelihood ratio for a 
negative test = 0.072). There was common binding to basal ganglia antigens of 40, 45, 
and 60 kDa. There was no difference in the antigen binding pattern between tic or chorea 
phenotypes using the 45 kDa and 60 kDa antigens. In contrast, reactivity to the 40 kDa 
antigen did appear to be more predominant in the patients with tics rather than chorea as 
reactivity to this antigen was present in 62.5% (10/16) compared to 30% (6/20) of the 
chorea patients (p < 0 .001).
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5.19 Conclusions
Western immunoblotting was a reliable method for detecting IgG responses against 
soluble basal ganglia protein. There was a significant difference between SC, PANDAS, 
TS and the various normal and diseased controls tested. Colorimetric development was 
better than ECL. In accordance with IF and ELISA antibody titres were low compared to 
paraneoplastic antibodies. A standard dilution of 1/300 appeared to be discriminatory of 
patients with post-streptococcal neurology and any control groups studied, including 
patients with non-neurological, post-streptococcal sequalae. The discriminatory power of 
Western blot appeared to be superior to ELISA as the positivity in controls was lower 
with Western blot.
Western immunoblotting confirmed the presence of IgG responses in SC, PANDAS 
and a subgroup of patients with TS. The basal ganglia antigens with the most 
reactivity were from the soluble SI fraction, so ABGA might be a marker of disease 
rather than functional as the antigens are not membranous but soluble. A 1/300 
dilution was used to screen multiple samples and controls so antibodies are low titre. 
Titration of many positive .samples to assess the end-point titre of antibody would be 
useful. Any future work could investigate the end point titres of ABGA in each 
group but this wasn’t done and that identification and characterisation of the SI 
antigens was the main aim of this thesis.
6 Other Laboratory evidence
Introduction
To assess the role of the immune system in Sydenham’s chorea and if pursuing ABGA as 
a potential disease marker of this disease was worthwhile other surrogate markers of 
immunity were investigated in Sydenham’s chorea including cytokines and oligoclonal 
bands.
6.1 Results of cytokine studies in serum and cerebrospinal fluid from 
patients with Sydenham’s chorea
Results
There was only a modest elevation of any cytokine in the CSF and serum of acute SC 
patients. As expected, there was no elevation in cytokine levels compared to normal in 
the neurological disease control group.
Serum results
Serum IL-4 was above the normal limit in 23% of acute SC whilst IL-10 was elevated in 
46% and IL-12 69% of acute SC (Table 6-1). In comparison, no elevation in cytokines 
was shown in the serum samples from the persistent SC group (Table 6-2). The mean 
serum levels of IL-4, IL-10 and IL-12 were all elevated in the acute SC group compared 
to the persistent SC group and controls (p=<0.001), (Wilcoxon rank-sum test). Serum 
INF-y was not detectable in any of the SC groups or controls (Tables 6-1 and 6-2).
Table 6-1 Serum cytokine levels in Acute Sydenham’s chorea; mean concentrations 
and ranges
Group Acute SC mean Normal range Proportion above
pg/mL (range) pg/mL normal range
Serum IFN-y 0.7 (0-1.1) <1.5 0%
Serum IL-4 3.9 (2.3-6.8) * <4.6 23%
Serum EL-10 20 (0-63)* <10 46%
Serum IL-12 94 (0-377) * <30 69%
*(p=<0.01); Wilcoxon rank-sum test (Mann-Whitney).
Table 6-2 Serum cytokine levels in persistent Sydenham’s chorea; mean
concentrations and range
Group Persistent SC mean Normal range Proportion above
pg/mL(range) pg/mL normal range
Serum IFN- y Not detectable (<0.6) <1.5 0%
Serum IL-4 2.50 (0.2-3.4) <4.6 0%
Serum IL-10 Not detectable (<0.5) <10 0%
Serum IL-12 5.2 (0-22) <30 0%
P=n/s; Wilcoxon rank-sum test (Mann-Whitney).
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CSF results
The normal upper-limit of cytokines in CSF was calculated from the mean level of 
cytokine in the neurological disease control group. In the CSF analysis, IL-4 was above 
the normal limit in 31% of acute SC (Table 6-3). Fifty percent of persistent SC cases also 
had raised IL-4, whilst CSF IL-10 was also elevated in 31% of acute SC but 0% of 
persistent SC (Table 6-4). Compared to neurological controls there was an increase in 
CSF IL-4, but not other cytokines in both acute and persistent SC (p<0.01). CSF IL-10 
was only raised in acute SC compared to controls (p<0.01). The concentrations of IFN- y 
were also not significantly elevated in either CSF or serum or any SC group or controls 
(Tables 6-3 and 6-4).
Table 6-3 CSF cytokine levels in acute Sydenham’s chorea; mean concentrations 
and ranges
Group Acute SC mean Control mean pg/mL Proportion above
pg/mL (range) (range) control mean
CSF IFN- y Not detectable (<0.6) Not detectable (<0.6) 0%
CSF EL-4 3.0 (2.6-3.7) * 1.5 (0.5-2.5)
CSF IL-10 1.9 (0-8) * Not detectable (<0.5)
31%
31%
CSF IL-12 N/A N/A N/A
*p=<0.01; Wilcoxon rank-sum test (Mann-Whitney).
247
Table 6-4 CSF cytokine levels in persistent Sydenham’s’ chorea; mean 
concentrations and ranges
Group Persistent SC mean Control mean Proportion above
pg/mL (range) pg/mL (range) control mean
CSF IFN- y Not detectable (<0 .6) Not detectable (<0.6) 0%
CSF IL-4 3.0 (2.8-3.3)* 1.5 (0.5-2.5) 50%
CSF IL-10 Not detectable (<0.5) Not detectable (<0.5) 0%
CSF IL-12 N/A N/A N/A
p=<0.01; Wilcoxon rank-sum test (Mann-Whitney).
6.2 IgG oligoclonal bands in Sydenham’s chorea 
Introduction
Oligoclonal bands are a useful laboratory test for diagnosis inflammatory neurological 
diseases such as MS and encephalitis.
Results
In the acute SC group 6 of 13 (46%) had the presence of oligoclonal IgG bands. Two 
patients had intrathecal synthesis only (CSF OCB) whilst 4 patients had a mirrored 
pattern of OCB (Serum and CSF matched OCB). The patients with detectable OCB had 
the highest levels of cytokines but did not reach statistical significance compared to OCB 
negative results (p=ns). There was no difference in the pattern of cytokines from the other 
OCB negative patients. All persistent SC patients and neurological controls were OCB 
negative. Typical results are presented in Figure 6 -1.
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Figure 6-1 Three paired CSF and serum from patients with acute Sydenham’s 
chorea Typical range of oligoclonal band results present in Sydenham’s chorea
serum serumserum
l=Mirror pattern of sample bands in serum and CSF; 2= Mirror pattern but extra bands in 
CSF; 3=Bands in CSF only, intrathecal synthesis.
6.3 Clinical comparisons between PANDAS and Sydenham’s chorea in the 
UK
There was no difference in mean age of onset in either PANDAS or SC studied during 
1999-2003 (Table 6-7). There was however, a male preponderance in PANDAS (tics and 
neuropsychiatric symptoms), (Table 6-7). In comparison patients with SC were more 
likely to be female (Table 6-7). Patients with PANDAS were more likely to have 
continuation of the movement disorder on follow up (p=<0.01). There was no difference 
in individual psychiatric manifestations between PANDAS and SC, although any 
psychiatric symptom was more common in patients with PANDAS.
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Table 6-5 Patients from the UK with PANDAS and Sydenham’s chorea: clinical and 
laboratory findings
Characteristic
Mean age of presentation (range) 
Male %
PANDAS (n=16) Chorea (n=20)
6.75 (2-13) 
69%
7.85 (1.5-13) 
35%
Length follow-up- mean (range)
Continuing movement disorder
Psychiatric co-morbidity-total 
• Obsessive-compulsive disorder 
• Generalised anxiety
• Major depression
• ADHD
• Conduct disorders (all)
Anti-basal ganglia antibodies indirect 
Immunofluorescence 
Anti-basal ganglia antibodies 
Western immunoblotting. antibody binding
• Positive binding
• 40 kDa
• 45 kDa
• 60 kDa
• 80 kDa
3.84 (0.2-13)
94%*
69%*
50%
19%
12.5%
25%
25%
94%
94%
62.5%*
50%
44%
12.5%
1.1 (0.2-7)
55%
45%
10%
25%
20%
15%
20%
90%
95%
30%
40%
45%
25%
P=<0.001; Fisher’s exact test (2 tailed). PANDAS versus Sydenham’s chorea.
Conclusions
There was no difference in the antigen binding pattern between PANDAS or chorea using 
the 45 kDa and 60 kDa antigens. In contrast, reactivity to the 40 kDa antigen did appear 
to be more predominant in the patients with PANDAS rather than chorea as reactivity to 
this antigen was present in 62.5% (10/16) compared to 30% (6/20) of the chorea patients 
(p < 0.001). Whilst there is some evidence for immune activation in SC this was not 
persuasive for an autoimmune syndrome
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7 Streptococcal serology results
Introduction
Streptococcal serology was investigated to assess the presence of GABHS in each group 
of patients.
7.1 Streptococcal serology in all Sydenham’s chorea samples and 
controls (Brazilian cohorts)
The results of the ASOT serology were plotted in a box-and-whisker graph for Brazilian 
SC cohorts and controls collected during 1999-2002. The line represents the median 
ASOT and the whisker is the range of results (Figure 7-1). The median values were used 
for statistical comparisons as the data was not normally distributed. The data was not 
normalised as ASOT is a WHO standardised assay and variability of antibody response to 
streptolysin O was expected.
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7.2 Anti-streptolysin O titre
Figure 7-1 Anti-Streptolysin O titres in 40 acute, 24 persistent Sydenham’s chorea 
and 40 normal and 25 Rheumatic fever controls
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Results of median ASOT comparisons
The median ASOT was 349 IU/mL in the acute SC group and 188 IU/mL in the 
persistent SC group. In the normal control group the median ASOT was 97 IU/mL whilst 
the RHF group was 300 IU/mL. In both the acute SC and RHF groups there was an 
increased ASOT compared to the normal control group (P=<0.01 in both instances). The 
ASOT level in the acute SC group was not different compared to the RHF group (p=n/s).
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The mean ASOT in the persistent SC group was not increased compared to normal 
controls or acute SC or RHF.
Results of comparisons of patients with controls using normal cut-off levels
Using the normal WHO cut-off value for normal ASOT levels (<200IU/mL); 72% 
(18/25) of the RHF group, 75% (30/40) of acute SC, 29% (7/24) of persistent SC and 
15% (6/40) of the control group had raised ASOT levels (>200 IU/mL). The numbers of 
patients with raised ASOT in the acute SC and RHF group was increased compared to 
both persistent SC and controls (p=<0.001, p=<0 .00 1 , Fisher’s exact test). There was no 
difference in the percentage of ASOT positive results in persistent SC compared to 
controls (p=0.2). There was also no difference in the number of ASOT positive samples 
between RHF and acute SC. Unfortunately throat cultures were not routinely taken in the 
Brazilian SC cohorts.
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7.3 Anti-DNAse B titres 
Introduction
The results of the anti-DNAse B serology were plotted in a box-and-whisker graph for 
both Brazilian SC cohorts and controls collected during 1999-2002. The line represents 
the median DNAse B results and the whisker is the range of results (Figure 7-2). The 
median values were used for statistical analysis as the data was not normally distributed.
Figure 7-2 Anti-DNAse B titres in 40 acute, 24 persistent Sydenham’s chorea and
40 normal and 25 Rheumatic fever controls the Sydenham’s chorea cohort 
(Brazilian)
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Results of median anti-DNAse B comparisons
The median anti-DNAse B result in the acute SC group was 372 IU/mL and persistent SC 
was 200 IU/mL. In the control groups the RHF group had a median anti-DNAse B titre of 
350 IU/mL whilst in the normal controls it was 92 IU/mL. The acute SC and RHF groups 
both had increased median anti-DNAse B levels compared to the normal control groups 
(P=<0.01 in both instances).The median anti-DNAse B in acute SC was not different 
from the mean anti-DNAse B in the RHF group. The median anti-DNAse B level in the 
persistent SC group was not different from normal controls (p=0.06) or acute SC or RHF 
(p=n/s).
Results of comparisons of patients with controls using normal cut-off levels
Using 300 IU/mL as a normal upper-limit cut-off value, 60% (15/25) of the RHF group, 
65% (25/40) of the acute SC, 36% (9/24) of persistent SC and 10% (4/40) of the control 
group had raised anti-DNAse B levels. The numbers of patients with raised DNAse B 
levels in the acute SC and RHF groups was increased compared to both persistent SC and 
controls (p=<0.01, p=<0.01, Fisher’s exact test). There was an increase proportion of 
patients with raised DNAse B positive results in the persistent SC group compared to 
normal controls (p=0.03). There was also no difference in the number of DNAse B 
positive samples between RHF and acute SC groups.
7.3.1 Comparison o f elevated ASOT and DNAse B titres in Sydenham’s chorea 
None of the acute SC patients had both negative ASOT and anti-DNAse B. There was no 
preponderance of either raised ASOT or DNAse B in acute SC. The persistent SC cases 
that were ABGA positive (15/24) had either raised ASOT or DNAse B whilst two
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patients who were ABGA negative (2/9) had raised ASOT in one case and raised anti- 
DNAse B in the other. Neither ASOT nor anti-DNAse B was more likely to be raised in 
the persistent SC patients who were ABGA positive. The ASOT was raised in 66% (7/15) 
and anti-DNAse B in 60% (9/15) of the persistent ABGA positive patients (p=ns). One 
patient with persistent SC was positive for both ASOT and anti-DNAse B. There was no 
difference in the amount of time chorea had been present in the persistent SC cases, so 
this did not influence the ASOT results.
7.4 Evidence for Streptococcus in Sydenham’s chorea and controls from 
the UK
7.5 Results of throat swab for the culture of Streptococcus from 17 UK 
patients with Sydenham’s chorea
In the UK group 3/13 (23%) of the acute SC patients tested were GABHS positive on 
throat culture. None of the 4 persistent SC patients were GABHS positive. One patient 
thought to have persistent SC, was later found to have chorea of a vascular pathogenesis 
and was ASOT and anti-DNAse B negative.
Further evidence for streptococcal infection was obtained from clinical history (RHF and 
pharyngitis). Streptococcal serology was used as surrogate marker of recent infection. 
There was no ethical approval for measuring streptococcal serology in UK patients with 
development delay.
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Results of median serology comparisons
The childhood controls with mixed neurological diseases where ASOT had been 
measured for the TS study, had a median ASOT of 151 IU/mL with 18% (9/50) having 
raised levels (>200IU/mL). This was lower than both UK SC and other streptococcal 
autoimmune controls (p=<0.01 in all instances). Streptococcal serology was measured in 
the SC and streptococcal autoimmune controls to see whether there was any differences 
in serology between phenotypes (CNS versus systemic).
7.6 Anti-streptolysin O titres 
Introduction
Box-and-whisker plot of ASOT in both UK SC cohorts and controls collected during 
1999-2002, (Figure 7-3). The line represents the median ASOT result and the whisker is 
the range of results. The median values were used for statistical analysis as the data was 
not normally distributed.
Results
The combined streptococcal autoimmune disease controls had a median ASOT of 480 
IU/mL (SD 584) compared to the acute SC group median (618 IU/mL) and was not 
significantly different (p=ns), (Figure 7-3). The persistent SC group, although small in 
number, had a median ASOT level of 330 IU/mL which was lower than both 
streptococcal controls and acute SC (P=<0.002), (Figure 7-3). This finding was similar to 
the Brazilian persistent SC cohort. In the streptococcal autoimmune controls 75% (33/44)
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had ASOTs greater than 200 IU/mL whilst in the acute SC patients 85% (11/13) had 
raised levels (p=ns). In the persistent SC group the numbers were too small for a 
meaningful comparison but there appeared to be a decrease in the number of patients with 
raised ASOT, i.e. 50% (2/4). The small numbers tested is a criticism of this study.
Figure 7-3 Anti-Streptolysin O titres in 13 acute, 4 persistent Sydenham’s chorea 
and 44 Streptococcal controls from the UK
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7.7 Sydenham’s chorea patients in the UK: Anti-DNAse B results 
Introduction
Box-and-whisker plot showing the results of anti-DNAse B serology for both UK SC 
cohorts and controls collected during 1999-2002. The box represents the median anti- 
DNAse B result and the 10-90% percentile of results; whilst the whiskers show the 1st 
and 99th percentiles of the anti-DNAse B results (Figure 7-4).
Results
The anti-DNAse B results showed a similar pattern to the ASOT levels. The median anti- 
DNAse B in acute SC was 670 IU/mL and persistent SC 190 IU/mL. In the streptococcal 
controls it was 422 IU/mL and there were no differences between anti-DNAse B in 
controls and acute SC (p=ns). However, anti-DNAse B in the persistent SC group was 
lower, although the numbers tested were too small to make statistically significant 
comparisons. Using the upper-limit of normal for anti-DNAse B, 66% (29/44) of the 
streptococcal, autoimmune controls were positive, comparable to the acute SC group 
(62%, 8/13). The anti-DNAse B in the persistent SC group was again lower; only 25% 
(1/4) of patients had raised levels (Figure 7-4).
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Figure 7-4 Anti—DNAse B results in 13 acute, 4 persistent Sydenham’s chorea and 
44 Streptococcal controls from the UK
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p=<0.001; Wilcoxon rank-sum test (Mann-Whitney).
7.8 Recrudescent Sydenham’s chorea 
The median ASOT was 190 IU/mL (50-210 IU/mL). One patient (1/5, 20%) had a raised 
ASOT of 210 IU/mL. The median anti-DNAse B level was 255 IU/mL (50-290IU/mL). 
No patient had raised anti-DNAse B. One patient (1/5, 20%) was subsequently diagnosed 
with Coeliac disease.
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7.9 Streptococcus and PANDAS
7.10 Results of throat swab for the culture of Streptococcus from 16 UK 
patients with PANDAS
GABHS was cultured from the throat in 31% (5/16) of the PANDAS patients. All 
patients (16/16) had a preceding illness compatible with a streptococcal pharyngitis. No 
patient had clinical or laboratory signs of RHF. The latency between infection and onset 
of tics and psychiatric symptoms was 2 weeks (2-47 days).
7.11 Streptolysin O and DNAse B in PANDAS and controls 
Introduction
A box and whisker plot was not done as the numbers of PANDAS patients tested was 
small. However, mean ASOT was used to assess statistical differences due to the large 
numbers of control groups investigated. The streptococcal serology was positive (ASOT, 
anti-DNAse B or both) in all PANDAS patients (Table 7-1).
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Table 7-1 Summary of streptococcal serology in PANDAS and controls
Result PANDAS Neurology
controls
Uncomplicated
streptococcal
infection
Streptococcal
autoimmune
controls
Normal
controls
Number 16 100 40 50 30
Mean ASOT 
IU/mL
505 151 348 621 130
ASOT 95% 
confidence 
intervals
(415-599) (102-200) (269-427) (351-891) (50-180)
Mean DNAse B 
IU/mL
580 213 423 576 220
DNAse B 95% 
confidence 
intervals
(410-436) (128-298) (346-500) (474_678) (75-305)
P value, 
(Wilcoxon non- 
parametric test)
<0.001 n/s n/s <0.001
Results
The mean ASOT in the PANDAS patients was elevated compared to the neurological and 
normal controls (p=<0.001), (Table 7-1). There was no difference in the mean ASOT 
compared to uncomplicated streptococcal infections and autoimmune complications of 
streptococcal infection (p=ns), (Table 7-1). The pattern of results was the same when 
testing anti-DNAse B. There was an increased mean DNAse B level in PANDAS 
compared to neurological and normal controls (p=<0.001) but not streptococcal controls 
(p=ns).
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7.12 Streptococcal serology in Tourette’s syndrome
7.13 ASOT results from paediatric Tourette’s syndrome
Only ASOT was measured due to unavailability of the anti-DNAse B assay at the time of 
the study. Mean ASOT was elevated in the child TS group compared to the neurological 
controls (p<0.001), but not the child streptococcal infection controls (p=0.4), (Figure 7-5, 
Table 7-2). Mean ASOT was also elevated in the adult TS cohort compared to the 
neurological disease (p=0.04) and healthy adult controls (p=0.04), (Figure 7-5, Table 7- 
2).
7.13.1 Analysis o f the number and percentage o f Child Tourette’s and controls 
with raised ASOT serology
The number and percentage of cases with raised ASOT (<200 IU/mL) in the child 
streptococcal controls (80%) and child TS (64%) were different compared to children 
with neurological disease (18%), (p=<0.01, p=<0.01, Fisher’s exact test). The number of 
children with raised ASOT after recent streptococcal infection (80%) was higher than the 
number with raised ASOT in TS (64%), (p=0.04), (Table 7-2).
7.13.2 ASOT results from adult Tourette’s syndrome
The number of cases with raised ASOT in the adult TS group (68%) was higher than in 
the neurological disease (12%) and healthy adult (8%) groups (p=<0.01 in all instances, 
Fisher’s exact test), (Table 7-2).
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Table 7-2 Summary of the Streptococcal serology data in Tourette’s syndrome
Group Mean ASOT Confidence intervals Raised ASOT
IU/mL >200 IU/mL (%)
Child TS 299* 262-335 36/56 (64%)**
Child neurological 151 101-201 9/50 (18%)
disease
Child streptococcal 349 270-427 45/56 (80%) n/s
infection
Adult TS ’ 298* 243-353 30/44 (68%)**
Adult neurological 140 92-188 6/50 (12%)
disease
Adult normal controls 122 101-143 4/50 (8%)
*p=<0.01; Wilcoxon non-parametric test, ** p=<0.01; Fisher’s exact test (2 tailed). Child and adult 
Tourette’s compared with controls
Figure 7-5 Anti-streptolysin O titres in Tourette’s syndrome and controls
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p=<0.01; Wilcoxon non-parametrlc test. Child and adult Tourette’s compared with controls
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7.13.3 Clinical comparisons between TS patients positive and negative with 
ABGA
The total TS cohort had a mean diagnostic confidence index of 64% (SD 20%, range 14- 
100%), (Robertson et al, 1999). The prevalence of OCD and ADHD in the total cohort 
was 31% and 43% respectively, (Table 7-3). The paediatric TS patients had a mean 
diagnostic confidence index of 64% (SD 21%, range 14-100%), 17% incidence of OCD 
and a 49% incidence of ADHD. The adult TS patients had a mean diagnostic confidence 
index of 63% (SD 20%, range 16-100%), 51% incidence of OCD and a 31% incidence of 
paediatric ADHD (Table 7-3). Analysis of the ASOT titres between ABGA positive and 
negative TS found that 91% (21/23) of TS patients with positive ABGA Western 
immunoblotting had raised ASOT which was greater compared to TS patients with 
negative ABGA Western immunoblotting 57% (44/77), (p<0.01).
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Table 7-3 Clinical comparisons in symptomatology between ABGA positive and 
negative TS patients
Result ABGA positive 
(n=24)
ABGA negative 
(n=77)
P value
Age of first tic (range) 6.56 (range 2-13) 6.81 (range 2-16) NS
Diagnostic confidence 62% 64% NS
index mean (SD, 
range)
(SD 20, range 36-96) (SD 21, range 14-100)
Obsessive-compulsive 27% 33% NS
behaviour/disorder %
Attention deficit 22% 50% <0.05
hyperactivity disorder
% •
Family history of 69.6% 75.3% NS
neuropsychiatric
disease in 1st degree
family member *
ASOT >200 IU/mL 91.3% 58.4% <0.01
P<0.01; Fisher’s exact test (2 tailed). *Family history of neuropsychiatric disease includes tic disorders, 
Tourette's syndrome and obsessive-compulsive disorder.
266
7.13.4 Follow-up studies in Tourette's syndrome 
Introduction
Due to a possible relationship between ABGA positivity and ASOT, patients with 
positive ASOT but negative ABGA were re-tested (Table 7-4). Six of the TS patients 
with a negative ABGA and positive ASOT in the cross-sectional study gave permission 
for repeat testing to see if there was a longitudinal relationship between ASOT and 
ABGA. The mean time for follow-up testing was 3 .5 months after first testing. ASOT 
reverted to normal in 4/7 cases but ABGA had become positive in 5/7 cases (Table 7-4).
Table 7-4 longitudinal results in 7 patients with Tourette’s syndrome: streptococcal 
serology and anti-basal ganglia antibodies
Case Serology
1 ASOT 
ABGA
2 ASOT 
ABGA
3 ASOT 
ABGA
1st Test 2nd Test
500 IU/mL 
Negative
260 IU/mL 
Negative
710 IU/mL 
Negative
(months after 1st visit)
133 IU/mL 
60 kDa 
(3/12)
185 IU/mL 
45 & 60 kDa 
(3.5/12)
220 IU/mL 
40 kDa 
(4/12)
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Case
4
5
6
Serology 1st Test 2nd Test
ASOT
ABGA
ASOT
ABGA
ASOT
ABGA
ASOT
ABGA
315 IU/mL 
Negative
980 IU/mL 
Negative
250 IU/mL 
Negative
300 IU/mL 
40, 45,60 kDa
(months after 1st visit)
<50 IU/mL 
40 & 95kDa 
(3/12)
180 IU/mL 
45 & 60 kDa 
(4/12)
220 IU/mL 
Negative 
(3.6/12)
1000 IU/mL 
40,45,60 kDa 
(3.8/12)
268
7.14 Summary of streptococcal serology results
This is the summary of all the streptococcal serology results
Table 7-5 Streptococcal serology results
Group Number Median ASOT Mean DNAse B
(% >200 IU/mL) (% >300 IU/mL)
Acute SC 40 349 IU/mL* (75%**) 372 IU/mL* (65%**)
Persistent SC 24 188 IU/mL (29%) 200 IU/mL (36%)
PANDAS 16 505 IU/mL* (94%**) 580 IU/mL* (81%**)
TS 56 299 IU/mL* (64%**) Not tested
Normal control 40 97 IU/mL (16%) 92 IU/mL (10%)
Neurological 50 151 IU/mL (18%) 213 IU/mL (10%)
controls
Rheumatic fever 40 300 IU/mL (72%) 350 IU/mL (60%)
Streptococcal 40 . 349 IU/mL (80%) 422 IU/mL (85%)
infection
Streptococcal 44 480 IU/mL (75%) 621 IU/mL (66%)
autoimmune
disease
*p—< 0.01 , Wilcoxon rank-sum test (Mann-Whitney), Acute SC, PANDAS and TS versus normal and 
neurological controls
**p=<0.01, Fisher’s exact test (2 tailed), Acute SC, PANDAS and TS versus normal and neurological 
controls.
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7.15 Potential cross-reactivity of anti-basal ganglia antibodies with
streptococcus isolated from a patient with Sydenham’s chorea
Introduction
GABHS was cultured from 1 patient with acute SC (2 days post symptoms) and used to 
investigate cross-reactive antibody response.
As strain specificity may and probably does influence antibody production, reactivity of 
IgG against brain might be different depending on strain. Therefore absorbing ABGA 
with streptococcus was not performed. Once, autoantigen has been found absorption 
experiments can be investigated.
Results
There was 1 band of IgG reactivity against both the Ml streptococcal homogenate (from 
the throat culture of the SC patient) and the M5 control homogenate (from a patient with 
PSGN), (Figure 7-6). This probably reflects the normal immune response (antibody) 
against streptococcal infection. In addition 2 bands were present in the Ml streptococcal 
homogenate that were absent from the control M5 serotype (Figure 7-6). This antibody 
reactivity to specific antigens was not removed by incubating serum with a human 
cerebellum homogenate, indicating that the antibody did not cross-react with cerebellum 
proteins. This antibody reactivity was totally removed by incubating the ABGA positive 
sera with the same concentrate of antigen but using the human basal ganglia homogenate 
used to detect the ABGA response (Figure 7-6). This supports cross-reactivity between 
the ABGA response, streptococcus and basal ganglia. The original report of the presence
of ABGA also showed that reactivity could be removed by incubating with streptococcal 
membranes (Rheumatogenic strains), (Husby etal., 1976).
Figure 7-6 Western blot of serum tested against streptococcus M l serotype from one 
patient with Sydenham’s chorea, and the same serum tested against a M5 serotype 
from a separate patient with nephritis
A
No
incubation
Cerebellum
incubation
Basal ganglia 
incubation
No
incubation
Cerebellum
incubation
Basal ganglia 
incubation
Serum  reactiv ity  against Streptococcus M l hom ogenate Serum  reactiv ity  against S trep tococcus M 5 hom ogenate
A: One band of IgG reactivity which appears similar in both Ml and M5 subtypes; B: Two bands reactive 
against Ml subtype removed by incubating with basal ganglia homogenate
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Conclusions
ASOT and anti-DNAse B results showed that serological evidence of persistent or recent 
streptococcal infection was common in acute SC. Unfortunately throat culture was not 
available in most cases so microbiological evidence of current infection could not be 
demonstrated. This is a major criticism of this thesis.
The high levels of antibodies against these streptococcal proteins could suggest high 
levels of toxin production from streptococcal infection in SC, although there is no 
evidence for this. In common with the ABGA findings, the presence of positive 
streptococcal serology was less pronounced in cases of persistent SC. This may mean that 
there are 2 populations within the persistent SC group. The first one showing evidence of 
recent or recurrent streptococcal infection with the presence of ABGA, whilst evidence 
for this in the other group is less persuasive.
Unfortunately only one acute GABHS culture was obtained for ABGA absorption 
experiments and although this did show that the antibody reactivity was associated with 
both basal ganglia and GABHS is not sufficient to prove this hypothesis. This experiment 
was only able to replicate the work performed by Husby et al, so further work on 
absorption and cross-reactivity is required.
Surprisingly the mean ASOT was higher in both adult and child TS compared to any 
control group except patients with uncomplicated streptococcal infection. From this data 
one would have expected a higher number of TS patients to be ABGA positive. This may 
reflect a lack of sensitivity in the existing ABGA assays or there may be an interval
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between acute streptococcal infection and the appearance of ABGA. Alternatively, the 
presence of high titres of antibody against a streptococcal toxin may imply that the toxin 
plays a role in the pathogenesis of these disorders rather than ABGA themselves.
This question can only be answered by investigating streptococcal serology, levels of 
streptococcal toxins such as streptolysin O and ABGA over time, and comparing them to 
the waxing and waning of symptoms in TS. Some evidence for an association between 
ABGA and ASOT was seen in the TS patients who agreed to take part in a follow-up 
study. This showed, albeit in a small number of patients, that some patients with high 
ASOT but negative ABGA became ABGA positive over time. Whether this is a 
phenomenon common to TS or just a small subgroup will need to be answered by a 
longiditudinal study.
In the adult movement disorder patients studied there was no evidence for ABGA and 
raised ASOT in the genetic movement disorders and blepharospasm (possible 
autoimmune-associated). There was evidence of both ABGA and raised ASOT in patients 
with idiopathic dystonia and “Tourettism”. This may support post-streptococcal 
autoimmunity in a wider spectrum of movement disorders than just chorea and tics.
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8 Isolation and identification of a basal ganglia 
candidate autoantigen
Introduction
Despite the fact that ABGA, or more properly anti-neuronal antibodies with axonal, 
cytoplasmic staining are of low concentration. Candidate antigens from the SI fraction of 
human basal ganglia were identified using proteomics. This was a major aim of this 
thesis.
8.1 Identification of a basal ganglia candidate autoantigen
Serum samples which reacted against a single putative autoantigen were studied where 
possible. There were several difficulties in employing a proteomic methodology, because 
patient serum contains poly specific antibodies and only a small percentage of the 
immunoglobulin was specific to any of the target autoantigens. The ABGA response is 
also of low concentration compared to other neuronal antibodies. Availability of basal 
ganglia tissue to conduct large scale separation and identification of candidate 
autoantigens was also a limiting factor in these studies. Reproducibility of the 
electrophoretic methods was also a problem.
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8.2 Results of the immunoprecipitation method
The samples were subjected to PAGE and silver stain but bands were only visible in the 
first elute collected from the spin-cup. Western immunoblotting of this elute coupled with 
probing of the electro-transferred protein with ABGA positive serums resulted in weak 
reactivity to 1 band. Mass spectroscopy of this band identified contaminating albumin 
and there was insufficient protein for identification of the other protein. The 
immunoprecipitation was repeated using the maximum concentration of antibody and 
antigen recommended (Perbio immunoprecipitation kit) with an increased number of 
washes to remove contaminants. The precipitated proteins were weakly reactive on 
Western blot with ABGA positive sera. A gel was also silver stained and the proteins 
were cut from the gel but, again the protein could not be identified by mass-spectroscopy 
because of low protein concentration.
Conclusion
To overcome the methodological problems the proteins recovered from the 
immunoprecipitation were concentrated, using a centrifugal filter concentrator 
(Millipore). Unfortunately mass-spectroscopy was still unable to identify the protein due 
to low concentration. The proteins were not able to be concentrated further as this 
resulted in insufficient volume for mass-spectroscopy.
The immunoprecipitation method was not investigated further proteomics (2-D 
electrophoresis and mass spectroscopy) were investigated.
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8.3 Identification of neuron-specific enolase as a candidate autoantigen
in Sydenham’s chorea using 2-D electrophoresis and proteomics 
Introduction
Two-dimensional electrophoresis was carried out using an 18cm long immobiline, pH 3- 
10, gel strips (Amersham Pharmacia) with silver staining of the second dimension PAGE 
gel.
Results
This resulted in several hundred protein ‘spots’. However, the acidic and basic areas of 
the gels contained some overlapping areas rather than discrete proteins. The proteins 
were transferred to nitrocellulose and probed with ABGA (40, 45, 60 or 98 kDa) positive 
sera. This resulted in spots in the acidic area of the gel when the proteins were Western 
blotted. Neurone-specific enolase was identified but resolution was poor, method 
required large amounts of protein, contaminating albumin, haemoglobin and IgG 
fragments were all methodological problems.
Conclusion
This method was abandoned and a pi 3-10 range IEF gel mini system (Invitrogen) was 
used to identify candidate antigens throughout.
This does not mean that other membranous autoantigens might be important in 
Sydenham’s chorea, the soluble antigens are still important as they might be a 
diagnostic marker of disease. This has implications for diagnostics and treatment so 
thus is important.
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8.4 Two-dimensional electrophoresis of human basal ganglia SI 
(soluble) fraction
Introduction
The S1 fraction was prepared as detailed in the methods section. An equal volume of 
homogenate was added to sample buffer (Invitrogen), mixed for 30 mins and subjected to 
2-D using a pH 3-10 gel (Invitrogen). The gel was silver stained (Amersham-Pharmacia).
Results
A typical stained IEF gel of human basal ganglia (soluble SI fraction) is shown in figure 
8-1. The soluble SI cytosolic fraction was used to identify putative antigens by 2-D 
electrophoresis as this had the most antibody reactivity in SC, PANDAS and TS. A 
stained 2-D gel is shown in Figure 8-2.
Figure 8-1 Commassie stained isoelectric focussed pH 3-10 gel of soluble SI fraction 
of human basal ganglia for second dimension PAGE incorporating 2-D 
electrophoresis
pI3
Gel is only stained for 5 minutes with commassie as per manufactures 
Instruction (Invitrogen), therefore proteins are only weakly stained
Figure 8-2 Typical silver stained 2-D electrophoretic separation of soluble basal 
ganglia fraction
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8.5 Reactivity to basal ganglia proteins in Sydenham’s chorea and controls 
Introduction
Five neurological disease controls and 5 SC patients were tested against Western blots of 
2-D electrophoretic gels.
8.6 2-D electrophoresis using five Sydenham’s chorea and five normal sera 
Introduction
Five patients with Sydenham’s chorea who had 40, 45, 60 or 98 kDa antibody responses 
against soluble SI basal ganglia fraction were tested and shown in figures 8-3 and 8-4.
Results
Comparison of the staining using ABGA or samples from controls showed that the 98 
and 45 kDa (Figure 8-2 and 8-3) proteins were localised at the acidic end of the IEF gel 
and had a pi of approximately 4. The proteins were cut out of the gel and subjected to 
mass-spectroscopy, and protein data base search.
Serum from a patient with Sydenham’s chorea bound to the 45 and 98 kDa proteins with 
a pi of approximately 4.0 (Figure 8-3). Additionally the serum also recognised a 45 kDa 
protein which has a pi of approximately 7.0 (Figures 8-3). A streak of IgG from the donor 
tissue was recognised by the secondary antibody (Figure 8-3). There is also trace binding 
to a 60 kDa protein (Figure 8-3). One patient also had weak binding to a 40 kDa protein 
(Figure 8-4). This could not be determined by mass-spectroscopy due to contamination 
with other proteins.
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Four of the 5 SC patients had binding to a 45 kDa acidic protein, 1 had binding just to the 
basic protein and 1 had binding to both. Three patients with SC also had binding to a 98 
kDa band. None of the controls had any binding.
Figure 8-3 Serum from one patient with Sydenham’s chorea diluted 1/300 and tested 
against a Western immunoblot of a 2-D electrophoretic separation of soluble basal 
ganglia fraction to confirm specificity of serum staining and molecular weight of 
proteins which were identified by mass spectroscopy
pI3 p i10
98 kDa
eo kDa V 98kDa IgG from donor
^ 4 5  kDa |
40 kDa
28 kDa 45 kDa
Serum diluted 1/300 recognised two proteins with a pi o f approximately 4.0. There was weak binding to a 
45 kDa protein o f pi 7.0. IgG from the donor was also recognised. All proteins were identified by mass 
spectrometry by Dr. R Wait, PhD.
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Figure 8-4 One patient with Sydenham’s chorea with basic 40 kDa antibodies and 
absent acidic 45 kDa
J
IgG t  
|  40 kDa
Conclusions
The 45 and 98 kDa bands could be detected using 2-D electrophoresis of a pH 3-10 
gel (Invitrogen). None of the controls had binding to these proteins. Contaminating 
IgG was a problem, therefore human soluble SI fraction of basal ganglia was 
incubated with anti-human IgG coated agarose beads to reduce this contamination. 
Additional SC samples were tested as well as these detailed in this experiment.
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8.7 Two-dimensional electrophoresis with donor IgG removed by
agarose beads incubated with 2 Sydenham’s chorea samples and 1 
normal control diluted 1/300
Introduction
Two further SC patients and 1 normal control were tested at 1/300. Donor IgG was 
removed from the S1 fraction by incubating with agarose coated anti-IgG beads 
following manufacturer’s guidelines (Sigma). Results are shown in figure 8-5.
Results
The SC samples tested bound to the same antigens as seen in Western blotting with 45,
60 and 98 kDa bands being the most common (Figure 8-5). Normal controls did not bind 
to any protein (Figure 8-5).
Conclusion
The 45, 60 and 98 kDa protein spots were subjected to mass-spectroscopy. The 40 kDa 
band did not appear to be present. Subsequently the 40 kDa band was identified as a basic 
protein using immunoprecipitation and 2-D electrophoresis by Dr. Russell Dale (Dale et 
al., 2006) which could explain why I couldn’t get reactivity to this protein on my gels.
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Figure 8-5 Two Sydenham’s chorea anti-basal ganglia positive sera tested against 2 
Western immunoblots of 2-D electrophoretic separation of soluble basal ganglia 
with IgG from donor removed
pi 3 pIlO pI3 pIlO
98 kDa 
60 kDa 
45 kDa
B
98 kDa
<#*0*60 kDa 
45 kDa
A: SC patient diluted 1/300, IgG reactivity to 98 kDa proteins which were excised from the gel at the same 
molecular weight points; B: SC patients with 45 kDa reactivity and possible 60 kDa reactivity. No 
reactivity to IgG or non-neuronal enolase. IgG was removed by incubating homogenates with agarose 
beads coated with anti-human IgG (Sigma).
C: Normal control diluted 1/300 and tested against the same SI fraction, no reactivity against any protein
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8.8 Neuron-specific enolase is a possible autoantigen in Sydenham’s chorea 
The 45 and 98 kDa proteins were cut from the gel and the amino acid sequence were 
identified by MALDI-TOF mass-spectroscopy. This was kindly carried out by Dr Robin 
Wait, PhD, Kennedy Institute of Rheumatology, Imperial College London. The proteins 
were identified using Entrez- protein data base (www.ncbi.nlm.nih.govT 
Results
The complete amino acid sequence of the protein identified by mass-spectroscopy is in 
the shaded area (Figure 8-6). The proteins of pi 4 were gamma, neuronal specific enolase, 
a glycolytic enzyme (Figure 8-6). The 45 kDa band was the monomer and the 98 kDa 
band the dimer. The 45 kDa protein of pi 7.0 was non-neuronal alpha enolase a 
ubiquitous enzyme. The highlighted sequences are individual ion scores >51 indicate 
identity or extensive homology. The summed Mascot ion score for the gamma enolase 
recognised was 500, (p=<0.05), (Dale et al., 2006). The pi of alpha enolase is reported to 
be 7.0 and gamma 4.0 (www.ncbi.nlm.nih.gov).
Figure 8-6 The amino acid' sequence of Homo-sapien gamma enolase with the 
shaded areas showing sequences found in the protein ‘spots’ excised from the gel
1 msiekiware ildsrgnptv evdlytakgl fraavpsgas tgiyealeTr dgdkqrylgk
61 gvlkavdhiti stiap-alisa glsweq<5kl dnlmleldgt enkskfgatia llgvslavck
121 agaaerelpl yrhiaqlagtl sdlilpvpaf nvinggshag nklamqefmi lpvgaesfrd
181 amrlg&evyh tlkgvikdky gkdatnvgde ggfapnllen aealelvkea idkagyfc-eki
241 vigrodvaase fyrdgkydld fksptdpsry itgdqlgaly qdfvrdypvv siedpfdqdd
301 waawskftan vgiqivgddl tvfcnpkrier aveekacncl llkvnqigsv teaiqackla
361 qengwgvmvs hragetedtf iadlwglC-t gqiktgapcr serlakynql mriaefclgde
421 arfaghnfrn psvl
The molecular weight of the enolase protein cut from the gel (45 kDa candidate) was 47kDa and had 57.8% 
coverage of human gamma enolase. The other identity of this protein was gamma enolase but from 
different species and alpha enolase. The 98 kDa candidate was the dimeric form of the same protein
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8.9 Confirmation of enolase as a candidate antigen 
Introduction
To confirm the identity of enolase a commercial, polyclonal anti-enolase antibody (C-19) 
(Figure 8-7) and monoclonal NSE (P-2) were purchased (Autogen Bioclear, UK).
8.9.1 2-D electrophoresis using commercial antibodies 
Introduction
The commercial antibodies were used to probe the same basal ganglia homogenate 
separated by 2-D electrophoresis and blotted onto nitrocellulose (Figure 8-7 and 8-8).
Figure 8-7 Commercial polyclonal anti-enolase antibody c-19 tested against a 
Western immunoblot of a 2-D electrophoretic separation of soluble basal ganglia 
fraction to confirm specificity of serum staining and molecular weight of protein
pi 3 pi 10
Commercial anti-enolase antibody (C-19) at 1:2000 dilutions with colorimetric development; C and D: 
Binding to the dimeric (98 kDa) and monomeric (45 kDa) forms of NSE; E: non-neuronal enolase (45 kDa) 
which has a pi of approximately 7.0.
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Figure 8-8 Commercial monoclonal P-2 anti-neurone specific enolase antibody NSE 
tested against a Western immunoblot of a 2-D electrophoretic separation of soluble 
basal ganglia fraction to confirm specificity of serum staining and molecular weight 
of proteins
pi 3 p i10
98 kDa 
iamma enolase dimer
98 kDa
60 kDa
40 kDa
28 kDa
\
45 kDa 
Gamma enolase monomer
Neuron specific enolase monoclonal antibody recognises two proteins with a Pi of approximately 4.0. The 
monoclonal antibody recognises the monomer 45 kDa and dimer 98 kDa of the enolase protein. No binding 
to the non-neuronal enolase.
Results The pattern of reactivity (protein ‘spots’) and molecular weights was similar to 
that seen with 98 kDa and 45 kDa ABGA positive SC serums. The commercial 
polyclonal antibody also recognised non-neuronal specific enolase which had a pi of
approximately 7, whilst (gamma, gamma) NSE was identified as a protein with a pi of 
approximately 4.0.
8.10 Homology between gamma and streptococcal enolase
Streptococcal species (including GABHS) have enolase on their cell surface as well as 
cytosolic (Fontan et al., 2000). This could support the hypothesis of molecular mimicry 
induced autoantibody production in SC and PANDAS. The structure of GABHS and 
human neuron specific enolase is presented in figure 8-9.
Figure 8-9 Streptococcus pyogenes enolase
Streptococcus pyogenes enolase
1 msiitdvyar evldsrgnpt levevytesg afgrgmvpsg astgeheave lrdgdksryl
61 glgtqkavdn vnniiaeaii gydvrdqqai dramialdgt pnkgklgana ilgvsiavar
121 aaadylevpl ytylggfntk vlptpmmnii nggshsdapi afqefmimpv gaptfkeglr
181 wgaevfhalk kilkerglvt avgdeggfap kfegtedgve tilkaieaag yeagengimi
241 gfdcassefy dkerkvydyt kfegegaavr tsaeqvdyle elvnkypiit iedgmdendw
301 dgwkvlterl gkrvqlvgdd ffvtnteyla rgikenaans ilikvnqigt ltetfeaiem
361 a k e a g y t a w  shrsgeteds tiadiavatn agqiktgsls rtdriakynq llriedqlge
421 vaqykgiksf ynlkk
Human neuron specific enolase
1 msiekiware ildsrgnptv evdlytakgl fraavpsgas tgiyealelr dgdkqrylgk
61 gvlkavdhin stiapaliss glsvveqekl dnlmleldgt enkskfgana ilgvslavck
121 agaaerelpl yrhiaqlagn sdlilpvpaf nvinggshag nklamqefmi lpvgaesfrd
181 amrlgaevyh tlkgvikdky gkdatnvgde ggfapnilen sealelvkea idkagyteki
241 vigmdvaase fyrdgkydld fksptdpsry itgdqlgaly qdfvrdypvv siedpfdqdd
301 waawskftan vgiqivgddl tvtnpkrier aveekacncl llkvnqigsv teaiqackla
3 61 qengwgvmv& hx 5get<3dtf iadlvvglct gqiktgapcr serlakynql mrieeelgde
421 arfaghnfrn psvl
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Results
A protein-protein blast sequence homology analysis was performed to investigate 
homology between these proteins using
http://www.ncbi.nlm. nih. gov/blast/bl2seq/wblast2 data base. There was 68% homology 
of amino acid sequence between the human and streptococcal enolase (score = 398 bits 
(1022), Expect = e-109 Identities = 211/430 (49%), Positives = 294/430 (68%), Gaps = 
14/430 (3%) were obtained), (Appendix 12.7).
Therefore identical sequence identities were: 49% between human and GABHS 
enolase with expected chance identities being 10~109. A list of homologous sequences 
is presented in appendix 12.7. The longest homologous sequence was: 
l i i i i i K i i i  and is highlighted in both GABHS and human enolase sequences in 
Figure 8-9 
Conclusion
Neuron specific enolase is a putative autoantigen in Sydenham’ s chorea, although as 
enolase is brain specific rather than basal ganglia, anti-basal ganglia antibodies are not 
specific to the basal ganglia. Homology with a streptococcal protein exists which does 
support the original hypothesis of molecular mimicry.
As NSE is considered to be cytoplasmic a functional effect of antibody binding is 
unlikely. Indeed antibodies against NSE might just be due to GABHS infection, are 
transient, and of no consequence. Sydenham’s chorea and normal control IgG 
responses to GABHS might help to examine the role of enolase antibodies further.
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8.11 Two-dimensional electrophoresis of a Streptococcus isolated from a 
patient with Sydenham’s probed with the commercial polyclonal 
anti-enolase
Introduction
A GABHS strain isolated from a patient with SC was homogenised and subjected to 2-D 
electrophoresis to investigate and compare (molecular weight and pi) enolase from 
GABHS (Figure 8-10). The gel was probed with same antibody used for basal ganglia. 
Results
Streptococcal enolase has the same molecular weight and pi on the basis of this 
experiment.
Figure 8-10 2-D electrophoresis of group A streptococcus probed with polyclonal 
anti-enolase antibody C-19
pI3 pi 10
98 kDa
\ 45 kDa
Commercial polyclonal enolase diluted 1/1000 identified 2 bands of molecular weights 45 and 98 kDa with 
a pi of 4. There was no reactivity with a basic isoforms of enolase unlike human basal ganglia
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8.12 Reactivity of IgG from Sydenham’s chorea and controls against a 2-D 
electrophoresis of Streptococcus
Introduction
To assess cross-reactivity of IgG anti-basal ganglia antibodies and GABHS proteins, 
streptococcus from a patient with SC was subjected to 2-D electrophoresis and 5 controls 
and SC patients (Figure 8-11 and 8-12) were tested.
Results in normal controls
There were multiple bands of reactivity in normal controls which shows the polyspecific 
nature of the IgG response against streptococcus.
Figure 8-11 2-D electrophoresis gel probed with 1/500 diluted serum from a normal 
(non-diseased) control
Multiple spots o f  reactivity was present
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Results in Sydenham’s chorea
There were multiple bands o f  reactivity in SC patients which shows the polyspecific  
nature o f  the IgG response against streptococcus.
Figure 8-12 2-D electrophoresis gel probed with 1/500 diluted serum from a 
Sydenham’s chorea patient
Multiple spots o f reactivity are present 
Conclusion
2-D  electrophoresis o f  G ABH S did not differentiate SC and controls. This may mean that 
anti-enolase antibodies are part o f  the normal immune response against GABHS  
infection.
However, this method does not differentiate anti-enolase antibody reactivity from 
background binding to other GABHS antigen. A purified or recombinant antigen 
source is required. The identification of NSE as a putative antigen in post­
streptococcal movement disorders has been published (Dale et al., 2006).
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8.13 Anti-Neurone specific enolase antibodies in Sydenham’s chorea and 
controls using Western Immunoblotting of human enolase antigen 
from a commercial source
Introduction
Ten micrograms of human Neurone specific enolase (NSE) (90% purity) was purchased 
(Sigma chemicals, N4773). One microgram per blot was subjected to a 4-12% NuPage 
gel electrophoresis and Western blotted onto nitrocellulose. Lane 1 was probed with 
1/500 diluted polyclonal anti-NSE antibody (C-19, Autogen Bioclear). Six neurological 
disease controls and six Sydenham’s chorea samples were tested.
Results
The commercial NSE antibody reacted against a 45 kDa band. Samples from patients 
with neurological disease were also tested against this blot but none of them had 
reactivity against the NSE band (Figure 8-13).
Sixty-six percent of patients with acute SC (4/6) had a definite band which aligned with 
that identified by the anti-NSE commercial antibody. Seventeen percent of patients with 
SC were negative (1/6) and 1 patient had only weak reactivity (Figure 8-14). The 
weakness of this experiment is the small number of patients tested but the expense of 
commercial antigen is prohibitive to large experiments. Therefore an alternative source of 
antigen is required. Recombinant antigen would be the next step.
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Figure 8-13 Six controls diluted 1/300 and tested against 1 microgram of neuron- 
specific enolase on a Western blot
45 k D iS S
w i P i i i Blank Anti-NSE m m m
Blank: Secondary detector antibody only; Anti-NSE: anti-neuron specific enolase commercial antibody; A: 
DYT1 positive dystonia; B: Huntington’s chorea; C: Parkinson’s disease; D: PSGN; E: streptococcal 
pharyngitis; F: multiple sclerosis.
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Figure 8-14 Samples from patients acute Sydenham’s chorea tested against 1 
microgram of neuron-specific enolase on a Western immunoblot
MW Blank Anti-NSE A B C D E F
MW: Molecular weight marker; Blank: Secondary detector antibody only; Anti-NSE: anti-neuron specific 
enolase commercial antibody; A-F: acute SC.
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8.14 Recombinant enolase as a source of antigen in future research 
Introduction
To investigate the role of anti-enolase antibodies in post-streptococcal neurology 
syndromes, recombinant proteins are essential for further research. A NSE recombinant 
protein was provided by Mr P. Candler (Neuroinflammation, Institute of Neurology, 
London).
Results
Recombinant antigen gave a similar pattern of results to commercial NSE (Figure 8-15). 
Figure 8-15 Recombinant gamma enolase Western immunoblot
**60 kDa 
<•*45 kDa
0
MW Blk 1 2 3 4 5 6
1: Parkinson’s disease; 2: commercial monoclonal ab NSE P2; 3: MS; 4: ?Adult 
PANDAS; 5: TS; 6: Basal ganglia stroke
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8.15 R eg io n a l b ra in  sp ec ific ity  o f  an ti-en o lase  an tib od ies
As NSE is neuronal specific rather than just basal ganglia, the original hypothesis of 
basal ganglia specificity has been cast into doubt. However, the reactivity of NSE 
antibodies in SC, PANDAS and TS might have been related to antigen presentation. A 
Western blot of soluble human basal ganglia, spinal cord, cerebellum and heart fractions 
was prepared, normalised for protein concentration (3pg per lane) and one SC patient 
with anti-NSE antibodies was diluted 1/300 and tested against all fractions (Figure 8-16)
Results
The reactivity to 45 kDa enolase was present in basal ganglia and cerebellum, but not 
spinal cord, this band was also present in heart tissue. However, the serum from a SC 
patient also reacted with the 98 kDa dimer of NSE, but this reactivity was only present in 
the basal ganglia and heart fractions (Figure 8-16). Therefore an anti-NSE antibody 
directed aginst the dimer (gamma gamma) of enolase might be specific to basal ganglia 
and heart (Figure 8-16).
Conclusion
However, only 1 sample was tested and this is only a hypotheis that requires much further 
research. Identifcation of a 98 kDa enolase dimer from GABHS is also essential. A grant 
from the Tourette’s society of America (TSA) has been awarded for this research and is 
being conducted in the Microbiology Department at the Institute of Child Health, Great 
Ormond Street Hospital. London.
Figure 8-16 One Sydenham’s chorea patient with anti-enolase antibodies tested 
Western blot against brain fractions and heart
60 kDa
98 kDa
45 kDa <—45 kDa
Blank BG Spc CrB
98 kDa
i
Heart
MW= molecular weight marker, Blank=2nd antibody only (Rabbit anti-Hu IgG), BG-basal ganglia, 
Spc=Spinal cord, CrB=Cerebellum, Heart=cardiac tissue.
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8.16 A possible functional effect of anti-enolase antibodies
To investigate whether anti-NSE antibodies might have a role in pathogenesis the effect 
on glycolytic function was studied in a pliot experiment by testing 1/300 diluted serum 
against purified rat brain enolase. The enolase was provided by Dr. Russell Dale, Institute 
of Child Health, Great Ormond Street Hospital. London.
8.16.1 Result o f baseline activity o f neuron specific enolase 
Measuring the baseline glycolytic activity of NSE was found to be consistently 
reproducible as expected.Three experiments of normal NSE activity were performed to 
assess this (Figure 8-17). The standard error of the mean for this assay was no greater 
than 0.08 absorbance units between replicate measurements. All data points are shown in 
Figure 8-17.
Figure 8-17 Reproducibility of enolase activity
B a se lin e  e n o la se  activity
1.4
1.2
o 1 | 0.8
8 06 
<  0.4
0.2
0 5 10 15 20 25 30
Time m inutes
rvv*
♦ Series 1 
■ Series2 
Series3
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8.16.2 Initial effects in activity when anti-enolase antibodies were incubated 
with neuron specific enolase
Purified IgG (Appendix) from a serum sample positive for anti-NSE antibodies and 
control IgG were incubated with NSE to assess changes in enzyme activity. This 
experiment was performed three times with no significant differences between the results 
of enzyme activity measured over time. There was no difference in enolase activity 
between control and anti-NSE IgG after 3 hours at room temperature.
8.16.3 The effect o f antibody incubation on enolase activity after five hours 
After 5 hour incubation of NSE with control IgG, enolase activity was slightly reduced 
compared to the baseline activity (Figure 8-18) however, there was a greater decrease in 
NSE activity in the presence of anti-NSE IgG compared to control IgG (Figure 8-18). 
This could not be explained by the observed reduction in enzyme activity seen with 
control IgG (Figure 8-18).
Anti-NSE IgG caused a mean decrease in absorbance of 48% (+/- 5% SEM) compared to 
baseline and a mean decrease of 58% (+/- 8% SEM) in absorbance when compared to 
control IgG (Figure 8-18). The differences in NSE activity (absorbances) were most 
apparent in the early stages of the measurement of enzyme activity (Figure 8-18). This 
lower activity from anti-NSE IgG compared to control IgG was seen throughout the 
measurement of NSE activity (Figure 8-18).
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Figure 8-18 Results of a five hour incubation of NSE with anti-enolase and control 
IgG
Enolase activity at baseline and five hour incubation 
with anti-basal ganglia antibody and control serum
Ec ft* = 0.9935
5  0.8
CO
ooc
0 10 15 20 25 305
Time minutes
B aseline eno lase  ac tiv ity  (-), en o lase  ac tiv ity  w ith  five  ho u r incubation  o f  norm al control ( -  ), enolase activ ity  w ith  five hour
incubation o f  A B G A  (. . . .).
8.16.4 The effect o f antibody incubation on enolase activity after an overnight 
incubation
Similarly, enolase activity with control IgG was reduced with an overnight incubation 
(Figure 8-19). However, there was a decrease in NSE activity incubated with anti-NSE 
IgG (Figure 8-19) compared to control IgG. There was a mean decrease in absorbance of 
72% (+/- 10% SEM) in the activity of this NSE compared to baseline and a mean 
decrease in absorbance of 38% (+/- 5% SEM) compared to control IgG. These 
differences were most apparent in the early stages of the activity experiment but were 
apparent throughout.
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Figure 8-19 Results of overnight incubation of enolase activity with anti-enolase and 
control IgG
Enolase activity after overnight incubation with 
control and anti-basal ganglia antibody
0 5 10 15 20 25 30
Time minutes
B aseline enolase  activ ity  (-), enolase  activ ity  w ith  five hour incubation  o f  norm al control ( ------- ), enolase activ ity  w ith five hour
incubation  o f  A B G A  (. . . .) .
Conclusion
There were no significant alterations in enzyme activity with anti-enolase positive IgG. 
However, an overnight incubation did show a decrease, although this may reflect 
methodology rather than a functional effect of antibody. This experiment does not rule 
out an effect on ATP production of the neuronal membrane. Cell culture experiments 
using primary striatal cultures are a possible method to examine this further.
R2 a 07341
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However, an alternative hypotheis for a functional effect of anti-enolase antibodies 
was reported by Dale et al., 2006). Compared to anti-Hu, anti-enolase antibodies 
induced a significantly higher rate of apoptosis in cultured cerebellar granule cells 
(Dale et al., 2006). Therfore an alternative functional effect of antibodies might be 
neuronal death.
8.17 Identification of the 40 and 60kDa putative antigens
Unfortunately, 2-D electrophoresis and proteomic investigation of the 40 and 60 kDa 
proteins yielded inconclusive results. There was contamination of the candidate protein 
‘spots’ with albumen and IgG fragments (identified by mass-spectroscopy). Combining 
the immunoprecipitation method with 2D-electrophoresis also resulted in no significant 
results, as the protein concentrations were too low for mass-spectroscopy. The main 
problem in identification of the 40 and 60 kDa autoantigens was the availability of basal 
ganglia tissue for 2-D electrophoresis.
Conclusion
The identification of the 40 and 60 kDa proteins was conducted as part of a separate PhD 
by Dr Russell Dale, PhD. The 40 kDa protein was identified as Aldolase C and the 60 
kDa protein as pyruvate kinase M l. This work was carried out by Dr Russell Dale, PhD 
using ammonium sulphate precipitation and Fluid Phase Liquid Chromatography (Dale et 
al., 2006). As the antigens are enzymes in the glycolytic pathway, a possible effect of 
antibody binding was proposed. The results of the enolase enzyme inhibition have shown 
blockade of glycolysis is probably not a major feature of anti-glycolytic enzyme 
antibodies.
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8.18 Final conclusions
It was surprising that this candidate autoantigen(s) were not basal ganglia specific as the 
original paper by Husby et al suggested it would be. However my IF studies suggested 
weak neuronal staining in basal ganglia, cerebellar granular layer and cortex.
Neurone- specific enolase has homology with a GABHS surface bound enolase and this 
does supports molecular mimicry as a hypothesis for ABGA production in SC and 
PANDAS. As an extension of this work we are synthesising recombinant NSE to 
establish an ELISA and Western immunoblotting method to test the percentage of SC, 
PANDAS and TS patients with anti-NSE antibodies. Purified NSE purchased from a 
commercial source did find anti-NSE antibodies in 4/6 patients with acute SC and no 
reactivity in controls.
To assess if anti-NSE antibodies could be pathogenic the effect of anti-NSE antibodies on 
glycolytic function was assessed. Antibodies against NSE did not have a major affect on 
the enzymatic function of NSE. However, the most profound effects of these antibodies 
appeared to be seen during the initial measurement of the enzyme activity method and 
overnight antibody incubation. This means that enzyme occupancy with antibody could 
be accumulative in its effect. The effect of anti-NSE antibodies on neuronal cell culture 
are experiments that are ongoing to assess whether metabolic stress could have an effect 
on neuronal survival and functioning.
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Human neuron specific enolase was found to be a candidate autoantigen for the 45 
and 98 kDa proteins. Dr Russell Dale, PhD, identified Aldolase C and Pyruvate 
Kinase M l glycolytic enzymes as the other candidate antigens in post-streptococcal 
movement and neuropsychiatric disorders (Dale et al, 2006).
This thesis adds to an antibody hypothesis of Sydenham’s chorea and other 
movement and neuropsychiatric disorders associated with streptococcal infection. 
How a common infection is associated with these conditions is still unclear, although 
an antibody driven or direct GABHS infectious hypothesis cannot be ruled out. 
Neuronal specific enolase is both cytosolic and membranous so an effect on neuronal 
membrane and particularly a functional effect of anti-neuronal antibodies cannot be 
ruled out. Further work is required, especially defining the cell type these antibodies 
bind to. It is probable that antibodies in Sydenham’s chorea, PANDAS and TS are 
just a marker of disease mediated by streptococcus or indeed are just non-specific. 
Sydenham’s chorea and TS may have different causes than autoimmunity.
The concentration of the antibodies is low compared with ant-neuronal antibodies 
associated with paraneoplastic disease. However, it is a similar titre to other 
autoantibodies such as ds DNA, ANCA, mitochondrial antibodies and others. Whilst 
antibodies are of low titre this does not imply that antibodies have no functional 
effect as complex interactions, including affinity of the antibody response are 
obviously important. Titration of SC samples against recombinant NSE is the next 
logical research step, although has considerable financial implications.
9 Discussion
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9.1 Background
The primary aim of this thesis was to investigate the presence of anti-basal ganglia 
antibodies (ABGA) in Sydenham’s chorea (SC) and the newly defined paediatric 
autoimmune neuropsychiatric disorders associated with streptococcal infections 
(PANDAS). The similarity of PANDAS to Tourette’s syndrome (TS) meant that the 
presence of ABGA could lead to the assessment of immunomodulatory treatments for 
this common disorder.
9.2 Evidence that Sydenham’s chorea is an autoimmune disease
Studies by Witebsky et al in experimental thyroiditis led to the theory that autoimmunity 
could be defined by a number of scientific criteria (Witebsky et al., 1957). These were: 
(1) the identification of autoantibodies or autoreactive cells; (2) The identification of a 
specific autoantigen; (3) The induction (with the use of immune adjuvants) of a similar 
disease in an experimental animal model (Witebsky e ta l., 1957), (Table 9-1). These 
criteria were revised to include the passive transfer of autoimmunity into an animal 
model using serum or cells from a host with autoimmunity (Rose et al., 1993), (Table 9- 
1). If SC is an autoimmune disease, then an equivalent set of criteria need to be fulfilled 
(Table 9-1).
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Table 9-1 Criteria for defining autoimmunity and the evidence to support 
Sydenham’s chorea and related conditions being autoimmune
Disease Rheumatic Sydenham’s PANDAS Tourette’s
fever chorea syndrome
Presence of autoantibody Yes Yes ? ?
Identification of Yes ?Enolase and ?Enolase ?Enolase and
autoantigen Myosin and others and others others
others
Induction of disease into Yes Yes (?) ?Conflicting ?Conflicting
animals data data
Passive transfer of disease Yes/No ? Yes Yes
The evidence for RHF being an autoimmune disease has not always been consistent but 
evidence now exists to fulfil each criterion (Table 9-1). The evidence for SC being an 
autoimmune disease has previously relied upon the presence of ant-neuronal antibodies in 
a small percentage of patients (Husby et al., 1976) and on incidental findings, such as the 
response of disease to immunomodulating agents such as corticosteroids. The 
identification of an autoantibody in a significant proportion of SC patients is an important 
step towards showing that SC and PANDAS and TS are also autoimmune. As TS and 
PANDAS appear to be phenotypically similar, the presence of an associated autoantibody 
may define an autoimmune subgroup, which could have major implications for
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treatments of these conditions. In addition the identification of an autoantigen would be 
important for diagnosis and allow the creation of an animal model.
Concerning the important question as to why some patients develop chorea whilst others 
have PANDAS or TS, it was found that there was no difference in the mean age of onset 
between PANDAS, SC and TS patients. Age does not therefore appear to be a major 
factor. There was, however, a male preponderance in patients with tics (TS and 
PANDAS), whilst those with chorea were more likely to be female, as had been reported 
previously (Nausieda et al., 1980). The difference in gender may mean that hormonal or 
subtle metabolic variations are important in the movement disorder phenotype, which 
manifests after a basal ganglia insult. There was no difference in the type of psychiatric 
manifestations between PANDAS and SC but the incidence of any psychiatric feature 
was higher in PANDAS. The main difference between SC and PANDAS was the 
presence of associated systemic disease in SC (RHF with carditis).
9.2.1 Additional evidence for autoimmunity in Sydenham’s chorea 
The data in this thesis does not rule out other immune mediators such as cells or indeed 
another mechanism being associated with chorea. Typically patients with SC do not have 
a CSF lymphocytosis (Prof. F.Cardoso, personal communication). CSF analysis of the 
UK samples did not reveal increased numbers of mononuclear cells, although a low grade 
lymphocytic infiltrate in the striatum may not necessarily be associated with a CSF 
pleocytosis. It is possible that cytokines, complement and other inflammatory mediators 
are an important feature of the pathogenesis instead of antibody binding in vitro.
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In common with other CNS autoimmune disorders such as MS, CSF IgG-specific OCB 
were present in acute SC although, unlike MS, OCB were only found in 50% of the acute 
SC samples and there was no predominant pattern of results. This may reflect different 
antibody responses in individual cases of SC, blood-brain barrier function or the focal 
nature of the pathogenesis of SC. The SC patients with OCB all had higher cytokine 
levels than the other patients with SC, although the numbers tested were too small to 
draw definite conclusions. The sampling of CSF occurred at different time points in the 
disease course and this may also have influenced the results, as initial intrathecal 
synthesis of OCB may be followed later by a “mirror” pattern of OCB in CSF and 
serum or vice versa. One patient with acute SC underwent lumbar puncture 1 week after 
initial presentation, to rule out metabolic disease. Serum ABGA was negative at this time 
but CSF was positive for a 40 kDa band. A subsequent follow-up serum sample one 
month later was ABGA positive with a 40 kDa band (unpublished data).
None of the persistent SC patients had CSF or serum OCB, although the numbers tested 
were too small (four) to rule out the presence of OCB in a proportion of this group. 
Absence of OCB together with a normal serum cytokine profile in persistent SC supports 
my hypothesis that a significant number of cases of persistent SC do not show evidence 
of an immune pathogenesis and the chorea may instead be a reflection of neuronal 
damage from the initial insult or an alternative cause. The OCB assay is also designed to 
detect responses in disseminated demyelinating diseases such as MS and encephalitis 
where inflammation is more widespread (Walker et al., 1983). As SC is a disease which
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appears to affect only a focal region of the brain the detection limit of this assay may also 
be too low. It would be important to measure the IgG and albumin index in paired CSF 
and serum samples in addition to OCB. This would give some indication as to whether 
there is any blood-brain barrier damage allowing cytokines, antibodies and cells into the 
brain. I was not able to examine this due to limitations in sample volume.
In addition to historical reports, T lymphocytes, and a preponderance of B-cells have 
been reported in the brain of 1 case of ABGA associated with Parkinsonism and 
encephalitis following streptococcal infection (not invading the CNS), (Dale et al., 2004). 
This may support the presence of an antibody-producing cellular response in some cases 
of post-streptococcal autoimmune movement disorders (Dale et al., 2004). The presence 
of an inflammatory cellular infiltrate in post-streptococcal CNS syndromes may, 
however, represent severe and permanent pathologies rather than typical SC or 
PANDAS. Standard diagnostic imaging studies are normally unremarkable, whereas in 
paraneoplastic syndromes (probably cell mediated) there is usually evidence of brain 
abnormalities. Patients with evidence of a post-streptococcal movement disorder with an 
encephalitic onset (ADEM and focal encephalitis) appeared to be less likely to make full 
recoveries than those with typical SC and PANDAS (Dale et al., 2001; Dale et al., 2004). 
As ADEM has also been associated with a cellular response it may imply that a cell 
mediated neuronal loss is an uncommon finding in SC, PANDAS and TS.
Other surrogate evidence for a Thl or Th2 immune basis for the pathogenesis of SC was 
investigated by investigating the cytokine levels. However, only a modest increase of any 
cytokine was present in acute SC with only 31% of patients having elevated Thl or Th2 
serum cytokines compared to controls. This low number could reflect the time of disease 
onset to sampling, the latency of the chorea post-infection and the assay sensitivity. 
Alternatively it may suggest that immune activation is not important in SC, or that the 
immune response is a focal rather than systemic, making evidence of immune activation 
difficult to detect. The CSF findings did, however, suggest a Th2 rather than a Thl 
response in acute SC, as both IL-4 and IL-10 (Th2 cytokines) were raised. The important 
Th-1 cytokine, INF-y, was undetectable in the acute SC group but this is difficult to 
measure accurately in body fluids so an undetectable level does not rule out a Thl 
(cellular) response being important in the pathogenesis of SC.
Additional evidence for the importance of Th-2 cytokines and hence antibody production 
came from the persistent SC results, as 50% of these cases had raised CSF IL-4 levels, 
whereas other serum and CSF cytokines were within normal ranges. I also demonstrated 
that only approximately 50% of persistent cases are positive for ABGA. Therefore the 
only consistent finding in both acute and persistent SC was raised CSF IL-4. As IL-4 is a 
pivotal mediator of Th-2 responses, this may suggest that SC is more likely to be an 
antibody-mediated disease. Whether IL-4 is from peripheral sources and acts on B- 
lymphocytes sequestered in the brain, or is produced intrathecally in response to ongoing 
brain antigen presentation is not clear from this study.
In conclusion, a possible mechanism for disease induction (streptococcal autoimmunity) 
is that following an infection or persistent colonisation with GABHS, there is a local 
immune response to streptococcal proteins. In some patients, perhaps due to genetic 
susceptibility or immune hyper-responsiveness, this immune activation produces a 
number of antibodies and T cells which also recognise self-antigens. These inflammatory 
and autoimmune mediators can cause a host of immune-mediated syndromes including 
PSGN, vasculitides, arthritis, RHF and chorea, although the predominant immune 
mechanism probably varies. If the immune response is coupled with blood-brain barrier 
damage or increased barrier permeability with over-expression of adhesion molecules, 
inflammatory mediators can enter the brain. This may be influenced by genetic 
susceptibility or toxins from GABHS. Recognition of streptococcal epitopes with 
homology to human protein may cause ABGA to be produced as a result of molecular 
mimicry. As a result these B cells are activated within the CNS and B-cell specific 
cytokines can be detected in the CSF. Identification of the antigens against which ABGA 
are directed will lead to further studies to see whether or not this antibody response is 
directly pathogenic.
9.2.2 Anti-basal ganglia antibody studies in Sydenham’s chorea using indirect 
immunofluorescence
The relatively low ABGA positivity rates in SC (Husby et al., 1976; Kiessling et al., 
1993) are only weak support for an autoimmune criterion. This has cast doubt as to 
whether ABGA are truly associated with autoimmunity, or are simply an epiphenomenon 
secondary to basal ganglia damage. The ABGA response could just be part of a repertoire
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of naturally-occurring antibodies found in GABHS infection or a response to local tissue 
inflammation or injury. In contrast to these earlier findings, a later study reported ABGA 
in 100% of acute and 93% of chronic SC using the same IF method (Kotby et al., 1993). 
The discrepancy might relate to the subjective nature of the IF method used in these 
studies.
I found that ABGA are not basal ganglia specific but staining may be enriched in humans 
in this area, the titre of antibodies is low and typically 1/50 is an ideal screening titre. 
Using the IF method I developed with human basal ganglia, I found that ABGA were 
positive in 95-100% of patients with acute SC. This could be in accordance with a 
specific autoimmune syndrome but, is far too low a titre when compared to other anti­
neuronal antibodies. Even though antibody titre was low, it was discriminating between 
SC, PANDAS, a subgroup of TS and controls so it might be a marker of disease in a 
similar fashion to anti-nuclear antibodies in connective tissue diseases such as SLE.
However, the IF studies conducted were just a pilot study due to lack of available 
funding. Therefore immunohistochemistry, confocal laser microscopy and electron 
microscopy using animal brain and/or striatal cultures could all be additional techniques 
to investigate. To determine if the neuronal-like staining present is afferent or efferent 
nerves, in situ hybridisation would be a useful technique to investigate as would multiple 
staining of sections with commercial antibodies against gabergic and dopaminergic 
markers.
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To ascertain whether the presence of ABGA is related to possible genetic differences, I 
compared results from Brazilian patients with SC and those of a UK cohort of SC. The 
prevalence of ABGA did not differ between these cohorts. I did not detect the presence of 
other significant (systemic) autoantibodies in SC patients, suggesting that the ABGA 
response is at least brain-tissue specific.
It had not been previously shown that ABGA bound to neurones alone, as differentiation 
of the ABGA IF staining from glial (accessory) cells had not been performed in any 
published study. The localisation and identification of glial cells in tissue sections of 
human striatum was investigated by staining with an antibody specific for a glial cell 
marker (GFAP) and a neuronal antibody, neurone-specific enolase and comparing the 
results to ABGA staining. The results with GFAP or ABGA antibody showed that each 
antibody recognised different cell populations thereby suggesting that ABGA didn’t 
appear to preferentially bind to astrocytes. The neuronal specificity of ABGA was shown 
by comparing the staining seen with ABGA with that of an antibody against NSE. The 
same pattern of staining was seen for both, showing that ABGA was neurone-specific.
The similarity of patterns also suggested that a possible target autoantigen for ABGA 
might by NSE. Other antibodies need to be investigated to show this further, this wasn’t 
done due to lack of money.
The weak staining in rat and monkey brain, especially cerebellar granule cells showed 
that ABGA are not striatum-specific. However, the striatum may just be an abundant 
source of the antigen compared to other areas of the brain. The staining I recorded in
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human striatum might be more pronounced than in other areas, although this needs to be 
investigated systematically as was not done here. Another possibility is that certain 
neuronal types have a different expression of the target antigen i.e. cytoplasmic versus 
membranous distribution.
None of the normal controls was ABGA positive, although 10% of patients with 
rheumatic fever (without neurological symptoms) were positive with the same pattern 
that was seen in SC. Rheumtic fever and SC are inextricably associated, and another link 
with the clinical presentation of RHF and SC is that a high percentage of psychiatric 
symptoms have been found in RHF patients without evidence of SC (Mercadante et al., 
2000). It is tempting to speculate that there may be a relationship between ABGA 
positive RHF patients and those with psychiatric symptoms similar to that which occurs 
in SC (Freeman et al., 1965; Moore., 1996; Swedo eta l., 1993). As no formal psychiatric 
assessment was made in the RHF patients I studied, this remains speculative but warrants 
further study, especially to ascertain why the RHF patients with ABGA can have 
psychiatric manifestations rather than obvious chorea. This might also be important in 
understanding the clinical and pathological relationship between SC and PANDAS.
There was no evidence of ABGA positivity in the neurological disease controls, which 
included: genetic, metabolic and vascular pathologies of the basal ganglia. This suggests 
that ABGA are not necessarily secondary to basal ganglia damage caused by a different 
pathological mechanism. However the numbers of controls with positive ABGA were 
higher in those with post-streptococcal, non-neurological, immune-mediated disorders.
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The presence of ABGA could therefore be a risk factor for the development of any post­
streptococcal autoimmune manifestation such as chorea, tics or psychiatric 
manifestations. Alternatively and possibly true is the notion that the anti-neuronal 
antibodies present in Sydenham’s chorea might be a transitory response to a GABHS 
infection with too low a titre to have any functional role.
Indeed, other autoantibodies have been associated with immune-mediated syndromes 
other than that originally described. This means the presence of ABGA may not always 
indicate a neurological syndrome reducing its usefulness. For example, it has been shown 
that anti-myosin antibodies are present in both RHF and Kawasaki’s syndrome, both of 
which are triggered by streptococcal infection (Cunningham et al., 1999). The 
neurological symptoms related to ABGA may require the presence of antibody with 
additional triggers, such as damage to the blood-brain barrier allowing such inflammatory 
mediators access to the brain. Or an alternative cause for SC might be the direct effect of 
GABHS rather than any immune-mediated cause.
9.2.3 Anti-basal ganglia antibody studies in Sydenham’s chorea using ELISA 
The ELISA was developed as a potential screening assay for ABGA. The disadvantages 
of the ELISA were that it was not clear whether patients with streptococcal-associated 
CNS disorders had the same reactive antibody repertoire. Unfortunately false positive 
results could be caused by several factors, including polyclonal increases in serum 
immunoglobulins, antibodies which reacted with blocking reagents (heterophile 
antibodies) and the presence of systemic (non-brain specific) autoantibodies. To help
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define whether the ABGA ELISA antibody response was specific, I also measured the 
IgG levels in SC patient serum, and found that they were not significantly different to 
controls. This was important as normal IgG levels would suggest that false positive, 
polyclonal binding to the basal ganglia antigens in the ELISA was producing the higher 
ELISA absorbances in SC. However, IgG was not normalised to age ranges and this is a 
criticism of this approach, but insufficient numbers in each age range were present to 
make meaningful comparisons.
An antigen preparation for the ELISA was optimised so that the antibodies detected were 
specific to basal ganglia proteins rather than lipids. This was because the lipid fraction of 
the basal ganglia homogenate contained elements of the myelin sheath. Antibodies 
against components such as myelin basic protein and myelin oligodendrocyte 
glycoprotein are a feature of a number of inflammatory CNS diseases, particularly MS 
and encephalitis (Berger et al., 2003; Desai et al., 1994; Egg et al., 2001). These anti­
myelin antibodies have also been reported in other inflammatory neurological diseases 
and are probably a consequence of neuronal damage (Reindl et al., 1999).
De-lipidated, soluble fraction of whole basal ganglia homogenate was used as the ELISA 
antigen. This did discriminate SC patients from controls although some neurological 
disease controls also had raised ELISA result. This suggests that the ELISA was 
detecting antibodies against a number of different epitopes. The best discrimination 
between SC patients and control groups occurred when using de-lipidated basal ganglia, 
protein (soluble) enriched fraction. I believe this finding supports soluble protein(s) being 
the likely candidate antigen(s) in the ABGA binding seen on IF in SC patients. This was
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confirmed by testing the insoluble basal ganglia homogenate fraction which did not 
discriminate between SC and controls.
During the development of the ABGA ELISA I also used a negative cut-off value (upper 
limit of normal) to assess the proportion of samples with raised ELISA results above the 
upper-limit of normal. This was important as the differences in mean ABGA absorbance 
may only reflect high absorbances in a small percentage of patients rather than in the 
majority of the cohort. The cut-off allowed semi-quantitative analysis of the ABGA 
results. The ELISA appeared to be as sensitive as IF when detecting ABGA in SC but 
specificity was not sufficiently high for the assay to be reliable.
The healthy and neurological control groups were both negative on ABGA ELISA using 
the cut-off value. However, 21% of streptococcal-associated autoimmune diseases 
control groups had raised ELISA results which mirrored IF findings. The RHF group also 
had similar results to those seen when using IF, as up to 20% of patients were positive 
compared to the ELISA cut-off. The number of UK controls with streptococcal- 
associated autoimmune conditions (PSGN, arthritis and vasculitis) who were ABGA 
ELISA positive was small, but higher than that seen from normal or mixed neurological 
disease controls. The specificity of the ABGA ELISA appears to be acceptable in normal 
and neurological control groups, with a typical specificity of approximately 90%. This 
was not mirrored in streptococcal controls, so the ELISA is not a suitable screening test 
and is not ideal for identifying ABGA.
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9.2.4 Anti-basal ganglia antibodies in Sydenham’s chorea using Western 
immunob lotting
IF is a subjective method and ELISA was unable to distinguish between antibody bound 
to single or multiple epitopes. A Western immunoblotting method was therefore 
developed using the same human basal ganglia antigen as ELISA in order to detect any 
specific ABGA responses to the same protein. The soluble SI fraction was used. The 
most frequent basal ganglia antigens recognised by serum from both acute and persistent 
SC patients had molecular weights of 40, 45, 60 and 98 kDa. The healthy adult controls 
and children with developmental delay did not have any specific reactivity against basal 
ganglia Western immunoblots. By comparison, approximately 30% of RHF patients had 
specific reactivity against basal ganglia proteins, and appeared to have the same bands 
that were present in SC. This confirms that some patients with RHF, without obvious 
CNS symptoms, have ABGA. This again suggests that IgG responses against brain might 
be related to GABHS infection, but doesn’t suggest a functional role as candidate 
antigens are soluble and from the cytoplasm.
9.3 Comparison of these ABGA results with current research 
Following publication of the ABGA study in SC (Church et al., 2002; Church et al., 
2003) another group also reported an ELISA and Western immunoblotting method for 
detecting ABGA (Singer et al., 2003). This group reported higher ELISA absorbances in 
their SC patients but these were not statistically different from controls (Singer et al., 
2003). They also used a cut-off value using the same method as in this thesis (Church et 
al., 2002; Singer et al., 2003) and reported that only 33% of SC patients had raised
ELISA absorbances against caudate and putamen antigens. Using Western 
immunoblotting they found no specific protein band exclusive to SC or controls and 
measuring the total area under each band using densitometry also failed to show 
significant differences (Singer et al., 2003). However, a statistical, multi-variant analysis 
of their results did show discrimination (ABGA positivity) between SC and controls. The 
use of soluble homogenate from the caudate had the greatest power of discrimination 
(Singer et al., 2003). My IF studies found that antibody (IgG) from SC patients 
predominantly bound to the caudate. The molecular weight of proteins which gave the 
highest statistical discrimination in the study by Singer et al was reported to be 126 kDa 
and 113 kDa. I had not identified these proteins in any Brazilian or UK patients.
The difference between Singers et aVs results and mine is the lower proportion of SC 
patients who were ABGA positive in the former. This could be reflected in the 
preparation of tissue for ABGA antigens. Singer et al performed their ABGA ELISA 
against separate fractions of caudate, putamen and globus pallidus whilst mine contained 
whole caudate and putamen. My antigen source may therefore have contained more of 
the target antigen because an intact striatum rather than a dissected one was used. There 
were also fundamental variations in methodology when preparing the homogenates for 
Western immunoblotting. I found that including a commercial detergent cocktail (T-per 
Pierce) improved the recovery of proteins compared to simple mechanical 
homogenisation. Singer et al used 10% homogenous PAGE gels for their Western 
immunoblotting whilst I found that a gradient PAGE gel (4-12%) increased the 
separation of proteins which gives better resolution. Discrimination between 2 closely
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aligned bands was easier in a gradient gel. I also found that IgG from the donor tissue 
reacted with the secondary detector antibody (anti-human IgG). As this was an expected 
result this band was always present and hence excluded from the analysis of differences 
between SC patients and controls in my results. This may have caused problems in the 
analysis of results in Singer et al's Western immunoblotting study.
Another reason for possible differences in results between the two studies may relate to 
the lipid fraction of the basal ganglia homogenate. Unlike Singer et al, I removed the 
lipid fraction before using the remainder for the detection of ABGA. The problems with 
identifying a specific signal were also shown from the ELISA results using the lipid 
fraction which was not discriminating. This may explain the multiple bands in SC 
patients and controls reported using crude basal ganglia homogenates (Singer et al.,
2003). The methods for detecting antibodies may also influence the results from different 
studies. Singer et al used enhanced chemiluminescence to detect ABGA in Western 
immunoblotting, which is a very sensitive method but can produce a multitude of 
responses in patients and controls, most of which are of doubtful significance. I proposed 
that colorimetric analysis of Western blots in this setting is preferable and improves 
specificity, although arguably at a cost of reduced sensitivity.
An alternative explanation fpr the presence of ABGA in SC, PANDAS and TS is that it 
occurs as an epiphenomenon secondary to basal ganglia damage. I believe this is unlikely 
as the control groups that were tested had inflammatory, metabolic and ischaemic basal 
ganglia diseases and were ABGA negative. In addition to the ABGA and streptococcal
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data in TS, a provocative study was carried out by Hallett and co-workers, in which they 
microinfused the sera or IgG from patients with TS into the striatum of rats to ascertain it 
effects on movement. This induced stereotypies which were proposed to be analogous to 
the involuntary movements seen in TS (Hallett et al., 2000). This was confirmed in a 
separate study of TS sera (Taylor et al., 2002). However, a recent study could not induce 
behavioral changes in a rat model (Loiselle et al., 2004). As I have found that the ABGA 
repertoire (40, 45, 60 and 98 kDa proteins) is similar in post-streptococcal tics or 
choreiform disorders, these observations suggest that ABGA may play a pathogenic role 
in SC, PANDAS and a subgroup of TS. This is important as it may be a useful laboratory 
test in patients presenting with idiopathic movement disorders.
9.4 Paediatric autoimmune neuropsychiatric disorders associated with 
streptococcal infections 
All the PANDAS patients studied had a IF binding pattern against basal ganglia neurones 
similar to that previously reported in SC and seen in my studies (Church et al., 2002; 
Church et al., 2003; Husby et al, 1976; Kotby et al., 1998). This may suggest that 
regardless of the phenotype of the movement disorder, (SC or PANDAS), the associated 
ABGA response is essentially the same. It is not surprising that ABGA could produce a 
range of extra-pyramidal movements and psychiatric manifestations, as rarely do diseases 
affecting the basal ganglia result in just a single movement disorder phenotype (van Dijk 
etal., 1986).
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The mean ABGA ELISA result in the PANDAS group was elevated in every comparison 
to the results from the neurological, streptococcal, autoimmune and normal controls. In 
addition, analysis of the PANDAS group showed that the mean ABGA ELISA derived a 
sensitivity of 82.4% and specificity of 79%. Analysis of the Western blotting results 
indicated that the same antigens (recognised by molecular weight) were present in 
PANDAS as SC. Interestingly the 40 kDa basal ganglia antigen was more common in 
patients with PANDAS than SC, so this may yet prove to be a useful marker for 
PANDAS.
ABGA was prevalent during the active phase of PANDAS and decreased during 
remissions (where follow up samples were available). This phenomenon may be 
important when attempting to identify autoimmune subgroups in other chronic 
neuropsychiatric syndromes where post-streptococcal autoimmunity is implicated, such 
as TS or OCD. This is important in chronic disorders as ABGA may only be present early 
on in the disease when it could cause permanent damage to neurones. The ABGA ELISA 
method was not useful in these chronic settings as sensitivity of the assay was too low. 
Western immunoblotting can define specific antigenic binding and I found this method, 
in conjunction with IF, to be the preferred marker.
In conclusion the results of this study suggest that ABGA Western immunoblotting and 
IF can be used as a marker in investigating patients with movement disorders where 
streptococcal infection has either been implicated as an initial trigger or associated with 
exacerbation of symptoms. This implies that cases of idiopathic dyskinesias where other
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causes have been eliminated should be investigated to see whether they have ABGA and 
Streptococcal infection. Importantly the range of hyperkinetic movement disorder should 
not be limited chorea or tics, as patients with other movement disorders, particularly 
dystonia have ABGA and evidence of recent streptococcal infection (Dale., 2003; Church 
e ta l ., 2002).
9.5 Tourette’s syndrome 
It has been reported that patients with TS also have significantly higher rate of positive 
streptococcal serology results (ASOT and DNAse B) compared to control subjects 
(Cardona et al., 2001; Morshed et al., 2001; Muller et al., 2000)thus supporting a 
hypothesis that TS could also be a post-streptococcal immune-mediated disorder. It is 
important to note that, as with SC, not all TS studies have reported a consistent elevation 
in streptococcal serology (Singer et al., 1998; Singer et al., 1999). To investigate the 
incidence of streptococcal infection one group investigated antibody reactivity to 
streptococcal M-proteins in TS (Muller etal., 2001). They demonstrated elevated 
antibody titres to M l2 and M l9 proteins using an ELISA, but not to M l, M4 and M6 in 
25 adult TS patients compared to 25 control subjects (Muller et al., 2001). This lends 
further support to the concept that particular strains of GABHS are associated with these 
disorders. Strain specificity is compatible with the observations that other post­
streptococcal immune-mediated disorders, i.e. RHF and PSGN are also strain-specific 
(Stollerman., 2001).
Increased antibody binding to putamen rather than caudate had been reported in TS, and 
basal ganglia antigens of molecular weights 60, 67 and 83 kDa have been suggested as 
common epitopes (Singer et al., 1998). A further study also suggested that 60 kDa was 
the most prevalent basal ganglia autoantigen in TS although a complex multivariate 
analysis was required to establish an association (Wendlandt et al., 2001). Preliminary 
results from another group also suggested that responses to 60 kDa and 83 kDa antigens 
were dominant in patients with tics, TS and/or OCD (Trifiletti et al., 2000). The same 
authors suggested that these antibodies recognized a calpain-calpastatin complex 
(Trifiletti et al., 2000 abstract). The consistent finding of a 60kDa antigen from my SC 
and PANDAS studies suggests that the 60 kDa antigen could be important in SC, 
PANDAS and TS.
In view of the conflicting ABGA results in TS, a large cohort of TS patients and various 
control groups was investigated using for the presence of ABGA. Results showed that 
27% of adult TS, 20% of children with TS and 2-4% of control groups were ABGA 
positive by Western immunoblotting. This was confirmed by IF of the positive samples. 
The IF staining pattern was the same as that seen in SC and PANDAS, with staining 
predominantly confined to the caudate rather than the putamen. The low percentage of 
ABGA positivity in TS compared to SC and PANDAS supports the heterogeneous nature 
of TS pathogenesis. As only approximately 20% of patients in this study were ABGA 
positive this could explain why many studies have found different results for ABGA and 
streptococcal serology (b. Church et al., 2003). A large cohort of TS patients needs to be
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studied to provide consistent results or to identify the small proportion of TS patients who 
have evidence of streptococcal infection and ABGA.
My results do not support the putamen as the predominant ABGA binding site in TS, 
unlike those of Singer et al. The putamen results were obtained from ELISA and Western 
immunoblotting methods so the differences could be related to antigen preparation. 
Contamination of putamen antigens by caudate proteins, perhaps during post-mortem 
removal of the striatum, may explain why they also reported a 60 kDa antigen common to 
TS patients (Singer et al., 1998). Using ABGA ELISA I found no difference in the mean 
absorbances between children and adults with TS compared to controls, and elevated 
ABGA was found in 16% of children and 11% of adults. This was not significantly 
different from controls. The failure of ELISA to discriminate between TS and controls 
suggested that either ABGA or streptococcus (or both) are not important in the 
pathogenesis of TS or they are important in only a small subgroup of patients. Western 
immunoblotting and IF, however, did discriminate and identified a proportion of patients 
with TS who were ABGA positive. The failure of ELISA to do this may be related to 
sensitivity of the assay, or TS may simply be associated with low concentrations of 
ABGA. Another possibility relates to the nature of the study, which was cross-sectional 
and recruited patients who had had TS for many years. That the fact that ABGA 
positivity was higher in children suggested that ABGA might be lost with time which is 
similar to the observations in persistent SC. ABGA may therefore only be important in 
the initial disease induction and chronic TS may simply be a consequence of damage to
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the basal ganglia. Alternatively ABGA might just be related to GABHS infections and 
have no role at all.
9.6 The importance of streptococcal infection 
The production of ABGA may be influenced by the streptococcal strain causing the 
infection, and unidentified co-factors and host susceptibility to autoimmunity. Genetic 
susceptibility probably plays a role in view of the familial association of SC and RHF 
(Read et al., 1938; Wilson et al., 1954) and the observation that specific racial groups 
appear to have increased susceptibility to RHF and SC (Carapetis et al., 1999; Haidan et 
al, 2000). No reproducible association with HLA has yet been found in SC or RHF 
(Donadi et al., 2000). Similarly, the presence of the putative B-cell marker D8-17 has 
also not been confirmed in RHF, SC or PANDAS.
Supporting evidence for the involvement of streptococcal infection in the SC patients 
studied came from the clinical observation of active carditis, previous streptococcal 
pharyngitis and in one case, GABHS skin infection. The SC patients from Brazil did not 
undergo routine throat cultures to detect GABHS. In 3 patients from the UK SC group 
GABHS was isolated from the throat. As the numbers of SC patients with raised 
streptococcal serology varied between historical studies (Ayoub et al., 1966; Eshel et al., 
1993; Moore., 1996), I measured both ASOT and anti-DNAse B to address this issue. No 
acute SC patient had both negative ASOT and anti-DNAse B compared to cut-off values. 
This demonstrated, albeit using serology, that evidence of GABHS was prevalent in the 
acute SC group and at a significantly higher rate than in normal subjects and neurological
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disease controls. The fact that ASOT or anti-DNAse B positive serology were relatively 
the same in acute SC patients could not be used to distinguish between past or present 
streptococcal infection and whether either is associated with SC. If SC is a manifestation 
of past infection one would expect the anti-DNAse B to be raised more frequently than 
ASOT. This is because ASOT declines soon after infection, whilst anti-DNAse B remains 
elevated for a longer period of time (up to 3 months).
Alternatively acute SC may be associated with persistent streptococcal infection or 
colonisation rather than a latent immune manifestation of a previous infection. This may 
have caused ASOT levels to remain elevated due to difficulty in clearing the infection. 
Evidence of the nature of GABHS infection in SC could be inferred by comparing to the 
rates in other GABHS pathologies. Serological evidence of streptococcal infection in 
other streptococcal diseases such as uncomplicated pharyngitis was similar to SC. This 
may indicate that acute infection or re-infection could be associated with some cases of 
acute SC. However, the rate of positive streptococcal serology in SC was similar to the 
rates in other autoimmune post-streptococcus disorders such as PSGN which are thought 
to be latent manifestations of streptococcal infection. This suggests that previous 
infection with a latent immune activation can also be the cause of some cases of SC. The 
streptococcal serology in persistent SC patients showed a lower percentage of raised 
ASOT and anti-DNAse B than in acute SC. This was the same for ABGA positivity. This 
supports the hypothesis that approximately half of the persistent SC cases are probably 
not driven by very recent streptococcal infection and/or the presence of ABGA.
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Interestingly, persistent SC cases who were ABGA positive were more likely to have a 
raised ASOT and/or anti-DNAse B.
In conclusion the immune response to GABHS which results in SC may be related to a 
particular individual’s immune response. Instead of SC being a latent immune 
manifestation, acute infection or persistent colonisation may be equally important but in 
different patients. Persistent colonisation may occur due to the ability of the streptococcal 
strains to internalise and colonise cells in the nasopharynx, so using ASOT or anti- 
DNAse B to interpret the time-course of infection may be unreliable. The variation in 
immune responses to GABHS might also be the reason why some patients with GABHS 
develop the ABGA response against the 40, 45 and 60 kDa proteins and some do not. 
Therefore ABGA might just be a response to infection, self limited and of no importance 
other than to be a marker of severe complications of infection such as RHF and SC.
Streptococcal serology results in patients with PANDAS was similar to that of patients 
with SC, i.e. a higher proportion of patients with PANDAS had raised ASOT and anti- 
DNAse B compared to patients with other neurological diseases or other control groups. 
Results from the normal control groups confirmed that streptococcal infection is common 
in childhood. Evidence from either serology or throat culture and a clinical history of 
pharyngitis indicate that GABHS infection is very common in patients with PANDAS. 
This supports the results of others (Swedo et al., 1998).
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Unexpectedly the majority of the subjects with TS had raised ASOT, although only a 
minority were ABGA positive, indicating that a higher proportion of patients with TS 
have evidence of recent or persistent streptococcal infections. If, as I suspect, ABGA are 
strongly related to streptococcal infection, the failure to find a higher proportion of 
patients who were ABGA positive may relate to the sensitivity of the ABGA assays. 
Alternatively, ABGA levels may fluctuate during the course of TS, possibly mimicking 
the waxing and waning of symptoms and signs of TS (Robertson., 2000). Indeed 6/7 
(85%) of the TS patients I followed with raised initial ASOT, but who were negative for 
ABGA, seroconverted and became ABGA positive. This coincided with a reduction in 
the ASOT, 3 months after the initial sample. A longitudinal study involving large 
numbers of known TS patients is underway to address the temporal association between 
ABGA-streptococcal infection and clinical course.
Unfortunately the anti-DNAse B assay was not available for this study. Serological 
evidence of recent GABHS infection was detected in 91% of patients with positive 
ABGA compared to 57% of patients who were negative for ABGA. The patients did not 
have routine throat culture as part of this study. If ABGA and a positive ASOT in patients 
with TS are related it is uncertain at present why ABGA are not found in all TS patients 
with evidence of recent streptococcal infection. A simple explanation may be that the 
current ABGA assay has a low sensitivity or that these responses are just transitory and 
of no importance. This will need to be explored using ELISA with a recombinant human 
protein as the antigen source. A high carriage rate of GABHS in patients with TS is 
intriguing and is persuasive evidence to support the argument that GABHS plays a
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pathological role in TS. The implications for this work are that alternative treatment 
strategies such as antibiotics or immune-modulating drugs such as steroids or IVIG may 
be useful in managing and alleviating the symptoms of TS.
A plausible alternative to the hypothesis that proposes ABGA as being the cause of these 
syndromes is that the presence of a streptococcal toxin such as streptolysin O, or a 
streptococcal pyrogenic exotoxin, might be responsible for the brain pathogenesis. There 
is evidence that a toxin plays a role in other streptococcal immune-mediated syndromes 
such as scarlet fever and Kawasaki’s syndrome. In these syndromes streptococcal toxins 
are implicated directly in cell death and indirectly via activation of the immune response 
and innocent-bystander damage of cells. Streptolysin O, for example, binds to cholesterol 
on cell membranes resulting in toxin-cholesterol aggregates which cause cell lysis 
through an osmotic mechanism (Bhakdi et al., 1985; Palmer et al., 1998; Sekiya et al., 
1993; Sekiya et al., 1996). Significant concentrations of streptolysin O in the brain could 
cause cell death or through binding to cholesterol cause a change in cell potential and 
disruption of neuronal function. As there is no evidence to support brain colonisation of 
GABHS, extracellular toxins would have to enter the brain via the vasculature.
A novel streptococcal toxin might be binding to a specific ligand only found on basal 
ganglia neurones, perhaps causing dysfunction of the dopaminergic pathway thus leading 
to complex movement disorders. A specific strain of streptococcus may therefore be 
capable of producing a neuronal toxin, and this could explain the elevated streptococcal 
serology. To date no novel GABHS strains have been found in these patients but due to
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the constantly changing pattern of virulence in streptococcus species, this might be less 
important than the ability to produce a particular toxin.
The presence of antibodies (ABGA) might also be related to an immune response to a 
toxin that binds to neurones. A similar pathogenesis had been proposed in post­
streptococcal nephritis (Rincon et al., 2003; Treser et al., 1969). To test this hypothesis 
the effect of extracellular toxins on neuronal cultures could be investigated. The 
particular streptococcal strains isolated from patients with SC, PANDAS and TS could 
also be investigated to see if they contain novel genes which differ from strains 
associated with uncomplicated infection.
9.7 Putative autoantigen 
The identification of the candidate proteins that ABGA bind may give some insight into 
the pathological relationship between the streptococcus and the brain. The cellular 
distribution of the proteins that ABGA recognised may also be important as a 
cytoplasmic localisation would cast more doubt on the pathological significance of these 
antibodies. It is unclear at present whether autoantibodies directed at intracellular 
antigens can affect the cell function. The identification of the proteins I found most 
commonly associated with ABGA binding in SC, PANDAS and TS was thus the next 
important step.
The isolation and identification of the candidate antigens (recognised by ABGA using 
human tissue) was problematic due to difficulties in obtaining large quantities of human
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tissue. Animal tissue would have been a usual route to identify putative antigens but as IF 
staining was weak against rat tissue, human was used. Sera which appeared to react 
against a single basal ganglia protein: 40, 45, 60 or 98 kDa were tested separately to 
facilitate identification of reactivity. The 45 kDa protein was found at the acidic end of 
IEF gel (pi 4-5) and reactivity was co-associated with the 98 kDa protein, even though 
not all sera reactive with the 98 kDa band had evident reactivity against a 45 kDa band 
using standard Western immunoblotting. Using 2-D electrophoresis probably increased 
the quality and quantity of protein separation, making the positivity of samples to both 
the 45 and 98kDa bands more apparent. The 2-D electrophoresis pattern showed that 
there were 2 reproducible protein ‘spots’ which corresponded to 45 and 98 kDa 
molecular weights. I did not find these proteins were reactive when testing control serum 
samples. The mass-spectroscopy analysis of the 2 spots identified them as the monomer 
and dimer of the same protein, neurone-specific enolase (NSE).
In comparison I used the same methods to investigate the 40 and 60 kDa bands. These 
were difficult to isolate from the 2-D gels as they migrated to a point where there were 
multiple, sometimes overlapping proteins. I decided to use different methods of protein 
separation and isolation by using immunoprecipitation. Unfortunately, despite using the 
maximum concentrations of antigen and antibody I was unable to extract target proteins 
in sufficient quantities to identify by mass-spectroscopy. I tried to overcome these 
problems by concentrating the proteins obtained from the immunoprecipitation method 
but the amino acid sequence still could not be determined because of the low protein 
concentration. I was unable to concentrate the proteins further as the mass-spectroscopy
system required a minimum sample volume. These results may imply that despite clear 
immunoreactivity using my methods, the 40 and 60 kDa proteins are not useful 
discriminate protein targets in streptococcal CNS disorders. Alternatively the 
concentrations of the antigen in neurones may be low. However Dale et al., using 
immunoprecipitation and Fluid Phase Liquid Chromatography of rat brain, identified 
these proteins as Pyruvate kinase Ml and Aldolase C (Dale et al., 2006). There may of 
course be more important antigens than those described but different methods are 
required to examine this hypothesis further.
An alternative method for identifying autoantigens would be to create hybridomas from 
peripheral lymphocytes and produce monoclonal antibodies which could be screened 
against streptococcal proteins. Kirvan et al using this technique have recently shown that 
a monoclonal antibody derived from one patient with SC recognised streptococcus 
GlcNAc (Kirvan et al., 2003). This antibody recognised lysoganglioside. As only one 
patient was used to produce this monoclonal antibody it is not known if this is a common 
finding in SC or whether the patient had had a previous disorder, for example GBS, 
which could have been responsible for the anti-ganglioside antibodies. The ability of this 
patient’s CSF to activate CAM II kinase (Kirvan et al., 2003) may not be related to the 
monoclonal specificity of thfe ganglioside antibody but may be secondary to other 
immunoglobulin reactivity.
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9.8 Neurone-specific enolase 
The identification of NSE as a putative autoantigen is interesting as a homologue of 
enolase is found on the cell surface of streptococci. This could support molecular 
mimicry as a method of antibody induction but does not imply a functional role. A 
comparison of high power IF between a commercial anti-NSE antibody and ABGA 
showed similar staining patterns. Interestingly, cell surface enolase has been reported on 
both encapsulated and un-capsulated streptococci but not staphylococci (Pancholi et al., 
1993). This has been used to suggest that enolase is an important feature of respiratory 
pathogens (Pacholi et al., 1998). The role of glycolytic enzymes such as enolase on the 
cell surface of bacteria is unknown at present, but enolase can bind plasminogen so it 
may play a role in bacterial attachment and infection (Derbise et al., 2004; Fontan et al.,
2000).
Antibodies raised to streptococcal surface enolase have been shown to react with human 
a-enolase (Fontan et al., 2000), which is found in the cytoplasm of all human cells (Kato 
et al, 1983). It has also been reported that levels of antibodies which react with human a- 
enolase and streptococcal enolase are raised in patients with RHF compared to those with 
uncomplicated streptococcal pharyngitis or normal controls (Fontan e ta l ,  2000). To date 
no studies have investigated antibodies against gamma enolase (NSE) in post­
streptococcal sequelae. Alpha and gamma enolase are isoforms, so why antibodies 
reacting to alpha enolase are found in RHF, whilst gamma enolase (neuron-specific) 
might be present in SC is unknown. It may be that antibodies recognise different enolase 
epitopes, so epitope mapping of both alpha and gamma enolase would be required to
answer this question. This may also be important in RHF and PSGN as there may be 
heart-and kidney-specific enolase isoforms. Indeed, antibodies against alpha-enolase 
from human kidney extracts have been found associated with kidney disease in mixed 
cryoglobuinemia (Sabbatini et al., 1997). Alternatively, differences in the streptococcal 
enolase protein between rheumatogenic and neurogenic streptococcal strains might be 
responsible for the different antibody profiles in RHF and SC. Studying the GABHS 
serotypes in each syndrome would be required to investigate this hypothesis.
9.9 Speculation as to the role of enolase
It was surprising that the 45 and 98 kDa basal ganglia proteins I identified were NSE 
rather than a protein specific just to the basal ganglia. The results from the ABGA IF 
suggested that the antibody response was linked to a specific or enriched source of 
antigen in the basal ganglia. This may be because the relative concentration of NSE is 
higher in a particular type of neurone in the basal ganglia. However, this is probably 
unlikely, since a histochemical study showed that NSE (gamma enolase) was present in 
neurones throughout normal human adult brain (Joseph et al., 1996; Royds et al., 1982).
However, although NSE is a cytoplasmic protein, a membranous distribution in neurones 
has also been reported (Lim et al., 1983, Leung et al., 1987). An important finding 
related to post-streptococcal basal ganglia autoimmunity is that multiple monoclonal 
antibodies raised against NSE have shown a different distribution of NSE within the 
brain (Frikke et al., 1987). It was suggested that there might be multiple conformational 
or structural forms of NSE, perhaps related to post-translational modification (Frikke et
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al., 1987). Therefore NSE expressed in basal ganglia neurones may be a different form, 
or possess different epitopes on the cell surface, to that in other areas of the brain.
There have been no studies as to the membrane distribution, concentration or exact role 
of NSE in different areas of the brain. A membrane localisation of NSE could be more 
pronounced in the caudate or a particular type of neurone in the basal ganglia. The 
distribution and levels of expression of NSE may be linked to the metabolic requirements 
of the basal ganglia since NSE is a glycolytic enzyme capable of producing ATP actually 
on the membrane (Lim et al., 1983). Indeed NSE exists as both monomers and dimers on 
the neuronal membrane surface (Ueta et al., 2004). This has lead to a hypothesis that 
glycolytic enzymes might have multi-functional “moonlighting” roles (Pancholi etal.,
2001). The reason why striatal enolase might be a different isoform from typical NSE 
might be related to the growing notion that many proteins have “moonlighting effects”, 
i.e. proteins can have functions different from that normally expected (Copley., 2003). 
Therefore striatum, NSE might have novel functions, perhaps mediated through a channel 
such as N+K+ATPase (Dale et al., 2006).
Dale et al showed increased apoptosis in cerebellar granule cells (Dale et al., 2006). They 
suggested that local energy failure, mediated by anti-enolase antibodies effecting ATP 
production on striatal, neuronal membranes could lead to cell death or other metabolic 
consequences. A functional effect of anti-NSE antibodies in subjects with SC might be 
interruption in glycolysis. However, anti-NSE antibody had no immediate, significant 
effect on enzyme. Provocatively, magnetic resonance spectroscopy studies have reported
increased glucose turnover and hypermetabolism in the basal ganglia of patients with SC 
(Goldman et al., 1993; Lee et al., 1999; Weindl et al., 1993) which could support a subtle 
energy distruption. A case of ABGA associated with minor chorea and a dementia like 
presentation was assessed by positron emission tomography which also showed 
hypermetabolism in the left striatum with a normal MRI (Leger et al., 2004). Treatment 
with corticosteroids improved her condition and the PET scan showed a return to normal 
in the left caudate (Leger et al., 2004).
These studies could suggest a hypothesis of local metabolic stress in the striatum in SC 
due to antibody binding and interruption of metabolic pathways. This causes disruption in 
the neuronal control of normal movements, resulting in development of chorea and tics.
A hypothetical pathway of antibody effect is shown in figure 9-1 and 9-2. Metabolic 
effects of antibody binding to enzymes (Figure 9-2) could be causing an effect on a 
membrane receptor as enolase can produce ATP on the cell surface (Lim et al., 1983). A 
possible hypothesis is local energy failure resulting in alterations of neuronal membrane 
function or apoptosis of neurones with medium spiny striatal neurones susceptible to such 
changes (Dale et al., 2006). As no direct effect on ATP production was shown in this 
thesis how energy failure might occur is unknown but it might be due to an accumulative 
effect of antibody binding.
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Figure 9-1 Summary of possible mechanism for anti-neuronal antibody effects in 
Sydenham’s chorea
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Toxins (ASO, DNAse B, SPE) Striatal neurones
Super antigens ?Effect on "-.x  \
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Figure 9-2 Role of enolase in glycolysis
• 3-Phosphoglycerate<-»2-Phosphogly cerate (Phosphoglyceromutase)
• 2-Phosphoglycerate<->phosphoenolpyruvate+H20 production of high energy 
phosphate (enolase)
• Phosphoenolpyruvate+ADP—>pyruvate+ATP production of pyruvate (pyruvate 
kinase)
Whilst enolase and pyruvate kinase are enzymes that appear in stage II of glycolysis, 
aldolase C is a stage I enzyme
• D-Fructose l,6-diphosphate<->dihydroxyacetone phosphate+D-glyceraldehyde 3- 
phosphate adol condensation yielding Idijferent triose phosphates (Aldolase C)
The glycolytic enzymes suggested as antigens in post-streptococcal neurological disorders are shown 
in their glycolytic role in bold type.
To examine a metabolic hypothesis further, in vitro experiments, using neuronal cell 
cultures are indicated. Anti-NSE antibodies could be introduced into a cell culture and, 
using a fluorescent antibody marker, the cellular distribution of the anti-NSE antibodies 
could be investigated over time. This would show whether or not ABGA bound primarily 
to the surface enolase before being endocytosed and localised in the cytoplasm. It would 
be useful to study the enolase homologue expressed by GABHS as it is not known 
whether all GABHS strains express enolase. Strain specificity in post-streptococcal CNS 
disorders may be related to the proteins expressed on the bacterial cell surface in 
conjunction with susceptibility to autoimmunity or hypersensitivity following infection. 
Further investigation of NSE as a possible target autoantigen would involve injecting the 
protein or peptides with adjuvant aimed at producing an animal model of CNS disease.
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Injecting homogenates of GABHS have also been proposed in a murine model of 
PANDAS, eliciting an antibody response which bound to deep cerebellar nuclei 
(Hoffman et al., 2004).
9.10 Final Conclusion 
In conclusion to determine the incidence and prevalence of streptococcal-associated CNS 
disorders associated with anti-NSE antibodies might be interesting to pursue further. The 
ideal method would be to use recombinant NSE protein in an ELISA, as human NSE is 
difficult to obtain commercially, expensive and purification of large quantities of NSE 
from human material is impractical. Samples with suspected positive anti-NSE antibodies 
could be confirmed by Western immunoblotting analysis using the same recombinant 
NSE.
Anti-basal ganglia antibodies do not appear to be specific to basal ganglia. However, 
an IgG antibody directed at neuronal glycolytic enzymes has been found in SC and 
PANDAS. Unlike paraneoplastic syndromes this antibody is of weak concentration 
although the affinity of these antibodies is unknown. The presence of this antibody 
probably represents an acute phenonomen related to streptococcal infection and the 
incidental presence of a neurological, extrapyramidal movement and psychiatric 
disorder. Further work, including longitudinal studies, is required to answer the 
relationship between these antibodies and clinical phenotypes.
Other work which may be carried out is to look for anti-neuronal antibodies 
directed to a channel. If functional autoantibodies exist in SC they might be directed 
against a neuronal membrane channel, so RIA assays of calcium or potassium 
channel antibodies is required. If other immune-mediated causes for SC and 
PANDAS are considered, T-cell responses need to be investigated. Animal studies of 
enolase antigen are required if enolase is accepted as an antigen. Histopathology is 
required in great detail to look at antibody binding.
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10.1 Appendix I. Indirect Immunofluorescence
Human tissue blocks and sections were kindly provided by the Neurological diseases 
tissue bank, Institute of Neurology, Queen Square. London WC1N 3BG.
Rat tissue sections were purchased from The Binding Site.
Sections were mounted with fluid containing 75% glycerol (Sigma G5516) and 25% PBS 
(Sigma P4417) which was pipetted onto each slide and a glass cover slip was placed on 
top of the section ensuring air bubbles were not present.
10.2 Appendix II. Brain Homogenate preparation T-per reagent (Perbio 
785101
T-Per is a cocktail of detergents, diluted in 25mM bicine, 150mM sodium chloride with a 
pH of 7.6. The tissue was weighed and lmL of T-per was added per gram of tissue. 
Homogenisation occurred in the presence of protease inhibitor cocktail (Sigma P-8340) 
using a ratio of 1 part inhibitor to 10 parts of tissue. Centrifuge the sample at 10,000 rpm 
for 5 mins to pellet the debris. Collect supernatant.
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10.3 Appendix III Enzyme linked immunoabsorbant assay 
Anti-basal ganglia ELISA template
Column 1-6 (IF positive SC) Column 7-9 (IF negative serum)
1 2 3 4 5 6 7 8 9 10 11 12
A BLK BLK BLK BLK BLK BLK BLK BLK BLK BLK BLK BLK
B 1/100 1/100 1/100 1/100 1/100 1/100 1/100 1/100 1/100 1/100 1/100 1/100
C 1/200 1/200 1/200 1/200 1/200 1/200 1/200 1/200 1/200 1/200 1/200 1/200
D 1/250 1/250 1/250 1/250 1/250 1/250 1/250 1/250 1/250 1/250 1/250 1/250
E 1/300 1/300 1/300 1/300 1/300 1/300 1/300 1/300 1/300 1/300 1/300 1/300
F 1/400 1/400 1/400 1/400 1/400 1/400 1/400 1/400 1/400 1/400 1/400 1/400
G 1/500 1/500 1/500 1/500 1/500 1/500 1/500 1/500 1/500 1/500 1/500 1/500
H 1/1000 1/1000 1/1000 1/1000 1/1000 1/1000 1/1000 1/1000 1/1000 1/1000 1/1000 1/1000
ELISA coating buffer: Carbonate buffer: Stock solution 0.5M, 13.85g anhydrous sodium 
carbonate (BDH 102405Y) 26. lg sodium hydrogen carbonate (BDH 102475W) in 1 litre 
of distilled water. Working strength 1/10 dilution (0.05M solution)
Acetate buffer for colour reagent: 0.2M Stock solution 136g sodium acetate trihydrate 
(BDH 102363P) and 22.5ml acetic acid (BDH 100016X), adjust pH to 5.1 and make up 
to 5 litres with distilled water. Dilute 1/10 for working strength solution (0.02M).
ELISA Colour reagent: o-Phenylenediamine dihydrochloride (OPD), (Sigma P I526). lg 
of OPD to 100ml of 0.2M acetate buffer and one ml aliquots were stored at -20 until use. 
One aliquot was added to 10ml of distilled water and 11 pi of hydrogen peroxide (Sigma 
H1009) added just before use.
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10.4 Appendix IV Western Immunoblotting (mini-gelsi:
500pl Multimark, multi-coloured molecular weight standard (3-188 kDa), (Invitrogen 
LC5925)
LDS sample buffer; 10% glycerol, 141mM Tris base, 106nM Tris-HCL, 2% LDS,
0.5 ImM EDTA, 0.175mM phenol red, 0.22mM brilliant blue, dissolved in ultra pure 
water and adjusted to pH 8.5. (Invitrogen NP0007).
Reducing agent, 0.05M dithiothreitol (Sigma D9163)
NuPage MES (2-(N-Morpholino) ethane sulfonic acid) running buffer;
50mM MES, 50mM Tris base, 0.1% SDS, ImM EDTA and adjusted to pH 7.3. 
(Invitrogen NP0002).
NuPage MOPS (3-(N-Morpholino) propane sulfonic acid) running buffer;
50mM MOPS, 50mM T Tris base, 0.1% SDS, ImM EDTA and adjusted to pH 7.7, 
(Invitrogen NP0001)
Electro-blotting transfer buffer; 25mM Bicine, 25mM Bis-tris, ImM EDTA, 0.05mM 
chlorobutanol and adjusted to pH 7.2. (Invitrogen NP0006). Working strength buffer. 
100ml Methanol (Fisher Scientific M/3950/17) 425ml distilled water and 25 ml transfer 
buffer concentrate (Invitrogen NP0006).
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NuPage 4-12% bis-tris, precast 10 well gels. (Invitrogen NP0321).
NuPage 4-12% bis-tris, precast 2D well gels. (Invitrogen NP0326)
Colloidal blue staining kit (cat: LC6025). To stain one gel, 20ml of stain A was added to 
55mL distilled water containing 20ml methanol (Fisher Scientific M/3950/17). The gel 
was left at room temperature for 10 minutes with gentle shaking before adding 5ml of 
stain B.
Fixation and de-staining solution for comassie staining of gel:
35ml Ethanol (Fisher Scientific E/0600/17), 10ml of glacial acetic acid (A/0360/PB17) 
and 55ml distilled water.
Colourmetric substrate for Western blotting: 50mg of the substrate 4-chloro-l-naphthol 
(Sigma C8890) was dissolved in 20ml of ethanol (Fisher Scientific E/0600/17) and 100ml 
of working strength acetate buffer. lOOpl of 30% w/w hydrogen peroxide (Sigma HI 009) 
was added just before use.
Minigel drying kit (cat: N12387)
After staining the gel the gel was transferred to the gel dry solution for lOminutes with 
gentle rocking. Two pieces of cellophane were also thoroughly soaked for 5minutes. The 
gel was laid on one sheet of cellophane and the other placed on top. I found that gentle 
rolling with a glass rod removed excess air and prevented ‘cracking’. The gel was placed
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in the gel drying frame and left for two days at room temperature. I found that it was 
important to keep out of sunlight as uneven drying lead to ‘cracking’.
10.5 Appendix V Two-dimensional electrophoresis: Minigel system 
500 pi IEF coloured marker (Invitrogen 39212-01).
IEF sample buffer pH 3-10; 20mM Arginine, 20mM Lysine and 15% glycerol 
(Invitrogen LC5311)
IEF Anode buffer: pH 3-10; 85% phosphoric acid (Invitrogen LC5300)
IEF Cathode buffer. pH 3-10; 40mM lysine (Invitrogen LC5300)
pH 3-10 pre-cast 1mm, 10 well gels (Invitrogen EC6655A)
Gel preservation fluid: 75mL ethanol (Fisher Scientific E/0600/17), 12mL glycerol 
(Sigma G5516) and 160ml of distilled water
Two-dimensional electrophoresis using large gel format
Protein solubilisation buffer was a solution containing 8M Urea, (Amersham Pharmacia 
17-1319-01) and 4% (w/v) CHAPS, (zwitterionic, non-denaturing detergent), (Amersham 
Pharmacia 17-1314-01) which had been dissolved in distilled water.
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Equilibration solution: 50mM Tris-HCL (Amersham Pharmacia 17-1321-01), 6M Urea 
(Amersham Pharmacia 17-1321-01), 30% v/v Glycerol (Amersham Pharmacia 17-1325- 
01), 2% w/v SDS (Amersham Pharmacia 17-1313-01), 0.001% bromophenol blue 
(Amersham Pharmacia 17-1329-01) and 0.05M DTT (Amersham Pharmacia 17-1318- 
01).
10.6 Appendix VI Immunoprecipitation 
Binding buffer/wash buffer 1: 0.14M NaCl, 0.008M Na2P 0 4, 0.002M KP04, 0.01M KCL 
dissolved in 500ml of ultra pure water and adjusted to pH 7.4. (Perbio 45225).
Quenching/wash buffer 2: 25mM Tris-HCL, 0.15M NaCl dissolved in 500ml of ultra 
pure water and adjusted to pH 7.2 (Perbio 45225).
Elution buffer: 50ml solution of primary amine, pH 2.8 (Perbio 45225).
10.7 Appendix VII Streptococcal and human enolase protein-protein sequence
comparison
Query: 4 
63
Sbjct: 3 
61
ITDVYAREVLDSRGNPTLEVEVYTESGAFGRGMVPSGASTGEHEAVELRDGDKSRYLGLG
I  ++ARE+LDSRG«PT-fEV+-tYT G F R VESGASTG +EA+ELRDGDK RYLG G
IEKIWAREILDSRGNPTVEVDLYTAKGLF-RAAVPSGASTGIYEALELRDGDKQRYLGKG
Q u e r y : 
121
Sb j c t : 
121
6 4 TQKAVDNVNNIIAEAII —  GYDVRDQQAIDRAMIALDGT PNKGKLGANAILGVSIAVARA
62
KAVD++N+ I A  A+X <St V  +Q+ -H3 M+ LDGT NK K GANAXLGVS+AV +A  
VL KAVD HIN STIAP ALIS S GL SVVEQEKLDNLMLELDGTENKS KFGANAILGVS LAVCKA
Q u e r y : 
178
Sbjct:
181
122 AADYLEVPLYTY LGGFNTKVLPTPMMNIINGGSHSDAPIAFQEFMIMPVGAPTFKEG
1 2 2
A  E+PLY + It G + +JLP P N+XNGGSH+ +A QEFWI+PVGA + F + +  
GAAERELPLYRHIAQLAGNSDLILPVPAFNVINGGSHAGNKLAMQEFMILPVGAESFRDA
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Query: 17 9 LRWGAEVFHALKKILKER—  GLVTAVGDEGGFAPKFEGTEDGVETILKAIEAAGYEAGEN 
236
+R GAEV+H LK + + « + +  T VGDEGGFAP + +E + + A I+  AGY
Sbj c t : 182 MRLGAEVYHTLKGVIKDKYGKDATNVGDEGGFAPNILENSEALELVKEAIDKAGYT--- E
238
Query: 237 GIMIGFDCASSEFYDKERKVYDYTKFEGEGAAVRTSAEQVDYLEELVNKYPIITIEDGMD
296
I+ IG  D A+SEFY + D i K + f  T + +4- V YP+-t-+IED D
Sbj c t : 239 KIVIGMDVAASEFYRDGKYDLDF-KSPTDPSRYITGDQLGALYQDFVRDYPWSIEDPFD
297
Query: 2 97 ENDWDGWKVLTERLGKRVQLVGDDFFVTNTEYLARGIKENAANSILIKVNQIGTLTETFE 
356
++DW W T +G +Q+VGDD VTN + + R ++E A S  +L+KVNQIG++TS + 
Sbjct: 298 QDDWAAWSKFTANVG— IQIVGDDLTVTNPKRIERAVEEKACNCLLLKVNQIGSVTEAIQ 
355
Query: 357 AIEMAKEAGYTAWSHRSGETEDSTIADIAVATNAGQIKTGSLSRTDRIAKYNQLLRIED 
416
A  4-+A+E G t XAD+ V GQI K*TG+ R++R+AKYHQb +A1 R-+
Sbj c t : 356 ACKLAQENGWGVMVSHRSGETEDTFIADLWGLCTGQIKTGAPCRSERLAKYNQLMRIEE 
415
Query: 417 QLGEVAQYKG 426 
+LG+ A4--+ <5 
Sbjct: 416 ELGDEARFAG 425
10.8 Appendix VII Enolase activity assay 
Purification of IgG: Protein A column (Amersham Pharmacia 17-042-03) primed with 
binding buffer (20mM sodium phosphate pH 7). Serum injected into the column using a 
syringe. The column was washed with 5-10 column washes (lmL volumes) and eluted 
IgG using 0.1M citric acid pH 3-6. Fractions assessed by Western immunoblotting and 
immunofixation electrophoresis for IgG.
386
Enzyme activity: the substrate consisted of lOOmM HEPES buffer (Sigma H0887), pH 7 
which contained 3.3mM magnesium sulphate (Sigma M7506), 0.2mM NADH (Sigma 
N5130), 0.3mM 2-phosphoglycerate (Sigma P-0257), 1.2mM ADP (Sigma A2754), 10.3 
IU lactate dehydrogenase (Sigma L-3888) and 2.7 IU of pyruvate kinase (Sigma P-9136) 
in a final volume of 1ml.
10.9 Appendix VIII Suppliers 
Amersham Pharmacia Biosciences 
Little Chalfont 
Buckingshire 
HP7 9NA
BDH-part of
VWR International Ltd
Merck House
Poole
Dorset
BH15 1TD
Tel: 1202 660444
Fisher Scientific UK
Bishop Meadow Road
Loughborough
Leicestershire
LEI 1 5RG
Tel: 01509 231166
Invitrogen Ltd
Inchinnan Business Park
3 Fountain Drive
Paisley
Scotland
PA49RF
Tel: 0800 269 210
Perbio Science UK limited
Century House
Tattenhall
Cheshire
CH3 9RJ
Tel: 01829 771 744
Public Health Laboratory service
61 Colindale Avenue
Colindale
London
NW9 5HT
0208 200 4400
Sigma-Aldrich company Ltd
Fancy Road
Poole
Dorset
BH12 4QH
Tel: 0800 717181
The Binding site 
P.O. BOX 4073 
Birmingham 
B29 6AT
Tel: 0121 414 2000
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post-streptococcal autoimmune CNS disease
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